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INTRODUCTION
Primary cutaneous lymphomas are a group of lymphoproliferative disorders, mostly derived 
from T-cells or B-cells, which present in the skin with no evidence of extracutaneous disease 
at the time of diagnosis Primary cutaneous lymphomas have a different clinical presentation, 
clinical behaviour and prognosis as compared to the histologically similar systemic lymphomas 
involving the skin secondarily, and require a different type of treatment. For that reason 
classification systems for non-Hodgkin lymphomas, such as the EORTC classification and 
the WHO classification, have included primary cutaneous lymphomas as separate entities. 
Comparison between both classification systems shows a great deal of consensus regarding 
the classification of cutaneous T-cell lymphomas (CTCL), although clinically significant 
differences remain. Differences in the classification and terminology of primary cutaneous 
B-cell lymphoma (CBCL) has resulted in confusion and ongoing debate. 
The controversies between the EORTC and WHO classification schemes regarding the 
terminology and classification of the different types of CTCL and CBCL are addressed by the 
different studies included in this thesis. The studies presented in this thesis have been focused 
particularly on those groups of cutaneous lymphomas that are classified differently in the 
EORTC and WHO classification. The initial goal of our studies was to formulate suggestions 
for  an updated version of the EORTC classification. However, very recently discussions 
between representatives of the EORTC and the WHO group resulted in a new classification 
for cutaneous lymphomas: the WHO-EORTC classification. 
In this introductory chapter a historical overview of the classification of primary cutaneous 
lymphomas will be presented first. Differences between the EORTC and the WHO classification 
and the goals of the different studies addressing these controversies will be outlined. The 
results of these studies are presented in CHAPTERS 2-8. Based on the results of these studies and 
recent literature the new consensus WHO-EORTC classification and therapeutic guidelines 
for different types of primary cutaneous lymphoma will be presented (CHAPTER 9).
CLASSIFICATION OF CUTANEOUS LYMPHOMAS: A HISTORICAL OVERVIEW
In the early 1970s the only types of cutaneous lymphoma that had been rather well defined 
were mycosis fungoides (MF), including the classical Alibert-Bazin type and clinical variants 
as MF d’emblée and erythrodermic MF, and some related conditions as Sézary’s syndrome 
(SS), pagetoid reticulosis and lymphomatoid papulosis (LyP). Reports on other types of 
cutaneous lymphoma were rare. These cutaneous lymphomas other than MF/SS were firmly 
believed to represent manifestations of systemic lymphoma and treated consistently.1
In 1975, based on the observation that the neoplastic cells in MF, SS and related conditions 
did not only have the same morphology showing atypical cells with cerebriform nuclei, 
but also a common T-cell phenotype, Edelson suggested the term CTCL for this group of 
diseases2. Within a short time this term gained wide acceptance, particularly in the USA. The 
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introduction of the CTCL concept can be considered as a landmark in the history of this 
group of diseases. However, a major disadvantage has been that in many subsequent studies 
no difference was made anymore between MF, SS and other T-cell neoplasms, which may 
vary considerably in clinical presentation and clinical behavior. 
At about the same time when the CTCL concept was introduced, several European groups 
started to classify cutaneous lymphomas according to the criteria of the Kiel classification, a 
classification system used by hematopathologist for the classification of nodal lymphomas.3 
It was then found that many types of CBCL and CTCL other than classical MF and SS 
can present in the skin without any evidence of extracutaneous disease at the time of 
diagnosis. It appeared that these primary cutaneous lymphomas often have a completely 
different clinical behavior and prognosis compared to morphologically similar lymphomas 
arising in lymph nodes, and therefore require a different type of treatment.4,5,6 In addition, 
differences in the presence of specific translocations and in the expression of oncogenes, 
viral sequences or antigens (eg Epstein-Barr Virus (EBV)), and adhesion receptors involved 
in tissue-related lymphocyte homing were found.7,8,9 Such differences underscored that these 
primary cutaneous lymphoma represent a distinct group, and may explain, at least in part, 
their different clinical behavior. Perhaps most important, it appeared that different types of 
CTCL and CBCL with a different clinical behavior and different therapeutic requirements 
may have an identical histologic appearance. This implies that histological features should 
always be combined with clinical and immunophenotypical data, before a definite diagnosis 
(classification) can be made.
In the last decade such an approach resulted in the delineation of several new types of CTCL 
and CBCL, and formed the basis of the European Organization for Research and Treatment 
of Cancer (EORTC) classification for primary cutaneous lymphomas.10
EORTC CLASSIFICATION
The EORTC classification is the only classification designed specifically for the group of 
primary cutaneous lymphomas (TABLE 1). It contains a limited number of well-defined types 
of CTCL and CBCL, which together comprise more than 95% of all primary cutaneous 
lymphomas, and some provisional entities, which have not yet been fully defined clinically10. 
Distinction is made between cutaneous lymphomas with an indolent, intermediate or aggressive 
clinical behavior. By including well-defined and recognizable disease entities, this classification 
provides the clinician with detailed information on staging, preferred mode of treatment, 
clinical behavior and prognosis, and may serve as a useful guide to optimal management and 
treatment. The clinical significance of this classification has been validated by several large 
studies containing over 1300 patients with a primary cutaneous lymphoma.10,11, 12, 13
promotie.indb   11 18-01-2005   21:52:51
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TABLE 1. Classification of disease entities of the EORTC in the WHO classification
EORTC-CLASSIFICATION WHO CLASSIFICATION
CTCL
Mycosis Fungoides Mycosis Fungoides
Mycosis Fungoides variants
• MF-associated follicular mucinosis
• Pagetoid reticulosis
• Granulomatous slack skin (provisional) 
Mycosis Fungoides variants 
• MF-associated follicular mucinosis
• Pagetoid reticulosis
• Granulomatous slack skin
Sézary syndrome Sézary syndrome
Lymphomatoid papulosis Primary cutaneous CD30-positive T-cell 
lymphoprolif-erative disorders (primary 
cutaneous anaplastic large cell lymphoma, 
lymphomatoid papulosis; borderline lesions)
CTCL, large cell CD30+
CTCL, large cell CD30- Peripheral T-cell lymphoma, unspecified (most)
Extranodal NK/T-cell lymphoma, nasal-type 
(some)CTCL, pleomorphic small/medium cell 
(provisional)
Subcutaneous panniculitis like T-cell 
lymphoma 
(provisional)
Subcutaneous panniculitis like T-cell 
lymphoma
CBCL
Primary cutaneous immunocytoma/marginal 
zone B-cell lymphoma
Extranodal marginal zone B-cell lymphoma or 
MALT type lymphoma
Primary cutaneous follicle center cell 
lymphoma
Extranodal marginal zone B-cell lymphoma *
Cutaneous follicle center lymphoma †
Diffuse large B-cell lymphoma ‡
Primary cutaneous large B-cell lymphoma of 
the leg
Diffuse large B-cell lymphoma
Primary cutaneous plasmacytoma Plasmacytoma
Intravascular large B-cell lymphoma Diffuse large B-cell lymphoma (intravascular)
* For cases with a predominance of small neoplastic cells
† For cases showing a follicular growth pattern
‡ For cases showing a predominance of large neoplastic B-cells (most cases)
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WHO CLASSIFICATION
Whereas previous classifications for non-Hodgkin lymphomas used by hematopathologists, 
such as the Working Formulation14 and the updated Kiel classification,15 were based on 
purely histologic criteria, more recent classifications, such as the Revised European-American 
Classification for Lymphoid neoplasms (REAL classification)16 and its successor the World 
Health Organization (WHO) classification,17 also acknowledge that malignant lymphomas 
should be viewed as a group of disease entities, defined by a constellation of morphological, 
immunological, genetic and clinical criteria. In addition, it is recognized that the site of 
presentation is important, and that extranodal lymphomas are not identical to their nodal 
counterparts. The different types of primary cutaneous lymphoma included in the EORTC 
classification and their corresponding categories in the WHO classification are presented 
in TABLE 1. It illustrates that the WHO classification has adopted many types of CTCL from 
the EORTC classification. In fact, about 90% of all CTCL patients will be classified in an 
almost identical manner when either the EORTC or WHO classification is used. However, 
some important differences remain, which in some instances may have important therapeutic 
consequences. In contrast to the group of CTCL, the WHO classification did not adopt 
the categorization of CBCL from the EORTC classification. The discrepant views on the 
classification of CBCL have resulted in considerable debate and confusion. 
In the remainder of this chapter the main characteristics of the different types of CTCL 
and CBCL included in the EORTC classification will be presented, differences between the 
EORTC classification and WHO classification will be highlighted and the questions addressed 
in the studies presented in CHAPTERS 2-8 will be formulated.
CUTANEOUS T-CELL LYMPHOMA
Mycosis fungoides
Mycosis fungoides (MF) is characterized by the subsequent evolution of patches, plaques and 
tumors, and histologically by the presence of epidermotropic infiltrates of small to medium-
sized atypical T-cells with cerebriform nuclei. It is the most common form of primary cutaneous 
lymphoma, accounting for approximately 45% of all primary cutaneous lymphomas.10 The 
disease has a long natural history with usually an indolent course with slow progression over 
the years. Classically MF presents with patches and plaques on the trunk or extremities with 
a preferential localization in the “swim-suit” area. With progression of the disease (ulcerating) 
skin tumors may develop, and in a proportion of patients lymph nodes and visceral organs 
may get involved.
Both in the EORTC and WHO classification three variants of MF are included:
• FOLLICULAR OR FOLLICULOTROPIC MF, a variant of MF, in which the atypical cells are 
folliculotropic rather than epidermotropic, and which characteristically presents in the 
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head and neck region. Because of the presence of deep (peri)follicular infiltrates rather than 
superficial epidermotropic infiltrates this type of CTCL is less accessible to skin-directed 
therapies. In most cases follicular mucinosis is observed. Recent studies showed that there 
is no difference in clinical presentation and clinical behaviour between cases with and cases 
without associated follicular mucinosis.18,19 Therefore the term folliculotropic or follicular 
MF rather than MF-associated follicular mucinosis is preferred.18
• PAGETOID RETICULOSIS is a rare variant of MF, characterized by the presence of localized 
patches or plaques, which are usually localized on the extremities, and are slowly 
progressive. In contrast to classical MF, extracutaneous dissemination or disease-related 
deaths have never been reported. Histologically, there is an intraepidermal proliferation 
of neoplastic T-cells, which may express either a CD3+, CD4+, CD8- or a CD3+, CD4-, 
CD8+ phenotype. CD30 is often expressed.20,21
• GRANULOMATOUS SLACK SKIN (GSS) is an extraordinarily rare type of CTCL characterized 
by the slow development of folds of lax skin and a granulomatous infiltrate with clonal 
T-cells.22 Although it may develop in patients with otherwise classical MF, the exact 
relationship between GSS and MF is uncertain.
Sézary Syndrome
Sézary’s syndrome (SS) is defined historically by the triad of erythroderma, generalized 
lymphadenopathy, and the presence of neoplastic T-cells (Sézary cells) in skin, lymph nodes 
and peripheral blood.23 There is at present no consensus on the diagnostic criteria of SS. 
Demonstration of at least 1000 Sézary cells per mm3 is often used as a decisive criterion, 
but is not generally agreed upon.24 Demonstration of clonal T-cells, the presence of an 
expanded CD4+ T-cell population resulting in a significantly increased CD4/CD8 ratio (>10) 
and cytogenetic evidence of a T-cell clone in the peripheral blood have been suggested as 
additional criteria.10,25 Using these strict criteria the prognosis is generally poor with an overall 
5-year-survival between 10% and 20%.10 In a recent report of the International Society for 
Cutaneous Lymphomas (ISCL) slightly modified criteria for the diagnosis of SS have been 
suggested.25
Since there is consensus between the EORTC and WHO classification systems regarding the 
definition and classification of both MF (variants) and SS, these conditions are not further 
discussed in this thesis.
Spectrum of primary cutaneous CD30-positive lymphoproliferative disorders.
Primary cutaneous CD30-positive lymphoproliferative disorders represent the second most 
common group of CTCL, accounting for approximately 30% of all CTCL.10 This group 
includes primary cutaneous CD30-positive large T-cell lymphoma, LyP, and borderline cases. 
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The term borderline case refers to cases with the clinical presentation of a CD30-positive 
large T-cell lymphoma, but with histologic features suggestive of LyP, and vice versa.26 It 
follows that differentiation between primary cutaneous CD30-positive large T-cell lymphoma 
and lymphomatoid papulosis (LyP) cannot only be based on histologic criteria. The clinical 
appearance and course are used as decisive criteria for the definite diagnosis and choice 
of treatment. The overlapping clinical, histological, and immunophenotypical features have 
resulted in the view that CD30-positive cutaneous large T-cell lymphomas and LyP are parts 
of a spectrum of primary cutaneous CD30-positive lymphoproliferative disorders.26,27
Primary cutaneous CD30-positive (anaplastic) large T-cell lymphoma
Primary cutaneous CD30-positive (anaplastic) large cell lymphoma (ALCL) generally presents 
with solitary or localized nodules or tumors, and often shows ulceration. Multifocal lesions 
are seen in about 20% of the patients. Skin lesions may show partial or complete spontaneous 
regression, as in LyP. These lymphomas frequently relapse in the skin, but extracutaneous 
dissemination is uncommon.28
Radiotherapy is the first choice of treatment in patients presenting with a solitary or few 
localized nodules or tumors. Whether patients presenting with multifocal skin lesions should 
be treated with doxorubicin-based multiagent chemotherapy (MAC) or with a maintenance 
treatment of low-dose methotrexate as in LyP, is debatable. The prognosis is usually favorable 
with a 10-year disease-related survival exceeding 90%.28,29
Histologically, these lymphomas show diffuse nonepidermotropic infiltrates with cohesive 
sheets of large CD30-positive tumor cells. The CD30-positive neoplastic cells often express a 
CD4-positive T-cell phenotype with variable loss of CD2, CD5, and/or CD3. Unlike systemic 
CD30-positive lymphomas, most primary cutaneous CD30-positive large T-cell lymphomas 
express CLA (the weg), but do not express EMA and anaplastic lymphoma kinase (ALK), 
indicative of the 2;5 chromosomal translocation.7,30,31
In most cases the tumor cells have the characteristic morphology of anaplastic cells. Less 
commonly (20% to 25%), they have a pleomorphic or immunoblastic appearance. Based 
on prior studies suggesting that there are no differences in clinical presentation and clinical 
behavior between anaplastic and nonanaplastic cases, in the EORTC classification, the term 
primary cutaneous CD30-positive large T-cell lymphoma rather than primary cutaneous 
anaplastic large cell lymphoma is preferred10. Using the WHO classification, cases with a 
nonanaplastic morphology will often be classified as peripheral T-cell lymphoma, unspecified, 
in particular when CD30 staining has not been performed, and consequently be treated 
with unnecessarily aggressive modalities.32,33,34 It is therefore of great clinical importance to 
ascertain that anaplastic and non-anaplastic cases have indeed the same clinical behaviour 
and prognosis. 
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Lymphomatoid papulosis 
Lymphomatoid papulosis (LyP) is defined as a chronic, recurrent, self-healing papulonecrotic 
or papulonodular skin disease with histologic features suggestive of a (CD30-positive) 
malignant lymphoma35. Characteristically, the dermal infiltrates contain scattered or small 
clusters of large atypical, sometimes multinucleated or Reed-Sternberg-like, CD30-positive 
cells, interspersed in an extensive inflammatory infiltrate. The large atypical cells have the 
morphological and immunophenotypical characteristics of the neoplastic cells in the primary 
cutaneous CD30-positive large T-cell lymphomas.
Several studies demonstrated that in up to 20% of patients, LyP may be preceded by, 
associated with, or followed by another type of malignant (cutaneous) lymphoma, generally 
MF, a CD30-positive large T-cell lymphoma, or Hodgkin’s lymphoma36,37. In a recent study 
however it was suggested that 80% of LyP patients will develop a systemic lymphoma within 
15 years after diagnosis.38 Risk factors for the development of a systemic lymphoma have 
however not yet been defined.
In CHAPTER 2 treatment modalities and outcome, potential risk factors and long-term follow-
up of 219 patients with primary and secondary CD30+ lymphoproliferative disorders were 
evaluated. Specific questions addressed in this study were:
• Are there differences in clinical outcome between primary cutaneous CD30-positive large 
T-cell lymphomas with an anaplastic or a non-anaplastic morphology?
• What is the risk to develop systemic lymphoma in patients within this spectrum of disease 
and which are potential risk factors?
• What is the best treatment of patients within this spectrum of disease, and in particular 
which patients should be treated with systemic multiagent chemotherapy? Based on the 
results of this study guidelines for diagnosis and treatment are provided.
Subcutaneous panniculitis-like T-cell lymphoma
Subcutaneous panniculitis-like T-cell lymphoma (SPTL) is a cytotoxic T-cell lymphoma, 
which preferentially infiltrates the subcutaneous tissue.39,40 SPTL is a rare lymphoma, which 
can occur in adults as well as in young children. Patients generally present with solitary or 
multiple nodules and plaques, which mainly involve the legs, or less commonly the trunk. 
Systemic symptoms such as fever, fatigue and weight loss may be present. The disease 
may be complicated by a hemophagocytic syndrome, which is generally associated with a 
rapidly progressive course41. Histopathology reveals subcutaneous infiltrates simulating a 
panniculitis showing a mixture of neoplastic pleomorphic T-cells of various sizes and often 
many macrophages. Rimming of individual faT-cells by neoplastic T-cells is a helpful, though 
not completely specific diagnostic feature.42 Necrosis, karyorrhexis and cytophagocytosis 
are common findings. Most cases show an α/β+, CD8+ T-cell phenotype with expression of 
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cytotoxic proteins, but up to 25% of cases have a γ/δ T-cell phenotype, are typically CD4-, 
CD8-, and often co-express CD56.43 In contrast to SPTL with an α/β T-cell phenotype, 
SPTL with a γ/δ T-cell phenotype show neoplastic infiltrates that are not confined to the 
subcutaneous tissue, but may involve the epidermis and/or dermis as well, and invariably 
have a very poor prognosis. Based on these observations it has been suggested that SPTL with 
an γ/δ T-cell phenotype should be considered as a separate group.43,44,45,46
In CHAPTER 6 6 cases of CD56+ SPLT, five of which with a confirmed γ/δT-cell phenotype are 
evaluated. The pros and cons of classifying α/β+ and γ/δ+ SPTL separately will be discussed 
in CHAPTER 9.
Primary cutaneous CD30-negative T-cell lymphomas (non-MF/SS/SPTL)
Approximately 10% of CTCL cases do not belong to one of the entities described before.10,47 
These primary cutaneous CD30-negative CTCL (non-MF/SS/SPTL) form a heterogeneous 
group, both clinically and histologically. In general they have a poor prognosis.10,11,12,48,49 In 
the EORTC classification these cases are classified as either primary cutaneous CD30-negative 
large cell CTCL or primary cutaneous CD30-negative small-medium sized pleomorphic 
CTCL. Distinction between these two categories, which is based on the presence of more or 
less than 30% large neoplastic T-cells is considered useful because of a significant difference in 
survival between both groups.11,12,50,51 The EORTC classification does not include cases with 
prior or concurrent extracutaneous disease, and does not make further distinction between 
CD4+ and CD8+ cases. In the WHO classification the overwhelming majority of these CD30-
negative large cell and small-medium sized pleomorphic CTCL are included in the group 
of peripheral T-cell lymphoma not otherwise specified (PTL, NOS), whereas rare cases are 
classified as extranodal NK/T-cell lymphoma, nasal-type (TABLE 1). The group of PTL, NOS 
includes both primary and secondary cutaneous cases, and further subdivision on the basis of 
cell size or phenotype is not made.
 
To find out if subdivision of these lymphomas on the basis of presentation with or without 
extracutaneous disease, cell size or phenotype is clinically significant, we evaluated the 
clinicopathologic features, treatment results and follow-up data of 82 patients with a PTL, 
NOS presenting in the skin. The results of this study are presented in CHAPTER 3.
CD56-positive hematologic neoplasms presenting in the skin
Cutaneous lymphomas are generally classified as cutaneous T-cell lymphoma (CTCL) or 
cutaneous B-cell lymphoma (CBCL). In European studies CTCL and CBCL account for 
approximately 75% and 25% of all (primary) cutaneous lymphomas, respectively10,52. The 
availability of monoclonal antibodies against CD56 that are active in paraffin sections has 
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resulted in the recognition of a subgroup of hematologic neoplasms mainly derived from 
natural killer (NK) cells or NK-like T-cells. These CD56+ hematologic neoplasms preferentially 
present at extranodal sites, not uncommonly the skin, and almost without exception have an 
extremely poor prognosis. In the WHO classification several groups of CD56+ neoplasms 
are distinguished, including extranodal NK/T-cell lymphoma, nasal-type and  blastic NK-cell 
lymphoma.17
Extranodal NK/T-cell lymphomae, nasal-type is an EBV positive, nearly always extranodal 
lymphoma of small, medium or large cells usually with an NK-cell, or more rarely cytotoxic 
T-cell phenotype.17 These lymphomas generally show prominent angiocentricity and 
angiodestruction often accompanied by extensive necrosis. These lymphomas have been 
reported most frequently in Asia and Central and South America, and are almost without 
exception strongly associated with EBV.53 The term nasal-type is used to draw attention to 
the fact that the nasal cavity/nasopharynx is the prototypic site of involvement (previously 
designated as lethal midline granuloma), but identical neoplasms can be seen in other extranodal 
sites as well. The skin is the second most common site of involvement after the nasal cavity/
nasopharynx.54 Clinically, these lymphomas show plaques and tumors preferentially on the 
trunk and extremities, often with ulceration. These skin lesions are generally a secondary 
manifestation of the disease, but rare primary cutaneous cases have been reported as well.55 
In the EORTC such primary cutaneous lymphomas were not included as a separate entity, but 
included in the groups of primary cutaneous CD30-negative large T-cell lymphoma or in the 
group of small/medium-sized pleomorphic CTCL. The prognosis is poor, despite aggressive 
treatment and new therapeutic options should be investigated.56,57
Blastic NK-cell lymphoma is a clinically aggressive neoplasm, which most commonly 
presents in the skin with or without concurrent extracutaneous disease. Histologically, 
these neoplasms are characterized by a diffuse monotonous infiltrate of medium-sized cells 
resembling lymphoblasts or myeloblasts.17 Characteristically, the neoplastic cells are positive 
for CD4 and CD56 and in some cases for TdT, but do not express surface CD3 and cytotoxic 
proteins, and are not associated with EBV.17 Previous studies suggested these blastic NK-cell 
lymphomas are derived form precursor NK-cells.17 More recent studies showed that the 
neoplastic cells strongly express the IL-3R alpha chain (CD123) and the lymphoid proto-
oncogene TCL1 suggesting a derivation from early plasmacytoid dendritic cells rather than 
from NK-cell (precursors). CD4+, CD56+ hematodermic neoplasm58 and early plasmacytoid 
dendritic cell leukemia/lymphoma59 have been suggested as more appropriate terms for this 
condition.
Blastic NK-cell lymphoma is an aggressive disease with a poor prognosis. Although the skin 
may be the only site of involvement at presentation, early dissemination to the bone marrow 
and/or peripheral blood is the rule. Systemic chemotherapy usually results in a complete 
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remission, but quick relapses unresponsive to further chemotherapy are normally seen. 
Recent studies suggest that patients can best be treated with regimens used in acute leukemias. 
Indeed, blastic NK-cell lymphoma should be differentiated above all from myeolomonocytic 
leukemia cutis, and is conceptually similar to so-called “aleukemic leukemia cutis”.42 
 
In addition to these two well-defined entities CD56 may be expressed in other types of 
lymphoma and leukemias such as primary cutaneous CD30+ LPD, SPTL, rare cases of PTL, 
NOS and myelomonocytic leukemias presenting primarily in the skin. CD56 expression in 
SPTL often indicates a γ/δ T-cell phenotype and an unfavorable prognosis. Whether CD56 
expression in primary cutaneous CD30+ LPD also suggests a more unfavorable prognosis 
requires further study. 
In an attempt to better define these different subgroups we evaluated the clinicopathologic 
and immunophenotypical data, treatment results and prognostic parameters of a large group 
of CD56+ haematologic neoplasms presenting in the skin, including 23 new cases and 130 
cases from literature. The results are presented in CHAPTER 4. In CHAPTER 5 a unique case of 
LyP showing co-expression of CD56 is described. Also in this chapter the question whether 
CD56 expression in primary cutaneous CD30+ lymphoproliferations is associated with a 
poor prognosis is addressed.
CUTANEOUS B-CELL LYMPHOMA
Unlike the situation for CTCL there is still considerable discrepancy between the EORTC 
and the WHO classification on primary cutaneous B-cell lymphoma. 
In the EORTC classification three major subgroups are distinguished: primary cutaneous 
immunocytomas (PCI)/marginal-zone B-cell lymphomas (PCMZL), primary cutaneous follicle 
center cell lymphoma (PCFCCL) and primary cutaneous large B-cell lymphoma (PCLBCL) of 
the leg. In addition primary cutaneous intravascular B-cell lymphoma and primary cutaneous 
plasmacytoma are included as provisional entities. 
Primary cutaneous immunocytoma / marginal zone B-cell lymphoma 
PCI/PCMZL are indolent lymphomas composed of small B-cells including marginal zone 
(centrocyte-like) cells, lymphoplasmacytoid cells and plasma cells. Clinically most cases 
present with papules, plaques or nodules preferentially located on the trunk or extremities. 
Presentation with multifocal lesions is not uncommon.60 Although cutaneous relapses occur 
frequently, extracutaneous dissemination is extremely rare. An association with Borrelia 
Burgdorferia is found in a minority of the European cases, but not in Asian cases or cases 
from the USA.61,62,63,64 The prognosis is excellent with a five-year-survival close to 100%.10 
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In the EORTC classification the term PCI/PCMZL was used mainly to convey the message 
that PCMZL was a new name for cases designated previously as immunocytomas using the 
criteria of the Kiel classification. When the EORTC classification was composed the term 
PCI was preferred because the term MZL was still ill-defined and used in different ways. 
Some authors even suggested that not only PCI, but also most PCFCCL were derived from 
marginal zone B-cells and should be classified accordingly.65 However, recent studies suggest 
that careful assessment of morphological and immunophenotypical features allows distinction 
between PCMZL and PCFCCL in most cases. Whereas PCFCCL consistently express bcl-6, 
rarely bcl-2 and CD10 to a variable degree, PCMZL almost consistently have a bcl-2+, bcl-6-, 
CD10- phenotype.60,66 Using these additional markers it is most unlikely that PCFCCL are 
classified incorrectly as PCMZL. In addition, the term immunocytoma has become highly 
confusing, since in the WHO classification the extranodal immunocytomas as defined in 
the Kiel classification, have been renamed MZL, whereas in the term immunocytoma is 
used for a small group of systemic lymphoplasmacytic lymphomas generally associated 
with Waldenströms macroglobulinaemia. For these reasons the term PCMCL is now widely 
accepted as the most appropriate term for this type of cutaneous B-cell lymphoma.
Primary cutaneous follicle center cell lymphoma and primary cutaneous large 
B-cell lymphoma of the leg 
In recent years the EORTC categories PCFCCL and PCLBCL-leg have been the subject 
of much debate. The term PCFCCL was introduced in 1987 as an encompassing term for 
cutaneous lymphomas, that were composed of cells with the morphology of follicle center 
cells, ie centroblasts and (large) centrocytes, and that were classified as either centroblastic/
centrocytic or centroblastic according to the Kiel classification.67 Whereas small and early 
lesions may show both small and large neoplastic B-cells and many admixed reactive T-cells, 
and may or may not have a (partly) follicular growth pattern, tumorous lesions generally 
show a predominance of large B-cells particularly large cleaved or multilobated B-cells, and 
less frequently a predominance of typical centroblasts and immunoblasts.10,67,68 In contrast 
to nodal follicular lymphomas these PCFCCL do generally not express bcl-2 and are not 
associated with the t(14;18) translocation.69,70 Clinically, most patients present with localized 
skin lesions on the head or trunk.  In particular on the trunk these tumors may be surrounded 
by papules and slightly indurated plaques, which may precede the development of tumorous 
lesions for months or even many years. In the past PCFCCL with such a typical presentation on 
the back were referred to as “reticulohistiocytoma of the dorsum” or “Crosti’s lymphoma”.71 
Presentation with multifocal skin lesions is observed in approximately 14% of patients.72 
Dissemination to extracutaneous sites is uncommon. Irrespective of growth pattern (follicular 
or diffuse) or the number of blasts cells, these PCFCCL have an excellent prognosis with a 
5-year-survival of over 95%.10,11,12,62,68,71 Radiotherapy is the preferred mode of treatment 
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in particular in patients presenting with localised disease. Whether patients presenting with 
multifocal skin lesions should be treated with multiagent chemotherapy or rather with non-
aggressive therapies is a matter of debate.73,74
The WHO-classification did not adopt this well-defined disease entity. In this classification 
PCFCCL with a (partly) follicular growth pattern were included as a variant of follicular 
lymphoma and designated cutaneous follicle center lymphoma, while cases with a diffuse 
growth pattern were classified as diffuse large B-cell lymphoma, which may result in 
overtreatment with multiagent chemotherapy rather than radiotherapy.
In the EORTC classification the term diffuse large B-cell lymphoma is only used for a special 
subgroup of patients presenting with tumours on the legs. These PCLBC-leg particularly affect 
elderly people, show a higher relapse rate and a more unfavourable prognosis as compared to 
PCFCCL with a diffuse large B-cell morphology (5-year-survival 95% vs 52%)10,75. For this 
reason they were included as a separate subgroup in the EORTC classification. Histologically, 
they show a predominance of centroblasts and immunoblasts rather than large cleaved cells, 
and consistently express the bcl-2 protein.69 Although delineation of this subgroup based 
on site has been criticized, recent clinicopathologic and genetic studies further support that 
PCFCCL and PCLBCL-leg are distinct groups of CBCL. In contrast to PCFCCL with a diffuse 
large cell morphology, most PCLBCL-leg express Mum-1/IRF476 and the polycomb gene 
HPH1,77 and frequently demonstrate translocations involving myc, bcl-6 and IgH genes.78 
Recent studies suggest that these PCLBCL-leg have an activated B-cell gene expression profile, 
while PCFCCL have a germinal center-like gene expression profile.79
The discrepant views of the EORTC and the WHO classification on the classification 
and terminology of PCFCCL and PCLBCL-leg is not merely a semantic discussion, but of 
great clinical importance. In fact, it concerns distinction between indolent (PCFCCL) and 
aggressive (PCLBCL-leg) types of CBCL, and consequently a choice between aggressive and 
non-aggressive types of treatment. 
Therefore a large European study on primary cutaneous large B-cell lymphoma, including 
both PCLBCL-leg and PCFCCL with a predominance of large cells, was performed. The main 
goals were to identify independent risk factors, to find out whether PCLBCL-leg and PCFCCL 
have indeed a different clinical behaviour and to define additional prognostic parameters 
within these groups of CBCL. The results are described in CHAPTER 6. 
Since there is uncertainty whether PCFCCL presenting with multifocal skin lesions have the 
same clinical behaviour and require the same therapeutic approach as PCFCCL presenting 
with localised disease, clinical and histological data of twenty-nine patients presenting with 
multifocal primary cutaneous B-cell lymphoma registered in the Dutch Cutaneous Lymphoma 
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Group were evaluated. The results of this study and proposals for management and treatment 
of this group is presented in CHAPTER 7. 
Dissemination to extracutaneous sites is a rare event in CBCL. Because the development of 
CNS involvement in two subsequent patients with a CBCL, the frequency of dissemination and 
in particular CNS involvement was evaluated for the different groups of CBCL (CHAPTER 8).
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PRIMARY AND SECONDARY CUTANEOUS CD30+ LYMPHOPROLIFERATIVE DISORDERS: A REPORT FROM THE DUTCH CUTANEOUS LYMPHOMA GROUP 
ON THE LONG-TERM FOLLOW-UP DATA OF 219 PATIENTS AND GUIDELINES FOR DIAGNOSIS AND TREATMENT
ABSTRACT
To evaluate our diagnostic and therapeutic guidelines, clinical and long-term follow-up data 
of 219 patients with primary or secondary cutaneous CD30+ lymphoproliferative disorders 
were evaluated. The study group included 118 patients with lymphomatoid papulosis 
(LyP; group 1), 79 patients with primary cutaneous CD30+ large T-cell lymphoma (LTCL; 
group 2), 11 patients with CD30+ LTCL with skin and regional lymph node involvement 
(group 3), and 11 patients with secondary cutaneous CD30+ LTCL (group 4). Patients 
with LyP often did not receive any specific treatment, whereas most patients with primary 
cutaneous CD30+ LTCL were treated with radiotherapy or excision. All patients with skin-
limited disease from groups 1 and 2 who were treated with multiagent chemotherapy had 
1 or more skin relapses. The calculated risk for systemic disease within 10 years of diagnosis 
was 4% for group 1, 16% for group 2, and 20% for group 3 (after initial therapy). Disease-
related 5-year-survival rates were 100% (group 1), 96% (group 2), 91% (group 3), and 
24% (group 4), respectively. The results confirm the favorable prognoses of these primary 
cutaneous CD30+ lymphoproliferative disorders and underscore that LyP and primary 
cutaneous CD30+ lymphomas are closely related conditions. They also indicate that CD30+ 
LTCL on the skin and in 1 draining lymph node station has a good prognosis similar to that for 
primary cutaneous CD30+ LTCL without concurrent lymph node involvement. Multiagent 
chemotherapy is only indicated for patients with full-blown or developing extracutaneous 
disease; it is never or rarely indicated for patients with skin-limited CD30+ lymphomas.
INTRODUCTION 
Primary cutaneous T-cell lymphomas (CTCL) represent a heterogeneous group of neoplasms 
derived from skin-homing T-cells. Apart from mycosis fungoides (MF), primary cutaneous 
CD30+ lymphoproliferative disorders are the most common group, accounting for 
approximately 25% of all CTCL. This group includes primary cutaneous CD30+ (anaplastic) 
large T-cell lymphomas (LTCL) and lymphomatoid papulosis (LyP), a chronic recurrent, self-
healing papulonodular skin eruption with histologic features of a (CD30+) CTCL.1-3 Because 
of overlapping clinical, histologic, and immunophenotypical characteristics, these conditions 
are considered to represent a spectrum of primary cutaneous CD30+ lymphoproliferations.4,5 
It is well established that these primary cutaneous CD30+ lymphoproliferations have favorable 
prognoses in most patients.6-12 Previous studies by our group demonstrated significant 
differences between primary cutaneous CD30+ (anaplastic) LTCL and morphologically 
similar systemic CD30+ anaplastic large-cell lymphomas.13 In contrast to these systemic 
lymphomas, primary cutaneous CD30+ LTCL are rare in children; they generally express 
the cutaneous lymphocyte antigen (CLA) characteristic of skin-homing T-cells but usually 
not the epithelial membrane antigen (EMA). They are not associated with Epstein-Barr virus 
or, according to most studies,14-17 with the t(2;5) translocation (ALK/p80-negative), and they 
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have a significantly better prognosis. For these reasons, primary CD30+ CTCL is included as a 
separate group in the revised European-American classification for non-Hodgkin lymphomas 
(REAL classification)18 and in the proposed World Health Organization classification.19 
Notwithstanding the many publications describing the characteristic features of these primary 
cutaneous CD30+ lymphomas and emphasizing their favorable prognosis, referral centers for 
cutaneous lymphomas are confronted regularly with patients who have been misdiagnosed or 
who have been treated with unnecessarily aggressive treatment regimens.20-22 In particular, the 
diagnosis LyP is often overlooked. Based on the histologic diagnosis of a CD30+ (anaplastic) 
LTCL and the presence of multifocal skin lesions, patients with LyP are routinely treated with 
multiagent chemotherapy by physicians unaware of the spectrum of LyP. Unfortunately, skin 
relapses during or shortly after systemic chemotherapy are almost the rule and give the false 
impression of a highly aggressive T-cell lymphoma requiring even more aggressive therapy. 
The current report describes the results of a recent evaluation of 219 patients with cutaneous 
CD30+ lymphoproliferation who were included in the Dutch registry for cutaneous lymphomas 
between 1983 and 1998. This study was conducted to evaluate our current diagnostic and 
therapeutic approaches for these patients and to define potential risk factors for tumor 
progression. Detailed clinical and long-term follow-up data of well-defined groups of primary 
and secondary cutaneous CD30+ lymphoproliferations are presented. Based on these data, 
practical guidelines for proper diagnosis, management, and treatment are presented. 
PATIENTS AND METHODS 
Patients 
Between 1983 and 1998, 247 patients with primary or secondary cutaneous CD30+ 
lymphoproliferation had been included in the database of the Dutch Cutaneous Lymphoma 
group. Patients with a follow-up less than 12 months unless they died of lymphoma (n = 14), 
patients with a CD30+ LTCL originating from MF (n = 8), and patients with HIV-associated 
(n = 4) or posttransplant (n = 2) CD30+ LTCL were excluded. The final study group contained 
219 patients, including 118 patients with LyP, 79 patients with primary cutaneous CD30+ 
LTCL, and 22 patients with cutaneous CD30+ (anaplastic) LTCL with concurrent or prior 
extracutaneous disease at the time of presentation. Of this latter group, 11 of 22 patients 
with skin lesions and regional lymph node involvement restricted to 1 site were evaluated 
as a separate group. All diagnoses were based on combinations of clinical, histologic, and 
immunohistochemical criteria23 and were made by an expert panel of dermatologists and 
hematopathologists at the time of diagnosis, before entry in the database. Because correct 
categorization (ie, diagnosis) of these lymphomas was crucial, these diagnostic criteria have 
been summarized in TABLE 1. It should be emphasized that, because of the histologic similarities 
between LyP and other types of CTCL (MF or CD30+ ALCL), the presence of a recurrent, 
promotie.indb   31 18-01-2005   21:53:00
chapter 2  page 32
PRIMARY AND SECONDARY CUTANEOUS CD30+ LYMPHOPROLIFERATIVE DISORDERS: A REPORT FROM THE DUTCH CUTANEOUS LYMPHOMA GROUP 
ON THE LONG-TERM FOLLOW-UP DATA OF 219 PATIENTS AND GUIDELINES FOR DIAGNOSIS AND TREATMENT
self-healing papular or papulonodular eruption is used as a decisive criterion for the diagnosis 
of LyP. For all patients in groups 2, 3, and 4 and for all patients with LyP type C (TABLE 1), 
adequate staging procedures including physical examination, routine examination of blood 
morphology and blood chemistry, radiography of the chest, and computerized tomography 
of the thorax (most patients) and abdomen were conducted, and bone marrow biopsies were 
taken. No extracutaneous disease was found in groups 1 and 2. In most other patients with 
LyP, staging procedures other than physical examination and routine blood examination 
were not performed. 
Follow-up data had been collected yearly for each patient and could therefore easily be 
retrieved from the database. If necessary, additional information was obtained from the 
referring physician or from the patient. 
Risk factors for tumor progression 
As endpoints of tumor progression, extracutaneous disease in patients who initially only had 
cutaneous disease (groups 1 and 2) and lymphoma-related death were selected. As potential 
risk factors, the following parameters were scored for each patient: age at diagnosis, sex, 
morphology, localization and extent of skin lesions (solitary or localized vs multifocal skin 
lesions), type and result of initial treatment, occurrence and site of relapse (cutaneous or 
extracutaneous), disease-free survival, and histologic subtype (type A vs type B vs type C in 
LyP; anaplastic vs nonanaplastic morphology in the other 3 groups). Definitions of the different 
histologic subgroups have been published previously5,23 and are summarized in TABLE 1. 
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Statistical analysis 
As indicators of survival, both disease-
specific survival (including only death 
related to lymphoma as event) and overall 
survival (including death related to any 
cause as event) were investigated. Actuarial 
survival curves were calculated from the 
date of diagnosis to the date of death or last 
contact using the Kaplan-Meier technique. 
Univariate analysis of possible risk factors 
for tumor progression was performed using 
log-rank test and Cox proportional hazards 
regression analysis. Multivariate analysis 
was performed using significant univariate 
variables from Cox proportional hazards 
regression analysis. All analyses were 
performed with the SPSS statistic software 
(SPSS, Chicago, IL). 
RESULTS 
The main clinical characteristics for the 4 
groups studied are summarized in TABLE 2. 
Additional information for these groups is 
given separately below. 
Lymphomatoid papulosis 
Group 1 consisted of 69 males and 49 
females with a median age of 45.5 years 
at diagnosis (range, 4 to 88 years). Patients 
initially sought treatment for papular, 
papulonecrotic, or nodular skin lesions, and 
8 patients (7%) also sought it for additional 
plaques or tumors. Characteristically, skin 
lesions in different stages of evolution 
were found next to each another (FIGURE 1). 
There was no preferential anatomic site of 
involvement. The group included 12 patients 
(10%) younger than 20 years of age at the 
promotie.indb   33 18-01-2005   21:53:02
chapter 2  page 34
PRIMARY AND SECONDARY CUTANEOUS CD30+ LYMPHOPROLIFERATIVE DISORDERS: A REPORT FROM THE DUTCH CUTANEOUS LYMPHOMA GROUP 
ON THE LONG-TERM FOLLOW-UP DATA OF 219 PATIENTS AND GUIDELINES FOR DIAGNOSIS AND TREATMENT
time of diagnosis (median, 12 years; range, 4 to 19 years). Interestingly, 3 of these children 
(6, 13, and 16 years of age) had papules and rapidly growing ulcerating nodules or tumors. 
Despite this alarming clinical presentation, the lesions slowly subsided within 6 to 10 weeks 
without any specific treatment. None of the 12 children had extracutaneous disease or died 
of lymphoma after a median follow-up of 52 months (range, 25 to 131 months). 
Throughout the course of their disease, 52 of 118 patients received no therapy other than 
topical steroids, which was not always recorded. Therapies most commonly applied in the 
other patients included psoralen-UV-A (PUVA) or UV-B phototherapy or chemotherapy 
(46 patients), topical nitrogen mustard (8 patients), and low doses of methotrexate (8 patients). 
Although partial or even complete remission was common, none of these therapies resulted 
in sustained complete remission. Similarly, remission after systemic chemotherapy or total 
skin electron beam irradiation, given for associated malignancies, was short-lived and did not 
affect the natural course of LyP. Associated lymphomas, either before, after, or concurrently 
with the development of LyP, were observed in 23 of 118 (19%) patients (TABLE 3). One of these 
23 patients had systemic CD30+ ALCL, which went into complete remission after multiagent 
chemotherapy, 6 years before LyP developed. Eleven of these 23 patients had concurrent 
LyP and MF. The diseases ran indolent clinical courses in all these patients. Large, persistent 
tumors developed in 4 patients with LyP; they were treated with radiotherapy (2 patients) 
or disappeared spontaneously (2 patients) (FIGURE 2). Extracutaneous disease developed 
in only 7 of 118 patients. Skin tumors with involved regional lymph nodes developed in 
4 of these 7 patients. Although 2 of these 4 patients were treated with cyclophosphamide-
doxorubicin-vincristine-prednisone (CHOP) courses, skin and lymph node localizations 
disappeared spontaneously in the other 2 patients, and planned chemotherapy was not given. 
Systemic lymphoma developed in the other 3 of those 7 patients (CD30+ LTCL with lung 
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multiagent chemotherapy. After a median follow-up of 77 months (range, 12 to 350 months), 
111 patients (94%) are alive, 5 patients (4%) died of nonrelated disease, and only 2 patients 
(2%) died of systemic CD30+ LTCL or Hodgkin disease 14 and 19 years, respectively, after 
the diagnosis of LyP. Both patients have been described in more detail.24,25 
Evaluation of risk factors 
for tumor progression by 
univariate analysis did 
not reveal statistically 
significant results (P > 0.1), 
which may be explained 
by the small proportion 
(4%) of patients with LyP 
in whom extracutaneous 
disease developed. Notably, 
none of the 8 patients with 
LyP whose skin biopsies 
revealed cohesive sheets of 
FIGURE 2. A large 
ulcerating tumor 
(diameter, 5 cm) 
developed in a 12-
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CD30+ cells (LyP type C) died of lymphoma. In addition, after a follow-up of 23 to 156 
months (median, 43 months), extracutaneous disease developed in only 1 (FIGURE 3). 
Primary cutaneous CD30+ large cell lymphoma 
Group 2 consisted of 59 males and 20 females with a median age of 60 years at diagnosis 
(range, 16 to 89 years). Only 1 patient was younger than 20 years of age, illustrating that 
there is no bimodal age distribution in this group. Patients usually sought treatment for a 
solitary (ulcerating) tumor (42 patients) or several grouped nodules or papules restricted to 
1 skin area (20 patients) (FIGURE 4). Only 17 patients (22%) had multifocal skin disease, ie 
2 (n = 9) or more (n = 8) lesions at multiple anatomic sites (FIGURE 5). Partial or even complete 
spontaneous remission of skin lesions, either at diagnosis or at relapse, were observed in 
33 (42%) patients. 
Initial treatment consisted of radiotherapy (47%) 
or surgical excision (22%). Only 6 patients 
(8%) received doxorubicin-based multiagent 
chemotherapy, including 4 of 17 patients who 
sought treatment for multifocal skin lesions. Twelve 
patients (15%) received no treatment because of 
spontaneous, complete remission of the skin lesions. 
Although 33 of 79 patients (42%) had 1 or more 
skin relapses, extracutaneous disease developed in 
only 8 of 79 patients (10%). Treatment consisted 
of CHOP courses (6 patients) or autologous bone 
marrow transplantation. After a median follow-
up of 61 months (range, 13 to 288 months), only 
4 patients died of lymphoma. 
Patients with multifocal skin lesions more often 
acquired extracutaneous disease (17% vs 8%) and 
more often died of lymphoma (12% vs 3%) than 
patients with solitary or localized skin lesions. 
However, univariate analysis demonstrated that 
neither extent of skin lesions, age at diagnosis, 
presence of spontaneous remission, histologic subtype, 
or any other variable tested was significantly related 
to disease progression or survival. Multivariate 
analysis, therefore, was not performed. 
FIGURE 3. 
Lymphomatoid 
papulosis (type C). 
(A) Approximately 10 
firm papules on the 
face and the chest. 
(B) Detail of dermal 
infiltrate showing 
a monotonous 
population of large 
anaplastic (CD30
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CD30+ LTCL with skin and draining lymph node involvement 
Group 3 consisted of 4 men and 7 women with a median age of 64 years (range, 27 to 
74 years). Ten of 11 patients had 1 (8 patients) or several (2 patients) ulcerating tumors in 1 
anatomic area and enlarged, histologically involved draining lymph nodes at that site. Initial 
therapy consisted of CHOP-like multiagent chemotherapy in 9 of 11 patients (82%) and 
resulted in complete remission in 8 of them. However, 5 of these 8 patients had skin relapses 
during follow-up. In 2 other patients not treated with systemic chemotherapy, skin and 
nodal lesions disappeared spontaneously after diagnostic excision of the skin tumor, and no 
further treatment was instituted. Neither of them had a relapse, and both are still in complete 
remission 24 and 79 months after diagnosis, respectively. After a median follow-up of 58 
months (range, 15 to 248 months), 9 patients are alive, 1 died of unrelated disease, and 1 died 
of lymphoma. The disease-related 5-year survival rate in this group was 91% (FIGURE 6). 
Secondary cutaneous CD30+ large T-cell lymphoma 
Group 4 consisted of 6 males and 5 females with a median age of 55 years (range, 7 to 
87 years). Seven patients had extensive cutaneous and extracutaneous disease. The age 
distribution was typically bimodal: 3 patients were younger than 22 years and 4 were older 
LEFT:
FIGURE 4. Primary 
cutaneous CD30
RIGHT:
FIGURE 5. Primary 
cutaneous CD30
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than 55 years. Treatment with multiagent chemotherapy resulted in complete remission in 
only 2 of 7 patients; 6 of these 7 patients died after a median period of only 13 months 
(range, 6 to 46 months). The remaining patient is alive and well more than 10 years after 
autologous bone marrow transplantation. 
Skin lesions developed in the other 4 patients 5 to 108 months (median, 53 months) after 
the diagnosis of systemic CD30+ ALCL was made. The ages of these patients (15, 24, 60, 
and 70 years) also suggested a bimodal age distribution. Treatment consisted of multiagent 
chemotherapy (3 patients) or radiotherapy at multiple sites (1 patient). Only 1 of 4 patients 
achieved complete remission. Two patients died 10 and 26 months after the development of 
skin lesions (63 and 132 months after initial diagnosis), the other 2 are alive 43 and 131 months 
after the development of skin lesions (48 and 185 months after initial diagnosis). 
DISCUSSION 
In the current study, clinical and histologic variables of a major group of 219 cutaneous 
CD30+ lymphoproliferations were evaluated. The primary goals of this analysis were a critical 
evaluation of our current diagnostic and therapeutic approaches and a definition of potential 
risk factors for tumor progression. Relevant features of the different groups of cutaneous 
CD30+ lymphomas are discussed, and guidelines for correct diagnosis and treatment are 
presented. 
Primary cutaneous CD30+ large T-cell lymphoma 
Primary cutaneous CD30+ LTCL predominantly affected adults but rarely affected children 
(see below). They generally appeared as solitary or localized skin lesions (78%), they had 
the tendency to regress spontaneously, they frequently relapsed on the skin (41%) but 
uncommonly disseminated to extracutaneous sites (10%), and their prognosis was excellent 
with 5- and 10-year disease-related survival rates exceeding 95%. These findings confirm and 
extend the results of previous studies on smaller groups of patients.5-11 
Risk factors predicting tumor progression or dissemination could not be found. This may 
be related to the small number of patients in whom extracutaneous disease developed (8 of 
79 patients) and the small number of tumor-related deaths (4 of 79 patients). No differences 
in survival rates for patients with lymphoma with or without typical anaplastic morphology 
were found. However, CD30+ LTCL with an LyP-like histology (few CD30+ cells) more 
often showed complete spontaneous remission (50%) than CD30+ LTCL with large clusters 
of CD30+ anaplastic (29%) or nonanaplastic cells (28%). Neither extent of skin lesions 
(solitary or localized vs multifocal skin lesions) nor age was significantly related to survival. 
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Interestingly, the group of patients with CD30+ LTCL with skin lesions and only 1 involved 
draining lymph node station (group 3) had the same clinical features (presentation with 
solitary or localized skin lesions, no bimodal age distribution, good response to therapy) 
and a similarly good prognosis as the group with primary cutaneous CD30+ LTCL. Recent 
studies demonstrated that systemic CD30+ anaplastic large-cell lymphomas expressing ALK 
have a much better prognosis than ALK-negative lymphomas (5-year survival rates, 93% vs 
37%).26 Immunohistochemical studies of 5 patients in group 3 demonstrated an ALK, EMA, 
CLA+ immunophenotype in each of them. As a comparison, the results of ALK staining in 28 
other patients showed a positive reaction in 3 of 4 patients with secondary cutaneous CD30+ 
LTCL but not in 15 patients with primary cutaneous CD30+ LTCL, and they showed neither 
in 9 patients with LyP.17 The favorable prognosis for our group 3 patients cannot simply be 
attributed to the fact that 9 of 11 patients were treated with systemic chemotherapy. If this were 
representative of skin localizations of an ALK-negative systemic lymphoma, a less favorable 
outcome would have been expected for this group. Our clinical and immunohistochemical 
observations suggest rather that these patients are in fact patients with primary cutaneous 
FIGURE 6. Survival 
curve of different 
groups of primary 
and secondary 
cutaneous CD30
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CD30+ LTCL with (early) dissemination to the regional lymph nodes. 
Major differences were found between the above-mentioned groups and patients with 
systemic CD30+ anaplastic large T-cell lymphomas with concurrent or secondary skin 
involvement. These patients more often sought treatment for generalized skin lesions. They had 
a bimodal age distribution, poor responses to often intensive treatment, and poor prognoses, 
with 5-year-survival rates of 44% after diagnosis and 23% after the development of skin 
lesionssuggesting that the appearance of skin lesions in CD30+ ALCL is a poor prognostic 
sign.11 
Therapy
In patients with a solitary or few localized nodules or tumors, local radiotherapy is the first 
choice of treatment. However, follow-up data indicate that if the lesion has been excised 
completely or has disappeared spontaneously, no further therapy is required. If a skin lesion 
relapses, spontaneous resolution can be awaited for some weeks or the patient can undergo 
radiotherapy or surgical excision. According to our existing guidelines formulated in 1991, 
patients with multifocal skin lesions should be treated with doxorubicin-based multiagent 
chemotherapy. However, only 7 of 17 patients with multifocal skin lesions in this study had 
ever been treated with systemic chemotherapy. More important, all patients who were treated 
with CHOP courses because of multifocal skin lesions (6 of 7 patients) had 1 or several skin 
relapses afterward. Moreover, in 3 of these 17 patients, all initial skin lesions disappeared 
spontaneously. Unlike LyP lesions, however, relapse did not occur during the 32- to 72-month 
follow-up. These observations suggest that multifocal skin-restricted CD30+ LTCL should 
not be treated routinely with multiagent chemotherapy. If spontaneous regression does not 
occur, these patients can best be treated with radiotherapy for a few lesions or with low-dose 
methotrexate as for LyP.20,27 In patients with full-blown or developing regional lymph node 
involvement, multiagent chemotherapy is still considered the safest option. However, skin 
relapses after chemotherapy are common, but they are not associated with an aggressive 
clinical behavior and therefore do not require an aggressive approach. Moreover, complete 
spontaneous resolution of skin and lymph node localizations may occur. In such patients an 
expectative approach seems justified. 
Lymphomatoid papulosis 
In this very large group of patients with LyP with a median follow-up of 77 months and of 
29 patients with a follow-up of more than 10 years, 23 of 118 patients (19%) had associated 
malignant lymphoma either before, after, or concurrent with LyP. However, only 7 of 118 had 
extracutaneous disease, and only 2 of 118 patients died of systemic lymphoma. The calculated 
risk for systemic lymphoma within the first 10 or 15 years after diagnosis was 4% and 12%, 
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respectively, in contrast with the 80% at 15 years in a study of Cabanillas et al.21 However, in 
that study, only patients with LyP who had initially been misdiagnosed or had another type 
of malignant lymphoma were included, suggesting that the striking difference between both 
studies results from differences in patient selection. As in earlier studies on smaller groups of 
patients,25,28,29 risk factors for disease progression could not be found. 
Therapy
Because a curative therapy is unavailable and none of the available treatment modalities 
affects the natural course of the disease, the short-term benefits of active treatment should be 
balanced carefully against the potential side effects.5,20 We believe that in patients with relatively 
few and nonscarring lesions, active treatment is not necessary. In patients with cosmetically 
disturbing lesions (eg, scarring lesions or many lesions), low-dose oral methotrexate (5 to 
20 mg/wk) or PUVA therapy can be administered to reduce skin lesions.20,27,30 When larger 
skin tumors develop in the course of LyP, spontaneous remission can be awaited for 4 to 6 
weeks. If spontaneous resolution does not occur, such lesions can be excised or treated with 
radiotherapy. Whether such isolated skin tumors developing in the course of LyP should be 
considered progression to CD30+ LTCL is debatable. 
Primary cutaneous CD30+ lymphoproliferations in children
Of the 12 children with LyP in this study, 3 had large, rapidly growing ulcerating lesions 
in addition to papular lesions. Because of this distressing clinical presentation suggesting 
aggressive lymphoma, multiagent chemotherapy was first considered in all 3 children. However, 
because the histologic appearance was highly suggestive of LyP and staging procedures 
did not show any evidence of extracutaneous disease, it was decided to wait for several 
weeks. In all 3 patients the larger skin lesions disappeared completely within 2 to 3 months, 
whereas the papular lesions continued to develop. This illustrates that the physician should 
be cautious before using aggressive chemotherapy to treat children with skin-limited CD30+ 
lymphoproliferations because they often simply have LyP (12 of 13 patients younger than 20 
in this study). A short period of watchful waiting is warranted and may avert unnecessary 
treatment. Previous studies also report an indolent course for children with LyP.28,31,32 
Guidelines for diagnosis, management, and treatment 
The central problem in the correct diagnosis and classification of this group of diseases is 
that there are no reliable histologic criteria to differentiate between the different types of 
primary and secondary cutaneous CD30+ lymphoproliferations. Patients with cutaneous 
CD30+ LTCL may show an LyP-like histology, whereas patients with the characteristic 
clinical presentation and clinical behavior of LyP may show large sheets of CD30+ cells 
with only few infiltrating reactive cells (LyP, type C). Consequently, the histologic diagnosis 
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should always be considered as a differential diagnosis and should never serve as a basis for 
therapeutic decisions. The definite diagnosis should always be based on a combination of 
histological and clinical criteria. This diagnostic process involves 2 steps (FIGURE 7). The first 
and most important question is whether it is a primary or a secondary cutaneous CD30+ 
lymphoproliferation. The second question is whether it is LyP or primary cutaneous CD30+ 
LTCL. 
Step 1: primary or secondary cutaneous CD30+ lymphoma?
Confronted with a patient with the histologic diagnosis of a cutaneous CD30+ 
lymphoproliferation, distinctions should first be made among primary cutaneous CD30+ 
lymphoproliferation, cutaneous CD30+ lymphoma secondary to MF (or another type of 
CTCL), and skin localizations of a systemic CD30+ (anaplastic) LTCL. Cutaneous CD30+ 
lymphomas secondary to MF can generally be recognized easily because of the presence of 
prior or concurrent patches or plaques with the typical histology of MF. If no extracutaneous 
disease can be demonstrated, patients can be treated routinely as for tumor-stage MF, 
primarily with skin-directed therapies such as local radiotherapy or total skin electron 
beam irradiation. Patients with skin and extracutaneous localizations require multiagent 
chemotherapy and generally have an unfavorable prognosis. MF with transformation into a 
FIGURE 7. Algorithm 
for the diagnosis 
and treatment of 
cutaneous CD30
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CD30+ LTCL should not be confused with MF with concurrent LyP, a combination observed 
in 9% of patients with LyP (current study) and in approximately 3% of patients with MF33 
and carrying, almost without exception, a very good prognosis.25,33,34 
To exclude secondary cutaneous CD30+ (anaplastic) LTCL, we suggest adequate staging in 
all patients with cutaneous CD30+ lymphoproliferation. An exception is made for patients 
with clinical and histologic features characteristic of LyP in whom meticulous physical 
examination suffices.20 
Step 2: management of primary cutaneous CD30+ lymphoproliferations.
Previous studies emphasize the many similarities between primary cutaneous CD30+ LTCL 
and LyP, suggesting that these are closely related conditions within a continuous spectrum.4,5 
Distinction between these 2 ends of the spectrum was considered important because patients 
with CD30+ LTCL were thought to be at much higher risk for extracutaneous disease than 
patients with LyP and, unlike patients with LyP, always required adequate staging and even 
systemic chemotherapy if they had multifocal skin lesions.5,11 However, the results of the 
current study suggest that the differences in disease progression and survival between both 
groups are smaller than anticipated previously (TABLE 2). In addition, skin relapses after 
systemic chemotherapy were not only observed in patients with LyP but also in all patients 
with skin-limited CD30+ LTCL,22 which argues against the use of systemic chemotherapy for 
patients with only skin lesions. Taken together, our observations indicate that the choice of 
treatment should be based above all on the size, the extent, and the clinical behavior of the 
skin lesions and not as much on the diagnosis of CD30+ LTCL or LyP (FIGURE 6). 
Following this approach, distinction is first made between patients with a solitary or few 
localized nodules or tumors and patients with multifocal skin lesions. The term localized refers 
to a few clustered lesions restricted to 1 anatomic area generally not exceeding 15 × 15 cm. 
These primary cutaneous CD30+ LTCL may show spontaneous resolution, either partial 
or complete, but they do not wax and wane as do LyP lesions. As discussed before, local 
radiotherapy is the first choice of treatment. Most patients with multifocal skin lesions have 
LyP. Characteristically, skin lesions wax and wane, and skin lesions coexist in different stages 
of evolution. These include early small red papules, fully developed papules or nodules with 
or without central ulceration, brown-red disappearing lesions, residual lesions, and sometimes 
residual scars. Complete disappearance of every single lesion, irrespective of the appearance 
of new lesions, is a prerequisite. Most patients do not require any specific treatment. If a 
patient has cosmetically disturbing lesions, low-dose oral methotrexate (5 to 20 mg/wk) or 
PUVA therapy may be considered. Multifocal skin lesions that do not wax and wane as in 
LyP are less common. Nevertheless, skin lesions in these multifocal primary cutaneous CD30+ 
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LTCL may also show partial, and sometimes even complete, spontaneous remission, which 
can often be recognized clinically by the skin lesions turning from red to brown. As discussed 
before, patients with such lesions should no longer be treated routinely with doxorubicin-
based multiagent chemotherapy because skin relapses after chemotherapy are likely to occur. 
If spontaneous remission does not occur, radiotherapy or low-dose methrotrexate is the best 
treatment if there are only a few lesions. 
In some patients with a brief history of multifocal skin lesions, the clinical behavior may still 
be unknown, and a definite diagnosis cannot yet be made. It is our experience in particular 
that such patientsnot uncommonly colleagues or close relatives are often treated with 
systemic chemotherapy. However, because extracutaneous disease has already been excluded, 
and because not only LyP but also primary cutaneous CD30+ LTCL has a low tendency to 
progress to extracutaneous disease, it is better to wait for several weeks while monitoring 
closely the natural evolution of the skin lesions. After a period of 4 to 8 weeks, a definite 
diagnosis can normally be made, and the appropriate treatment can then be selected. 
In conclusion, the results of this study confirm the indolent clinical behavior and excellent 
prognosis of a group of primary cutaneous CD30+ lymphoproliferations. Close collaboration 
between dermatologists, pathologists, and hematologists/oncologists is the best guarantee 
for a correct diagnosis and proper treatment. If a definite diagnosis cannot yet be made, an 
expectative approach seems justified. Multiagent chemotherapy is only indicated for patients 
with existent or developing extracutaneous disease. It is indicated rarely or not at all for 
patients with only skin lesions. For all patients, however, long-term follow-up is required. 
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ABSTRACT
In the present study the clinicopathologic and immunophenotypic features of 82 patients 
with a CD30– peripheral T-cell lymphoma, unspecified, presenting in the skin were evaluated. 
The purpose of this study was to find out whether subdivision of these lymphomas on the 
basis of cell size, phenotype, or presentation with only skin lesions is clinically relevant. 
The study group included 46 primary cutaneous CD30– large cell lymphomas and 17 small/
medium-sized T-cell lymphomas as well as 17 peripheral T-cell lymphomas with both skin 
and extracutaneous disease at the time of diagnosis. Patients with primary cutaneous small- 
or medium-sized T-cell lymphomas had a significantly better prognosis (5-year-overall 
survival, 45%) than patients with primary cutaneous CD30– large T-cell lymphomas (12%) 
and patients presenting with concurrent extracutaneous disease (12%). The favorable 
prognosis in this group with primary cutaneous small- or medium-sized T-cell lymphomas 
was particularly found in patients presenting with localized skin lesions expressing a 
CD3+CD4+CD8– phenotype. In the primary cutaneous T-cell lymphoma (CTCL) group and 
in the concurrent group, neither extent of skin lesions nor phenotype had any effect on 
survival. Our results indicate that peripheral T-cell lymphomas, unspecified, presenting in the 
skin have an unfavorable prognosis, irrespective of the presence or absence of extracutaneous 
disease at the time of diagnosis, cell size, and expression of a CD4+ or CD8+ phenotype. 
The only exception was a group of primary cutaneous small- or medium-sized pleomorphic 
CTCLs with a CD3+CD4+CD8– phenotype and presenting with localized skin lesions. 
INTRODUCTION
Mature or peripheral T-cell or natural killer (NK) cell lymphomas are uncommon, 
accounting for approximately 12% of all non-Hodgkin lymphomas in the Western world.1 
These peripheral T/NK-cell lymphomas frequently involve the skin, either as primary or 
as secondary manifestation of the disease. With respect to the primary cutaneous T-cell 
lymphomas (CTCLs), both in the European Organization for Research and Treatment 
of Cancer (EORTC) classification for primary cutaneous lymphoma2 and in the World 
Health Organization (WHO) classification,3 mycosis fungoides (MF), Sézary syndrome 
(SS), the group of the primary cutaneous CD30+ lymphoproliferations, and subcutaneous 
panniculitis-like T-cell lymphomas are recognized as distinct well-defined entities, which 
together constitute approximately 85% of all primary CTCLs.2 In the EORTC classification 
most cases of primary CTCL that do not belong to one of these entities are included in the 
group of CD30– large-cell CTCLs and in the provisional group of CD30– small/medium-
sized pleomorphic CTCLs. Distinction between the two categories, which is based on the 
presence of more or less than 30% large neoplastic T-cells, is considered useful because of a 
significant difference in survival between the groups.4,5 The EORTC classification does not 
include cases presenting with prior or concurrent extracutaneous disease, and it does not 
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make further distinction between cases with a CD4+ T-cell phenotype and those with a CD8+ 
T-cell phenotype, although recent studies have suggested that epidermotropic CD8+ CTCL 
with a cytotoxic phenotype should be considered as a distinct disease entity.6 In the WHO 
classification most of these CD30– large-cell and small/medium-sized pleomorphic CTCLs 
are classified as peripheral T-cell lymphomas (PTLs), unspecified, and rare cases as extranodal 
T/NK-cell lymphoma, nasal-type. In the group of PTLs, unspecified, no further subdivision 
is made by site of presentation (eg, distinction between primary and secondary cutaneous 
involvement), cell size, or phenotype. 
In ongoing attempts to evaluate the clinical usefulness of the EORTC and WHO classifications, 
we evaluated the clinicopathologic features of 82 patients with PTL, unspecified, presenting 
in the skin. The primary goal of this study was to find out whether subdivision of these 
lymphomas on the basis of cell size, phenotype, or presentation with or without concurrent 
extracutaneous involvement is clinically and prognostically relevant. 
PATIENTS AND METHODS
Patient selection
Between October 1985 and December 1999, a total of 883 patients with skin manifestations 
of a T/NK-cell lymphoma were included in the registry of the Dutch Cutaneous Lymphoma 
Group (Figure 1). For this study 3 groups of patients were selected for further evaluation: 
patients with primary cutaneous CD30– large T-cell lymphoma (n = 49), patients with 
primary cutaneous CD30– small/medium-sized pleomorphic CTCL (n = 26), and a group 
of 18 patients with both cutaneous and extracutaneous involvement of a CD30– T-cell 
lymphoma at the time of first diagnosis. Nine patients with history of a primarily noncutaneous 
T/NK-cell lymphoma—including 5 patients with a nasal T/NK-cell lymphoma, 3 with an 
angioimmunoblastic T-cell lymphoma (AITL), and 1 with a nodal PTL, unspecified—who 
developed specific skin lesions during follow-up were not included in this study. 
The 2 groups of primary CTCLs were defined according to the criteria of the EORTC 
classification.2 In all cases adequate staging procedures, including physical examination, 
complete blood cell counts, computed tomography of chest and abdomen, and a bone marrow 
biopsy, had failed to demonstrate extracutaneous disease at time of diagnosis. The third group 
of patients, who also presented with skin lesions but after staging appeared to have also 
extracutaneous disease at the time of first diagnosis, was included to find out whether patients 
presenting with skin-limited disease had a better prognosis. These cases do not represent 
primary CTCLs and are not included in the EORTC classification. Following the criteria of 
the WHO classification, all 93 patients were classified as having PTL, unspecified.3 
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In all cases the clinical records and the results of routine histology and immunostaining 
performed at diagnosis were reviewed. In cases in which the original paraffin blocks were 
available, additional staining was performed using antibodies against CD3, CD4, CD8, 
CD20, CD79a, CD30, CD56, CD68, TIA-1, and granzyme B, if not performed previously. 
Biopsy samples of all cases were re-evaluated at a multiheaded microscope by 3 expert 
(dermato)pathologists (C.J.L.M.M., P.M.K., R.W.) and a consensus diagnosis was reached. 
From the initial study group of 93 cases, 11 cases were excluded: 2 patients because of 
insufficient follow-up data, 3 patients with unavailable or uninterpretable histology, and 
6 patients in whom after thorough clinical and histologic review a diagnosis of MF was 
considered more likely. The final study group consisted of 82 cases. 
FIGURE 1. Patients with 
cutaneous T/NK-cell 
lymphomas included 








with T-cell leukemia 
(n - 4), HIVrelated 
CTCL (n - 2), adult 
T-cell lymphoma/
leukemia (n - 2), 
and T-lymphoblastic 
lymphoma (n 
- 1). #Numbers in 
parentheses denote 
number of patients 
included in this study.
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In all cases the diagnosis of T-cell lymphoma was based on demonstration of mature, although 
often incomplete, T-cell phenotype, including expression of surface CD3 (sCD3) as assessed 
by a positive membrane staining with monoclonal antibody Leu-4 on frozen sections in all 
but 7 cases. Staining for CD30 antigen was completely negative in most cases, expressed by 
few (< 5%) scattered neoplastic cells in some cases, and weakly expressed by approximately 
25% of the neoplastic T-cells in one case. 
Statistical analysis
Variables analyzed for prognostic value were as follows: age at diagnosis; sex; extent of skin 
lesions at presentation (ie, single or localized [a solitary or multiple skin lesions restricted to 
one anatomic region] vs “multifocal” [2 or more anatomic regions involved]); the presence of 
extracutaneous disease at the time of diagnosis; occurrence of spontaneous resolution; type 
of therapy (multiagent chemotherapy vs radiotherapy vs monoagent chemotherapy vs no 
or only palliative skin-directed therapies such as psoralen and ultraviolet A [PUVA], topical 
steroids, and excision); tumor cell size (more vs less than 30% large neoplastic T-cells); and 
phenotype (CD3+CD4+CD8– phenotype vs CD3+CD4–CD8+ phenotype vs CD3+CD4–
CD8– phenotype vs CD3+CD4+CD8+ phenotype). Disease-free survival (DFS) was calculated 
as the time of relapse or disease-related death after reaching a complete remission. Cases that 
did not reach remission were excluded; patients without a relapse or death unrelated to 
lymphoma were censored. Survival duration was calculated from time of diagnosis to date of 
death or censoring. Overall survival was estimated using the method of Kaplan and Meier.7 
For overall survival analysis, deaths were taken into account whatever the cause. Prognostic 
factors in the entire group were evaluated by overall survival univariate and multivariate 
analyses using a Cox proportional hazards model. Factors significant at the .1 level in 
univariate analysis were included in a stepwise regression multivariate analysis. Comparisons 
between different subgroups of patients were performed using the 2 of Fisher exact test for 
categorical variables (cross-table) or the Mann-Whitney test for continuous variables and log 
rank for survival data. For statistical analysis the software package for social sciences (SPSS 
10.0; SPSS, Chicago, IL) was used. 
RESULTS
Characteristics of the total group of 82 patients with PTL, unspecified
Clinical features
The clinical characteristics and follow-up data of the total group of 82 patients are summarized 
in TABLE 1. The total group included 50 males and 32 females (male-female ratio, 1.6:1), with 
a median age of 68 years (range, 8-87 years). The duration of skin lesions prior to diagnosis 
varied between 1 and 100 months, but was usually short (median, 6 months). Most patients 
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presented with nodular or tumorous skin lesions, which were either solitary (21 of 82 [26%]), 
localized (11 of 82 [13%]), or multifocal (50 of 82 [61%]). Partial (n = 10) or even complete 
(n = 3) spontaneous disappearance of skin lesions had been noted in 13 of the 82 patients. 
Initial therapy was variable, but consisted in most cases of doxorubicin-based systemic 
chemotherapy, radiotherapy, or a combination of both. In general, radiotherapy was the first 
choice of treatment in patients presenting with only localized skin lesions, whereas patients 
presenting with multifocal skin lesions or with concurrent cutaneous and extracutaneous 
disease were treated with doxorubicin-based chemotherapy with or without additional 
radiotherapy. Complete remission was achieved in 22 (71%) of 31 patients treated with 
radiotherapy and in 10 (28%) of 36 patients treated with doxorubicin-based chemotherapy. 
However, complete remissions were generally short-lived. The median DFS for complete 
responders was only 8 months (95% confidence interval [CI], 2-14 months). No correlation 
between initial type of treatment and clinical outcome was detected. 
After a median follow-up of 19 months (range, 1-179 months) 60 patients (73%) had died of 
lymphoma and 9 (11%) had died of unrelated disease, whereas only 13 patients were alive, 
with (n = 1) or without (n = 12) lymphoma. The overall 5-year survival was 20% (TABLE 1). 
Histologic features
Histologically, these lymphomas showed considerable variation. On the basis of the 
cytomorphology of the neoplastic cells, most cases would have been classified as pleomorphic 
T-cell lymphoma in the updated Kiel classification.8 A minority showed a monotonous 
proliferation of blasT-cells with the appearance of immunoblasts, in 2 cases even resembling 
large anaplastic T-cells, but with negative CD30 staining in repetitive stainings. Based on 
the presence of more or less than 30% large cells within the tumor population, 57 cases 
were classified as large-cell and 25 cases as small- or medium-sized-cell lymphoma. There 
was a variable admixture with small lymphocytes and histiocytes, and less commonly with 
eosinophils and plasma cells. Considerable numbers of admixed B-cells (5%-10%) were 
observed in 6 biopsies. 
With respect to the architecture of the neoplastic infiltrates, these were either diffuse 
(49%), nodular (33%), or band-like (18%). Pronounced epidermotropism was observed in 
27% of cases, with no significant differences between the different subgroups. In 3 cases 
there was extensive infiltration of the follicular epithelium. Angiocentricity with marked 
angiodestruction was observed in 8 cases; 5 of these 8 cases belonged to the group of primary 
cutaneous small/medium-sized pleomorphic T-cell lymphomas. 
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Immunophenotype
The phenotypes of the neoplastic T-cells in all 82 cases are summarized in TABLE 2. A CD3+/
CD4+/CD8– phenotype was observed in 59 cases, a CD3+/CD4–/CD8+ phenotype in 12 
cases, a CD3+/CD4–/CD8– phenotype in 9 cases, and a CD3+/CD4+/CD8+ phenotype in 
2 cases. Coexpression of CD56 was noted in 3 cases. Expression of TIA-1 by more than 
50% of the neoplastic cells was observed in 17 of 55 cases tested, including 5 (13%) of 38 
cases with a CD3+/CD4+/CD8– phenotype and 8 (89%) of 9 cases with a CD3+/CD4–/
CD8+ phenotype. Granzyme B was always expressed by a minor proportion of the TIA-1+ 
neoplastic T-cells, except for 2 cases with a CD3+/CD4–/CD8+ and a CD3+/CD4–/CD8– 
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phenotype, respectively, showing expression of both TIA-1 and granzyme B by more than 
75% of the neoplastic T-cells. 
Prognostic factors in the total group of 82 patients
Univariate and multivariate analyses of overall survival were performed on the total group 
of 82 patients to identify independent prognostic risk factors. Univariate analysis showed 
that the following variables were 
adversely related to survival: 
concurrent extracutaneous disease 
at diagnosis (P = .0004), large cell 
size (P = .003), lack of spontaneous 
resolution (P = .004), age older 
than 70 years at diagnosis 
(P = .02), male sex (P = .05), 
and presentation with multifocal 
lesions (P = .005). Therapy 
(P = .19) was not significantly 
related to survival. Multivariate 
analysis showed that concurrent 
extracutaneous disease (relative 
risk [RR] = 3.5; 95%CI,1.9-6.8), 
large cell morphology (RR = 3.1; 
95%CI, 1.7-5.7), presentation 
with multifocal lesions (RR =  2.3; 95%CI, 1.4-4.0), age older than 70 years (RR = 2.1; 
95%CI, 1.3-3.6), and absence of spontaneous resolution of skin lesions (RR = 2.6; 95%CI, 
1.1-5.9) were independent prognostic factors (TABLE 3). Kaplan-Meier overall survival and 
DFS curves of different subgroups are shown in FIGURE 2A and 2B, respectively. 
Subgroup analysis
Since multivariate analysis demonstrated both cell size and the presence of extracutaneous 
disease at the time of diagnosis as the most significant prognostic parameters, the main 
features of the group of primary cutaneous CD30– large T-cell lymphomas, the group of 
promotie.indb   56 18-01-2005   21:53:16
chapter 3  page 57
PERIPHERAL T-CELL LYMPHOMAS UNSPECIFIED PRESENTING IN THE SKIN: ANALYSIS OF PROGNOSTIC FACTORS IN A GROUP OF 82 PATIENTS.
primary cutaneous small/medium-sized pleomorphic T-cell lymphomas, and the group of 
peripheral T-cell lymphomas presenting with both cutaneous and extracutaneous disease 
will be described below. The main clinical features and the results of phenotyping of these 
3 groups are summarized in TABLES 1 and 2, respectively.
Primary cutaneous CD30– large T-cell lymphomas (n = 46)
This group included 33 males and 13 females (male-female ratio, 2.5:1), with a median age of 
68 years (range, 20-87 years). Although most patients presented with multifocal skin lesions 
(27 of 46 patients [59%]), a significant proportion had either a solitary lesion (15 of 46 patients 
FIGURE 2. Overall 
and disease-free 
survival curves. (A) 
Overall survival 
curves of different 
groups of patients 
with peripheral T-cell 
lymphomas presenting 
in the skin (n 
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[33%]) or localized skin lesions (4 of 46 patients [9%]) at presentation, which explains the 
relatively high number of patients treated with radiotherapy in this group (TABLE 1). 
Following initial treatment, complete remission was achieved in only 21 (45%) of 46 patients, 
including 12 (63%) of 19 patients treated with radiotherapy and 5 (27%) of 18 patients treated 
with doxorubicin-based chemotherapy. The median overall survival for patients treated with 
radiotherapy was 28 months (95% CI, 12-44 months); the DFS for this group was 6 months 
(95% CI, 0-18 months). For patients treated with systemic chemotherapy, the median overall 
survival was 16 months (95% CI, 10-22) and DFS was 10 months (95% CI, 0-25 months). 
With respect to the extent of skin disease, complete remission following initial treatment was 
observed in 21 of 46 patients, including 13 (86%) of 15 patients with a solitary lesion, but 
only 1 (25%) of 4 patients with localized lesions and 7 (26%) of 27 patients presenting with 
multifocal lesions. 
However, no difference in overall survival was found between patients with localized 
disease (median, 24 months; 95% CI, 13-35 months) and patients with multifocal disease 
(median, 21 months; 95% CI, 13-29 months). In patients presenting with a solitary tumor, 
radiotherapy (11 cases) and doxorubicin-based chemotherapy (4 cases) showed similar 
complete response rates (72% vs 75%), median DFS rates (6 months, 95% CI, 10-28 months 
vs 10 months, 95% CI, 10-24 months), and overall 5-year-survival rates (24% vs 25%). 
These data illustrate that most patients presenting with solitary or localized skin lesions 
rapidly developed generalized skin lesions and/or systemic disease. After a median follow-up 
of 21 months (range, 1-118 months), 42 patients had died (37 patients of lymphoma and 
5 of an unrelated disease), whereas only 4 were still alive and in complete remission, 20, 
31, 89, and 118 months after diagnosis. One of these 4 patients presented with a solitary 
nodule on the right shoulder, histologically characterized by the presence of a monotonous 
proliferation of CD3+CD4+CD8– blasT-cells with prominent eosinophilic nucleoli, suggesting 
a CD30+ anaplastic large T-cell lymphoma, but with negative CD30 stainings on 3 different 
(follow-up) biopsies. Another patient presented with a solitary tumor on the trunk, in which 
approximately 25% of the CD3+CD4+ large pleomorphic T-cells expressed CD30. Both 
patients had initially been treated with radiotherapy. The other 2 patients had presented 
with multifocal skin lesions, which had disappeared spontaneously in one of them. Five-year 
overall survival in this group of 46 patients was 12%. 
Statistical analysis showed no significant difference (P = .98) in overall survival between the 
34 patients with a CD3+CD4+CD8– phenotype (median survival, 21 months; 95% CI, 11-31 
months) and the 6 patients with a CD3+CD4–CD8+ phenotype (median survival, 28 months; 
95% CI, 14-42 months; TABLE 4). 
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Primary cutaneous small/medium-sized cell CD30– pleomorphic T-cell 
lymphoma
This group included 6 men and 13 women, with a median age of 69 years (range, 45-87 
years). Ten patients presented with multifocal skin lesions, 5 with localized disease, and only 
4 with a solitary lesion. In a relatively large proportion of patients (32%), partial (4 cases) or 
even complete (2 cases) spontaneous clearing of the skin lesions was noted. 
Histologically, 5 of 19 patients showed marked angiocentricity and angiodestruction. 
Previous studies on this group, including 3 cases with a CD4+ phenotype and 2 cases with a 
CD8+ phenotype, had shown that they were Epstein-Barr virus (EBV)–negative.9 In the whole 
group, 13 cases (68%) had a CD3+CD4+CD8– phenotype; 4 cases (21%), a CD3+CD4–
CD8+ phenotype; and 2 cases (10%), a CD3+CD4–CD8– phenotype (TABLE 2). 
Following initial treatment, 12 (63%) of 19 patients reached a complete remission, 
including 10 (83%) of 12 treated with radiotherapy and 2 (40%) of 5 patients treated 
with doxorubicinbased chemotherapy. The median DFS for the complete responders was 
58 months (95% CI, 0-120 months). After a median follow-up of 47 months (range, 9-120 
months), 8 patients had died of lymphoma, 3 had died of unrelated disease, and 8 were alive 
with (n = 1) or without (n =7) lymphoma. Overall 5-year survival was 45%. Univariate 
and multivariate analysis for overall survival showed that patients presenting with localized 
disease had a better prognosis (P = .03). Overall median survival was significantly better in 
patients with localized disease (median survival not reached) than in patients presenting with 
multifocal skin lesions (median survival, 54 months; 95% CI, 22-88 months). Patients with a 
CD4+ phenotype tended to have a better prognosis, but this was only borderline statistically 
significant (P = .05). Owing to the small number of patients, the significance of these findings 
should be considered with caution. Nevertheless, 6 of the 7 patients presenting with solitary 
or localized skin lesions and having a CD3+/CD4+ phenotype are alive at the time of writing, 
as compared with 2 of 12 of the remaining cases in this group. 
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Taken together, patients with a primary cutaneous CD30– small/medium-sized pleomorphic 
T-cell lymphoma had a much better prognosis than did patients with a primary cutaneous 
CD30– large T-cell lymphoma. However, this favorable prognosis appears to be restricted to 
patients with a CD4+ lymphoma with solitary or localized skin lesions. 
PTL, unspecified, presenting with both cutaneous and extracutaneous 
disease
This group contained 6 cases with a predominance of small/medium-sized neoplastic T-cells 
and 11 cases with a predominance of large neoplastic T-cells. Statistical analysis did not 
reveal significant differences between the 2 groups (data not shown). The results for the total 
group of 17 patients (11 males and 6 females, with a median age of 65 years [range, 8-85 
years]) are presented in Table 1. Most (13) of the 17 patients presented with multifocal skin 
lesions. Concurrent extracutaneous disease at presentation involved lymph nodes (14 cases), 
bone marrow (2 cases), peripheral blood (2 cases), oropharynx (2 cases), central nervous 
system (CNS; 1 case), and lung and adrenal glands (1 case). 
Initial treatment, which consisted of multiagent chemotherapy in 13 of 17 patients, resulted 
in a complete remission in only 3 of 17 cases; 8 patients showed a partial response. The 
prognosis is clearly worse in this group than in the primary cutaneous CD30– groups 
(P < .0001). After a median follow-up period of 8 months (range, 1-179 months), 15 patients 
had died of lymphoma and one of unrelated disease, whereas only one patient was still alive 
after a follow-up of 179 months. The overall 5-year survival was 12%. 
DISCUSSION
In the present study, 82 patients with a PTL, unspecified, with skin lesions as first manifestation 
of the disease were evaluated. The goal of this study was to find independent parameters 
of survival in this heterogeneous group of lymphomas. More specifically, we wondered if 
presentation with only skin lesions, the extent of skin lesions, cell size, or the presence of a 
CD4+ or CD8+ T-cell phenotype had any effect on survival. 
Considering the whole group, these patients appeared to have a poor prognosis, with an 
overall survival at 5 years of 20%, which is consistent with the results of previous studies.10-12 
It was found that primary cutaneous -small/medium-sized T-cell lymphomas had a much better 
prognosis than primary cutaneous CD30– large T-cell lymphomas and patients presenting 
with both cutaneous and extracutaneous disease. The difference in survival between primary 
cutaneous large-cell and small/medium-sized-cell lymphomas is consistent with the results of 
previous studies.4,5 A new finding in the present study was that this favorable prognosis was 
observed only in cases with a CD3+CD4+CD8– phenotype and presenting with solitary or 
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localized skin lesions. Five of 6 patients in this small subgroup were still alive, compared with 
8 of 76 patients who did not belong to this group. 
Primary cutaneous CD30– small/medium-sized pleomorphic T-cell lymphoma is a diagnosis 
by exclusion. Confronted with a CTCL with a neoplastic infiltrate showing a predominance of 
small- to medium-sized pleomorphic T-cells, the clinician should exclude diagnoses of tumor 
stage MF, SS, lymphomatoid papulosis, subcutaneous panniculitis-like T-cell lymphoma, and 
pseudo–T-cell lymphoma. Particularly, differentiation from (tumor stage) MF and pseudo–
T-cell lymphomas may be difficult, and requires detailed analysis of clinical, histologic, and 
immunophenotypic data.13-15 In this study, 4 cases originally diagnosed as small/medium-sized 
pleomorphic CTCL were excluded, since in retrospect a diagnosis of MF was considered 
more likely. Pseudo–T-cell lymphomas characteristically present with a solitary plaque or 
nodule. Additional criteria favoring a pseudo–T-cell lymphoma include lack of an aberrant 
T-cell phenotype, lack of clonality, and a considerable admixture with reactive CD8+ T-cells, 
B-cells, and histiocytes.13,14 In a recent EORTC workshop on primary cutaneous small/
medium-sized pleomorphic T-cell lymphomas, the large majority of submitted cases concerned 
patients presenting with a solitary lesion, which also proved to have an excellent prognosis 
(J. Wechsler, manuscript in preparation). 
After exclusion of the small subgroup of CD3+CD4+CD8– small/medium-sized pleomorphic 
CTCLs with solitary or localized skin lesions, neither presentation with skin-limited disease, 
cell size, extent of skin lesions at presentation, nor phenotype had any significant effect on 
survival. All subgroups had a poor prognosis, with a median overall survival of 28 months 
or less (TABLE 4). 
From a clinical point of view it is important to note that, apart from the group of primary 
cutaneous small/medium-sized CD4+ T-cell lymphomas, patients presenting with a solitary 
skin lesion or a few localized skin lesions had no better survival than patients presenting with 
multifocal skin lesions. In the group of primary cutaneous CD30– large T-cell lymphomas, 
which comprised 46 of 82 patients, the median overall survival for patients presenting with 
solitary, localized, or multifocal skin lesions was 24, 12, and 21 months, respectively. These 
observations illustrate that patients presenting with solitary or localized skin lesions almost 
without exception rapidly develop widespread disease. 
The results of the present study also indicate that current treatment strategies in these PTLs, 
unspecified, are not effective, which is in agreement with the results of previous studies.10-12 
Comparison of the type of treatment between survivors and nonsurvivors did not show major 
differences. In the group of 13 survivors, which included 9 patients presenting with only 
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solitary or localized skin lesions, 8 patients had been treated with radiotherapy and only 3 
with doxorubicin-based chemotherapy. Following the guidelines of the Dutch Cutaneous 
Lymphoma Group, most patients with only solitary or localized skin lesions at presentation 
were treated with radiotherapy, whereas patients presenting with multifocal skin lesions or with 
concurrent cutaneous and extracutaneous disease were generally treated with doxorubicin-
based chemotherapy (CHOP [cyclophosphamide, doxorubicin, vincristine, and prednisone] or 
CHOP-like courses), with additional radiotherapy in some cases. Initial radiotherapy resulted 
in a complete remission in 22 (71%) of 31 patients. However, these complete remissions 
were generally short-lived, requiring additional multiagent chemotherapy soon afterward. In 
general, a beneficial effect of radiotherapy may be expected only in the subgroup of primary 
cutaneous CD3+/CD4+ small/medium-sized pleomorphic CTCLs presenting with solitary 
or localized skin lesions. The results of doxorubicin-based chemotherapy were equally 
disappointing, both in patients presenting with solitary or localized disease and in patients 
presenting with multifocal skin lesions or with concurrent extracutaneous disease. Complete 
remission was observed in only 10 (28%) of 36 patients, and the median DFS for complete 
responders was only 3 months (95% CI, 0-15 months). Recent studies suggest that more 
intensive regimens are also not effective in these PTLs, unspecified.10,11 Two patients in the 
present study were treated with intensive chemotherapy followed by autologous bone marrow 
transplantation, but they also experienced relapses and died of lymphoma (12 and 49 months 
after transplantation). It is fair to conclude that it is as yet unknown how such patients with a 
PTL, unspecified, can best be treated. Because of the inefficacy of current standard regimens, 
new therapies should be investigated in prospective trials. 
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ABSTRACT
Background
To define prognostic parameters and guidelines for diagnosis and treatment for CD56+ 
lymphomas and leukemias with first presentation in the skin.
Patients and Methods
The studygroup included 153 cases (23 new and 130 from literature). According to the 
WHO classification the group included 15 nasal and 38 nasal-type NK/T-cell lymphomas, 63 
blastic NK-cell lymphomas, 14 cutaneous CD30+ lymphoproliferations, 10 cases of myeloid 
leukemia, 6 cases of subcutaneous panniculitis-like T-cell lymphoma and 7 peripheral T-cell 
lymphomas, unspecified.
Results
In general these CD56+ lymphomas/leukemias had a poor prognosis with only 27% of patients 
alive after a median follow-up of 12 months. The median survival was 13 months. Nasal and 
nasal-type NK/T-cell lymphomas and CD56+ SCPLTCL, had the worst prognosis with a 
median survival of 5, 6 and 5 months, respectively. Only nasal-type NK/T-cell lymphomas 
presenting with only skin lesions had a somewhat better prognosis (median survival, 27 
months). In blastic NK-cell lymphomas (median survival, 14 months), age ≤ 40 years, 
aggressive treatment with acute leukemia protocols and high TdT expression were associated 
with a more favorable prognosis. Striking similarities in histology, immunophenotype, 
clinical presentation and clinical behavior were found between blastic NK-cell lymphomas 
and CD56+ myeloid leukemias. 
Conclusion
CD56+ lymphomas/leukemias presenting in the skin have a poor prognosis except for 
primary cutaneous CD30+ lymphoproliferations. The striking similarities between blastic 
NK-cell lymphomas and CD56+ myeloid leukemias presenting in the skin provide a rationale 




The availability of monoclonal antibodies against CD56 that are active in paraffin sections 
has resulted in the recognition of a subgroup of cutaneous lymphomas derived from natural 
killer (NK) cells or NK-like T-cells. CD56 or neuronal-cell adhesion molecule (N-CAM) 
is a 175 to 185 kd surface glycoprotein involved in cell adhesion and migration, which is 
expressed on all NK-cells and subsets of CD4+ and CD8+ T-cells and monocytes.1 
These CD56+ T/NK-cell lymphomas preferentially present at extranodal sites, not 
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uncommonly the skin, and almost without exception have an extremely poor prognosis. In 
the WHO classification several groups of CD56+ lymphomas are distinguished, including 
extranodal NK/T-cell lymphoma, nasal/nasal-type and blastic NK-cell lymphoma.2 Nasal 
NK/T-cell lymphoma, previously designated lethal midline granuloma, typically presents in 
the nasopharynx and often shows an angiocentric growth pattern with prominent necrosis 
and vascular destruction. The neoplastic cells express cytotoxic proteins (TIA-1, granzyme 
B and perforin) in most cases. These lymphomas have been reported most frequently in Asia 
and Central and South America, and are almost without exception strongly associated with 
Epstein Barr virus (EBV). Lymphomas with similar histology and phenotype arising at other 
extranodal sites are designated extranodal NK/T-cell lymphoma, nasal-type.
Blastic NK-cell lymphoma most commonly presents in the skin with or without concurrent 
extracutaneous disease. Histologically, these lymphomas are characterized by a diffuse 
monotonous infiltrate of medium-sized cells resembling lymphoblasts or myeloblasts. 
Characteristically, the neoplastic cells are positive for CD4 and CD56 and in some cases for 
TdT, but do not express surface CD3 and cytotoxic proteins, and are not associated with 
EBV.
In addition to these three groups, cases of myeloid leukemia presenting primarily in the skin 
as well as other well-defined types of CTCL, such as primary cutaneous CD30+ (anaplastic) 
large T-cell lymphomas, subcutaneous panniculitis-like T-cell lymphoma (SCPLTCL) and 
CD8+ epidermotropic CTCL, may show co-expression of CD56 in a proportion of cases. 
These CD56+ (cutaneous) lymphomas are an extremely difficult group both for pathologists 
and clinicians. For pathologists correct classification of these lymphomas is difficult, expensive 
and time-consuming, since it requires application of several complimentary techniques, such 
as extensive phenotyping, EBV analysis and T-cell receptor (TCR) gene rearrangement studies. 
It is therefore important to know if such a detailed analysis is useful from a therapeutic or 
prognostic point of view. Clinicians are confronted with an aggressive clinical behavior and a 
fatal outcome often within a year after diagnosis, and may consider more intensive therapies 
as in acute leukemia’s as initial therapy. Whether patients presenting with only localized 
skin lesions have a somewhat better prognosis, and require another therapeutic approach is 
uncertain. It is also unknown whether co-expression of CD56 in well-defined types of CTCL 
is associated with a more unfavorable prognosis, and should be treated more aggressively.
In an attempt to answer some of these questions and to better define these different subgroups 
we evaluated the clinicopathologic and immunophenotypical data of a large group of CD56+ 
lymphomas/leukemias presenting in the skin, including 23 new cases and 130 cases from 
literature.
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MATERIAL AND METHODS
Patients
The two main selection criteria for this study were CD56 expression by the neoplastic 
T/NK-cells or myeloid-cells and the presence of skin lesions at the time of first diagnosis. 
Twenty-three patients meeting both criteria were found in the registry of the Dutch 
Cutaneous Lymphoma Group. Fourteen patients had been diagnosed in the last two years, 
when CD56 staining had been routinely applied. Retrospective analysis of a large group of 
CTCL other than mycosis fungoides and cases of leukemia cutis (presenting with skin lesions) 
yielded another nine CD56+ cases. Sixteen of 23 patients had only skin lesions at the time of 
diagnosis as assessed with routine staging procedures,3 whereas 7 patients had presented with 
concurrent cutaneous and extracutaneous disease. Additional immunostainings for CD2, 
CD3, CD4, CD5, CD7, CD8, CD30, CD68, TIA-1, granzyme B and myeloperoxidase and 
in situ hybridization for EBER were performed, when appropriate and possible. The clinical 
and histological data were retrieved and re-evaluated, and all cases were classified according 
to the criteria of the WHO-classification.2
REVIEW OF LITERATURE
Our literature search focused on reports of CD56+ lymphomas/leukemias with 
 a)  skin lesions at presentation, 
 b) a follow-up of at least 12 months unless prior death to lymphoma, and 
 c)  sufficient immunophenotypical data to allow categorization according to the 
WHO-classification.2
A Medline survey using “skin” and “CD56” in the PubMed search engine including papers 
until 1st of December 2002, revealed 87 English papers containing patients with a cutaneous 
CD56-positive lymphoma/leukemia. Fifty-seven papers included CD56+ lymphomas/
leukemias with skin lesions at first presentation, which had been designated variously as 
nasal(-type) NK/T-cell lymphoma, NK/T-cell lymphoma, angiocentric lymphoma, blastic 
NK-cell lymphoma, lymphoblastic NK-cell lymphoma, NK-cell leukemia/lymphoma, 
CD4+/CD56+ (“hematodermic”) lymphoma, CD30+/CD56+ lymphoma, myeloid leukemia, 
granulocytic sarcoma, cytotoxic T-cell lymphoma, SCPLTCL, lymphomatoid papulosis and 
(primary cutaneous) CD30+ (anaplastic) lymphoma4-60. 
A total number of 130 cases met all three criteria mentioned above. Using the WHO-
classification2 these cases from literature included 14 nasal NK/T-cell lymphomas, 
38 extranodal NK/T-cell lymphomas, nasal-type, 52 blastic NK-cell lymphomas, 10 cutaneous 
CD30+ lymphoproliferations, 7 cases of AML, 5 cases of SCPLTCL, and 4 peripheral T-cell 
lymphoma, unspecied (all with co-expression of CD56).
promotie.indb   68 18-01-2005   21:53:23
chapter 4  page 69
CD56+ HEMATOLOGICAL NEOPLASMS PRESENTING IN THE SKIN: A RETROSPECTIVE ANALYSIS OF 23 NEW CASES AND 130 CASES FROM THE LITERATURE
Statistical analysis
Comparison between different subgroups of patients were performed using the chi-square of 
Fisher’s exact test for categorical variables (cross-table) or Mann-Whitney test for continuous 
variables. Survival duration was calculated from time of diagnosis to date of death or 
censoring. Overall survival rates were estimated using the method of Kaplan and Meier61. For 
overall survival analysis deaths were taken into account whatever the cause, disease specific 
analysis was not performed because only one case died from an unrelated cause. 
Prognostic factors in the different subgroups were evaluated by overall survival univariate 
and multivariate analyses using a Cox proportional hazards model. Factors significant at the 
0.1 level in univariate analysis were included in a stepwise regression multivariate analysis. 
The following parameters were analyzed: clinical prognostic factors including gender, age, 
extent of cutaneous and extracutaneous disease and therapy; histological factors including 
cell-size, angiocentricity, expression of cytotoxic proteins and expression of several 
immunohistochemical markers, in particular CD30 and TdT, expression of EBV and the 
presence of clonal T-cell rearrangement, if performed or described. 
For statistical analysis the software package for social sciences (SPSS 10.0, Chicago Illinois) 
was used. 
RESULTS
The clinical, histological and immunophenotypical data of our 23 new cases are summarized 
in TABLES 1 and 2. Cumulative data on the whole group of 153 cases are summarized in TABLES 
3 and 4, and described below.
Total group (n=153)
The total group consisted of 89 male and 56 female patients (male:female ratio= 1,6:1), 
whereas no information on gender was available in 8 cases. The median age was 56 years 
(range 2-94 years). Sixty-seven of 153 (44%) cases had no evidence of extracutaneous disease 
at presentation. Treatment mostly consisted of multiagent chemotherapy (69%). A complete 
remission was reached in 47% of the cases, but 89% relapsed usually after only a short time. 
The prognosis was poor with a median survival of 12 months (95% CI: 9-15 months), a 
2-year-survival of 34% and a 5-year-survival of 12%. (see TABLE 4) The two largest groups 
were the blastic NK-cell lymphomas (n=63) and the nasal (n=15) and nasal-type (n=38) NK/
T-cell lymphomas (n=53).
Nasal NK/T-cell lymphoma (n=15)
This group consisted of 10 males and 5 females with a median age of 58 years (range 
19-90 years). All cases presented with lesions in the nasopharyngeal area combined with skin 
lesions, whereas other sites were affected infrequently (see TABLE 4). Initial treatment, mostly 
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multiagent chemotherapy (73%), resulted in a complete remission in only 3 cases. All cases 
died of lymphoma. This was the group with the worst prognosis; the median survival was 
only 5 months, whereas the 2-year-survival was not reached (see TABLE 4). Two cases were of 
T-cell origin as proven by TCR and CD3s expression.
Nasal-type NK/T-cell lymphoma (n=38)
This group included 19 males, 15 females and 4 cases with unknown gender. The median age 
at diagnosis was 50 years (range 16-79 years). Fifteen of 38 cases presented with only skin 
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lesions. Treatment mostly consisted of multiagent chemotherapy (n=26; 68%) and resulted 
in a complete remission in 10 of 40 cases. Only 3 cases did not relapse and 29/38 (76%) died 
of lymphoma. The prognosis was poor with a median survival of only 6 months (CI: 2-10 
months) and a 2-year-survival of 28% (see TABLE 4). Four cases were of T-cell origin as proved 
by TCR-analysis.
Univariant analysis showed that only presentation with skin-limited disease (p=0.006) and 
presentation with localized as opposed to multifocal skin lesions (p=0.05) were associated 
with a significantly better prognosis. In multivariant analysis only presentation with skin-
limited disease was significantly related to a better survival (p=0.03), RR 2.7; CI: 1.1-6.4. 
The median survival of patients presenting with skin-limited disease was 27 months (CI: 9-45 
months) compared to 4 months (CI: 3-5 months) for patients presenting with both cutaneous 
and extracutaneous disease (see FIGURE 1)
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Comparison between nasal and nasal-type NK T-cell lymphoma
When comparing these groups of nasal and nasal-type NK/T-cell lymphomas, there were no 
differences in expression of T-cell related antigens (CD2, CD3, CD4, CD5, CD7 and CD8), 
CD30-expression, clonality and histology/angiocentricity (see TABLE 3). EBV-expression was 
present in 100% and 76% of the nasal and nasal-type lymphomas, respectively (p=0.05) After 
exclusion of 17 nasal-type NK/T-cell lymphomas presenting with only skin lesions (median 
survival 27 months, CI: 12-42 months), no difference in survival was found between 15 nasal 
cases (median survival 5 months; CI: 3-7 months) and 23 nasal-type cases (median survival 
4 months; CI:3-5 months), see FIGURE 1.
Blastic NK-cell lymphoma (n=63)
This group consisted of 41 male and 20 female cases (male:female ratio=2:1), 2 cases were of 
unknown gender. The median age at diagnosis was 67 years (range 8-89 years); 13 cases were 
younger than 40 years. A strikingly high percentage of patients had bone marrow involvement: 
46% at presentation and 72% in the course of the disease (see TABLE 3). Initial treatment 
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consisted of multi agent chemotherapy in the majority of patients (70%). Most patients had 
received CHOP or CHOP-like regimens (56%), whereas 8 patients had been treated more 
aggressively with schemes used in acute leukemias followed by autologous bone marrow 
or stem cell transplantation. Six of these 8 patients are alive and although the follow-up is 
mostly short (median, 25 months; range, 6-40 months) they proved to have a significant better 
prognosis when compared to all other cases (p=0.01) and compared to cases that received 
adriamycin containing chemotherapy (p=0.04). The prognosis of these lymphomas was poor 
with a median survival of 14 
months, and 2- and 5- year- 
overall survival of 33% and 
6%, respectively (see table 4). 
Patients presenting with only 
skin lesions (median survival 
21 months, CI: 14-28 months) 
had a better prognosis than 
patients presenting with both 
cutaneous and extracutaneous 
disease (median survival 12 
months, CI: 10-14 months), see 
FIGURE 2. 
Univariant analysis showed 
that the following parameters 
were associated with a better 
prognosis: age of 40 or younger 
(p<0.0001), presentation with 
only skin lesions (p=0.03), initial 
treatment with BMT-directed 
regimens (p=0.01) and TdT 
expression by more than 50% 
of the neoplastic cells (p=0,03). 
Multivariant analysis showed 
that young age (≤40 years) and 
TdT expression of more than 
50% of the neoplastic cells were 
both independent prognostic 
variables (RR of 18.3; CI: 
4.2-80.8 and 8.4; CI:2.4-30.0) 
respectively. 
FIGURE 1. Overall 
survival curves of 
different groups of 
nasal(-type) natural 
killer (NK)/T-cell 
lymphoma (n = 53) 
presenting in the 
skin. Dashed line, 
nasal-type NK/T 
(skin lesions only, 
n = 15); solid line, 
nasal-type NK/T (skin 
and extracutaneous 
localizations, n = 23); 
dotted line, nasal 
NK/T (n = 15). 
FIGURE 2. Overall 
survival curves of 
different groups of 
blastic natural killer 
(NK)-cell lymphoma 
(n = 63) presenting 
in the skin. Solid 
line, blastic NK 
(skin lesions only, n 
= 27); dashed line, 
blastic NK (skin 
and extracutaneous 
localizations, n = 36). 
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CD56+ Myeloid leukemia first presenting in the skin(n=10)
This group included 7 males and 3 females with a median age of 54 years (range 2-94). 
Seven of 10 cases presented 
simultaneously with skin lesions 
and bone marrow and/or blood 
involvement. The other 3 cases 
presented with only skin lesions, 
but developed frank leukemia 
after 3-12 months. Initial 
treatment, including CHOP-like 
courses in 3 cases and AML-
schemes in 4 cases, resulted in 
complete remissions in 6/10 
cases. The prognosis was poor 
with a median survival of 6 
months and a 2-year-survival of 
20% (see TABLE 4). 
Comparison between blastic NK cutaneous CD56+ myeloid leukemia
In view of recent reports that blastic NK and a proportion of myeloid leukemias, presenting 
in the skin are possibly derived from precursor plasmacytoid dendritic-cells type 2 46,62,64, we 
compared the 63 cases diagnosed as blastic NK to the ten CD56+ myeloid leukemias. Striking 
similarities between both groups were noted in histology, immunophenotype, including 
expression of CD34, CD68 and 
TdT (but with the exception of 
CD33, myeloperoxidase and 
lysozyme used as exclusion 
criteria for blastic NK). Clinical 
presentation, including the 
percentage of bone marrow 
involvement at presentation 
(46% versus 60%), response 
to therapy and prognosis (see 
TABLE 4 and FIGURE 3).




cell lymphoma and 
myeloid leukemia 
presenting with skin 
localizations (n = 
73). Solid line, blastic 
NK (n = 63); dashed 
line, CD56+ myeloid 
leukemia presenting 
on the skin (n = 10).
FIGURE 4. Overall 
survival curves of 
the main groups of 
CD56+ lymphomas/
leukemias presenting 
in the skin (n = 
140). Dashed line, 
cutaneous CD30+ 
lymphoproliferation 
(n = 14); solid line, 
blastic natural killer 
(NK)/CD56+ myeloid 
leukemia (n = 73); 
dotted line, nasal(-
type) NK/T (n = 53). 
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Cutaneous CD30+ Lymphoproliferations with CD56 expression (n=14)
This group consisted of 5 males, 8 females and 1 case with unknown gender. The median 
age was 45 years (range 4-89). The group included 10 primary cutaneous CD30+ large cell 
lymphomas, including 6 cases designated previously CD56+ NK/NK-like T-cell lymphoma 
with expression of CD30 antigen, 3 cases of LyP and one case of anaplastic (ALK-positive) 
CD30+ lymphoma presenting with lesions in the skin, bone, lymph nodes and parotis. 
Initial therapy consisted of multi agent chemotherapy in 6/14, whereas five cases were 
not treated at all. Three cases died, two of them within 2 months, due to side effects of 
chemotherapy, and one of unrelated disease. The median survival was not reached; the 2 and 
5-year-survival were 75% and 56%, respectively. 
Subcutaneous panniculitis-like T-cell lymphoma (n=6)
This group consisted of 3 males and 3 females, the median was 50 years (range 12-56 years). 
Two cases presented with solely skin lesions, whereas 3 cases had concurrent involvement of 
lymph nodes. Chemotherapy resulted in a complete remission in only one of six patients, and 
all but one died of lymphoma. The median survival was only 5 months (CI: 1-9 months); the 
2-year-survival was 33% (see TABLE 4). The only patient still alive had an alpha/beta phenotype, 
whereas the other 5 patients who died had a gamma/delta phenotype. 
Peripheral T-cell lymphoma not otherwise specified (n=7):
This group consisted of 2 males, 4 females and 1 case with unknown gender. The median age was 
67 years (range 28-75 years). All cases presented with skin lesions only. It was a heterogenous 
group, including 4 epidermotropic CD8+ CTCL63, two CD30- large primary cutaneous 
T-cell lymphomas3, and one large granular NK/T-cell leukemia with skin localizations. Initial 
treatment resulted in a complete remission in four cases, but all but one patient relapsed. 
Four of seven patients died of lymphoma. The median survival was 66 months (CI: 32-100 
months); the 2 and 5-year-survival were 83% and 56%, respectively. 
DISCUSSION
In the present study 153 CD56+ lymphomas and leukemias, first presenting in the skin and 
with a minimum follow-up of 12 months or prior death to lymphoma, were evaluated. This 
group included 23 new cases and 130 cases retrieved from literature. The goals of this study 
were to assess whether the different groups of CD56-positive lymphomas recognized in the 
WHO classification differ in clinical behaviour, to define prognostic parameters and to deduct 
guidelines for diagnosis and treatment. In general these CD56+ lymphomas/leukemias had a 
poor prognosis with a median survival of 13 months. After a median follow-up of 12 months 
only 27% of patients alive with or without disease. Survival curves of the main groups of 
cutaneous CD56+ lyphomas/leukemias are presented in FIGURE 4.
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Blastic NK-cell lymphomas were by far the largest group (63 of 157 cases; 40%). In recent 
literature such cases have had been designated variously as blastic or blastoid NK-cell 
lymphoma and (haematodermic) CD4+/CD56+ leukemia/lymphoma2,18,23,46. These patients 
had a poor prognosis with a median survival of only 14 months. CHOP(-like) courses may 
result in initial complete remissions in these patients, but quick relapses unresponsive to further 
chemotherapy are characteristic of these tumors. Multivariate analysis revealed that age ≤40 
years and high expression of TdT by the neoplastic cells were independently associated with 
a better prognosis. Young patients treated with aggressive regimens used in acute leukemias 
had a better prognosis than patients treated with CHOP(-like) regimens6,18,29,30,48,59. Further 
studies are necessary to confirm these findings and to find out if more aggressive therapies are 
also superior in older patients. 
Comparison between blastic NK-cell lymphomas and CD56+ myeloid leukemias presenting 
in the skin showed striking similarities in histology, immunophenotype, clinical presentation, 
including the percentage of bone marrow involvement at presentation (46% compared to 
60%) and prognosis. Also in a recent workshop of the EORTC Cutaneous Lymphoma Study 
group on cutaneous CD56+ lymphomas the great similarities between both groups were 
noted (Muche et al, in preparation). These observations suggest that these two conditions 
are closely related. In addition, the development of acute myeloid leukemia in patients with 
blastic NK-cell lymphoma has been reported28. 
Recent studies demonstrated that blastic NK-cell lymphomas express markers typical of 
plasmacytoid dendritic cells, in particular the IL-3R alpha chain (CD123) and the lymphoid 
proto-oncogene TCL1 62. Expression of CD123 has also been reported in a proportion of 
myeloid leukemias presenting in the skin46,64.
The overlapping clinical, histological and immunophenotypical features of blastic NK-cell 
lymphoma and CD56+ myeloid leukemias presenting in the skin provide also a rationale to 
treat these patients with more aggressive regimens used in myeloid leukemias rather than with 
convential CHOP(-like) regimens. Moreover, the term blastic NK-cell lymphoma is probably 
a misnomer, because the disease is neither of NK-cell origin nor a lymphoma. 
Nasal and nasal-type NK/T-cell lymphomas together represented the second largest group in 
this study (55 of 157 cases; 35%). In cases with a true T-cell phenotype as defined by expression 
of surface CD3 and/or the presence of a clonal TCR gene rearrangement, which express 
cytotoxic proteins, but no EBV, it is arbitrary to decide whether a diagnosis of nasal-type 
NK/T-cell lymphoma or peripheral T-cell lymphoma not otherwise specified (NOS) should 
be made. In this study such EBV-negative cases were classified as PTL, NOS. Angiocentricity 
proved not very helpful in distinguishing both groups, because this feature was observed in 
all groups investigated in this study (see TABLE 3). Nasal and nasal-type NK/T-cell lymphoma 
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showed many similarities (see TABLE 4). No difference in survival was found between nasal 
NK/T-cell lymphomas (presenting with concurrent cutaneous disease) and nasal-type NK/
T-cell lymphomas presenting with cutaneous and extracutaneous disease (median survival 5 
and 4 months, respectively). Nasal-type NK/T-cell lymphomas presenting with skin-limited 
disease had a somewhat better prognosis, which is consistent with the results of previous 
studies in primary cutaneous angiocentric lymphomas65(see figure 1). The poor survival data 
in these nasal (type) NK/T-cell lymphomas also indicate that current standard regimens, -
generally doxorubicin-based chemotherapy-, are insufficient in these cases, and that other 
approaches should be investigated.
Apart from the entities discussed above, other types of CTCL can occasionally show co-
expression of CD56. Within the group of CD56+ SCPLTCL 5 of 6 cases appeared to have 
a gamma/delta phenotype. These gamma/delta-positive cases are often not confined to the 
subcutis, but may extend into the dermis66. In such cases differentiation between SCPLTCL and 
nasal-type NK/T-cell lymphomas extending into the subcutis may be difficult12. Noteworthy, 
both groups have a similar poor prognosis, and do not respond sufficiently to CHOP(-like) 
therapy. The only patient with a CD56+ SCPLTCL still alive in this study had a alpha/beta 
T-cell phenotype. This observation is consistent with the results of other studies indicating 
that SCPLTCL with an alpha/beta phenotype have a much better prognosis than cases with a 
gamma/delta phenotype, and that both groups should be considered separately49,67
Previous studies in systemic CD30+ anaplastic large cell lymphoma suggested that expression 
of CD56 is associated with a more unfavorable prognosis68. The favourable prognosis of the 
patients with a primary cutaneous CD30+ lymphoma and LyP included in this study suggests 
that CD56 expression does not affect clinical behaviour and outcome in the group of primary 
cutaneous CD30+ lymphoproliferations. Similarly, the four cases with an epidermotropic 
CD8+ CTCL, with co-expression of CD56 did not differ clinically from CD56- cases, 
described previously63.
Classification of lymphomas which are defined primarily by phenotype, such as these CD30+ 
lymphomas and CD8+ CTCL, and which at the same time express CD56 may be difficult. 
This problem is well illustrated by the 8 CD30+/CD56+ lymphomas in the study of Mrasz 
et al.38. In that study on NK/NK-like T-cell lymphoma, primarily defined by the presence of 
CD56 expression, it was found that cases that co-express CD30 had a much better prognosis 
than CD30-negative cases. Seven of eight cases are alive and well after initial treatment and 
did not relapse. It seems that these patients have a clinical presentation and course similar to 
that observed in primary cutaneous CD30+ CTCL7,69. Although EBV-expression was noted 
in 3/8 cases, one wonders why at least some of the cases were not simply classified as primary 
cutaneous CD30+ CTCL with co-expression of CD56. Therefore, studies on larger number 
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of patients with co-expression of CD30 and CD56 are necessary. If confirmed that primary 
cutaneous CD30+ CTCL with co-expression of CD56 do not have another clinical behaviour 
than CD56-negative cases, cases with localized disease can better be treated with radiotherapy 
than multi agent chemotherapy.
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ABSTRACT
Lymphomatoid papulosis (LyP) is defined as a recurrent self-healing papulonodular eruption 
with the histological features of a (CD30+) cutaneous T-cell lymphoma. The atypical cells 
usually have a CD3+/-, CD4+/-, CD8-, CD30+, CD56- T-cell phenotype. We report an 
unusual case of LyP, in which the atypical cells expressed a CD3-, CD4-, CD8-, CD30+, 
CD56+ phenotype. Detailed phenotypic and genotypic analysis confirmed that these cells 
had a natural killer NK-cell phenotype. Lymphomas with an NK-cell phenotype usually have 
a poor prognosis. However, the waxing and waning of papular lesions for more than 20 
years and the excellent response to low-dose oral methotrexate in this patient suggest similar 
clinical behaviour to LyP cases with a T-cell phenotype.
 
INTRODUCTION
Lymphomatoid papulosis (LyP) is characterized by a chronic recurrent, self-healing 
papulonodular skin eruption with histological features of a (CD30+) cutaneous T-cell 
lymphoma.1,2 Characteristically, the skin lesions show a wedge-shaped to diffuse dermal 
infiltrate with variable numbers of CD30+ large, often anaplastic cells in a background of 
inflammatory cells. These atypical cells normally express a T-cell phenotype with variable 
loss of pan-T antigens (CD2, CD3, CD5, CD7). Most cases have a CD4+ T-cell phenotype, 
whereas only some cases express a CD8+ T-cell phenotype.3 Expression of CD15 is rare. We 
describe a patient with LyP in whom the atypical cells expressed a natural killer (NK) -cell 
phenotype. Whereas CD56+ NK-cell lymphomas usually have a poor prognosis, the disease 
in this patient showed a chronic indolent clinical course characteristic of LyP. Additional 
studies in another 10 patients with LyP and 10 patients with a primary cutaneous CD30+ 
large T-cell lymphoma (LTCL) showed expression of CD56 in two of 20 cases, both with a 
T-cell phenotype.
CASE REPORT 
A 47-year-old white man was referred with a 20-year history of generalized papular skin 
lesions that had been treated with various topical steroids without effect. The lesions 
always disappeared spontaneously after 6-8 weeks, but new lesions appeared at other sites 
simultaneously. His general medical history revealed diabetes mellitus type II and a myocardial 
infarction. His medication consisted of acetylsalicylic acid, an angiotensin-converting enzyme 
inhibitor and tolbutamine. On examination, dozens of papular and papulonodular lesions 
were observed on the trunk, arms and legs, sparing the head. On the abdomen the papular 
lesions coalesced to form a large plaque (FIG. 1). A tumorous lesion of 3 cm diameter had 
recently developed on the right leg (FIG. 2). No lymphadenopathy or hepatosplenomegaly was 
found.
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Histological and immunohistochemical analysis 
Histological evaluation of the tumorous lesion on the right leg and of a fully developed 
papule on the abdomen showed essentially the same picture. Both lesions showed a diffuse, 
non-epidermotropic infiltrate containing clusters of large anaplastic cells with a considerable 
admixture of small T-cells, histiocytes and small clusters of B-cells (FIG. 3A). The atypical cells 
strongly expressed CD30, CD43 and CD56, but were negative for CD2, CD3 and leu4, CD4, 
CD5, CD7, CD8, CD15, CD20, CD34, CD57, CD68, lysozyme, myeloperoxidase, anaplastic 
lymphoma kinase (ALK, p80), granzyme B, TIA-1 and F-1 (FIG. 3B-D). Analysis for Epstein-
Barr virus (EBV)-encoded RNA and latent membrane protein-1 did not show the presence 
of EBV. Analysis of T-cell receptor (TCR)- gene rearrangement using the heteroduplex 
polymerase chain reaction 4 did not identify a T-cell clone. Taken together, these results are 
consistent with a NK-cell phenotype of the neoplastic cells.
Clinical course 
Because of this unusual phenotype and the extent and size of the skin lesions, routine staging 
procedures, including thoracic and abdominal computed tomographic scan, bone marrow 
biopsy, blood analysis and an examination by an ear/nose/throat specialist were performed, 
but these failed to demonstrate extracutaneous involvement. Clinical observation during 
FIGURE 1. Numerous 
papular lesions 
coalescing to form a 
large plaque on the 
abdomen
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hospitalization confirmed the recurrent, self-healing nature of the skin lesions. Based on a 
combination of the clinical picture of recurrent self-healing skin lesions with the histological 
picture of a CD30+ lymphoproliferation the diagnosis LyP was made. When treatment with 
low-dose oral methotrexate (22·5 mg weekly) was instituted, no further lesions developed and 
the existing lesions slowly resolved. Methotrexate was tapered off and our patient remains 
free of skin lesions on a maintenance dose of 10 mg weekly.
Evaluation of 20 primary cutaneous CD30+ lymphoproliferations for CD56 
expression 
To evaluate the frequency of CD56 expression in primary cutaneous CD30+ lymphoproli-
ferations the phenotype of 10 other patients with LyP and 10 patients with a primary 
cutaneous CD30+ LTCL was analysed. Only one of 10 patients with LyP and one of 10 with 
primary cutaneous CD30+ LTCL 
expressed CD56. Both were of 
T-cell phenotype [CD3+(leu4)/
CD4-/CD8+ and CD3+(leu4)/
CD4+/CD8-, respectively,]. There 
was no difference in clinical 
behaviour in these two patients 
as compared with CD56- cases.
DISCUSSION
The CD56 marker reactive 
with the neuronal cell adhesion 
molecule is a marker for 
NK-cells. Owing to the recent 
availability of an anti-CD56 
monoclonal antibody reactive 
on paraffin-embedded tissue 
(clone 123C3),5 several types of 
non-Hodgkin’s lymphoma with 
NK/T-cell phenotype have been 
recognized.6 Nasal NK/T-cell 
lymphoma, previously known 
as lethal midline granuloma, 
usually expresses CD56 and is 
considered to be the prototype 
of NK-cell lymphoma.7 It has a 
FIGURE 2. Tumerous 
lesion on the right 
leg.
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strong association with EBV and is more frequent in Asia and South and Central America.6,7 
Lymphomas with similar histological and immunohistochemical features presenting at other, 
mostly extranodal, sites are described as NK/T-cell lymphoma of nasal-type.8,9 The association 
with EBV in this type is variable. More recently, a subtype with a monotonous infiltrate 
of medium to large sized blasts with an NK/T-cell phenotype designated blastoid NK-cell 
lymphoma has been reported.8,10,11 This type of lymphoma is not associated with EBV and 
differentiation from skin localizations of acute myeloid leukaemia (AML) may be extremely 
difficult,12 as AML can also express CD56. Differentiation is especially difficult if blood and 
bone marrow involvement cannot be demonstrated (aleukaemic leukaemia cutis). In addition 
to the three above-mentioned NK/T-cell lymphoma subtypes, several other well-defined types 
of lymphoma can coexpress CD56, such as subcutaneous panniculitis-like T-cell lymphoma13 
and CD30+ anaplastic large cell lymphomas.14-17 
FIGURE 3. 
(A) Histological 
evaluation of a 
papular lesion 





eosin). The atypical 
cells express CD30 
(B), CD56 (C), but not 
CD3 (D). Original 
magnification 200x.
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This report describes the first patient with LyP expressing CD56. Detailed immunophenotypical 
and genotypical analysis indicated that the atypical cells in this patient were of true NK-cell 
origin rather than T-cells coexpressing CD56. The absence of TCR- chain gene rearrangement 
cannot be attributed to under-representation of too low a number of CD30+/CD56+ atypical 
cells, as these constituted approximately 50% of the total number of cells in the dermal 
infiltrate. Clinically the patient showed classical features of LyP, with a history of 20 years 
of waxing and waning of papulonodular lesions. Whereas staging is usually not indicated in 
patients with LyP, we decided to stage this particular patient because of the extent and size 
of the skin lesions, the uncertainty at the first visit whether there was complete clearance of 
all individual lesions, and in particular the uncommon phenotype of the atypical cells, given 
that CD56+ non-Hodgkin’s lymphomas are usually associated with a poor prognosis. After 
exclusion of extracutaneous disease he was treated with low-dose methotrexate (22·5 mg 
weekly), which resulted in almost immediate cessation of the development of new lesions and 
the slow clearing of the existing lesions. Methotrexate was tapered off to 10 mg weekly, but 
no new lesions have appeared.
Recent studies have indicated that CD56 expression is an independent marker of poor 
prognosis in both ALK+ and ALK-CD30+ anaplastic large cell lymphoma.16 Moreover, a 
recent report described a patient with a primary cutaneous CD30+ anaplastic large cell 
lymphoma coexpressing CD56 who did not respond to systemic chemotherapy.15 It was 
suggested that coexpression of CD56 might identify a subset of primary cutaneous CD30+ 
lymphomas with a more aggressive clinical behaviour.15 To find out if coexpression of 
CD56 may be considered as a prognostic marker in the group of primary cutaneous CD30+ 
lymphoproliferations, CD56 expression was evaluated in 10 additional cases of LyP and 
10 cases of primary cutaneous CD30+ LTCL. Coexpression of CD56 was found in one of 
10 patients with LyP and one of 10 patients with primary cutaneous CD30+ LTCL. Both cases 
showed a mature CD3+ (leu4)/CD4+ /CD8- or CD3+ (leu4)/CD4-/CD8+ T-cell phenotype. 
Neither of these two patients developed extracutaneous disease during follow-up (14 and 
84 months, respectively). This and other studies14-17 do not suggest that coexpression of CD56 
in primary cutaneous CD30+ lymphoproliferations has prognostic significance in contrast to 
systemic anaplastic CD30+ LTCL.18 They also indicate that most primary cutaneous CD30+ 
lymphoproliferations coexpressing CD56 are of T-cell origin (expressing leu4), and that cases 
with a NK-cell phenotype, as reported here, are exceedingly rare.
The authors thank Prof. Dr J.J.van Dongen of the Erasmus University Rotterdam, the 
Netherlands, for performing the heteroduplex polymerase chain reaction analysis.
promotie.indb   90 18-01-2005   21:53:37
chapter 5  page 91
LYMPHOMATOID PAPULOSIS WITH A NATURAL KILLERCELL PHENOTYPE
REFERENCES
1 Macaulay WL. Lymphomatoid papulosis. A continuing self-healing eruption, clinically 
benignhistologically malignant. Arch Dermatol 1968; 97: 23-30.
2 Bekkenk MW, van Geelen FA, Voorst Vader PC et al. Primary and secondary cutaneous CD30+ 
lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the 
long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.  
Blood 2000; 95: 3653-61.
3 Kadin ME. Characteristic immunologic profile of large atypical cells in lymphomatoid papulosis. 
Possible implications for histogenesis and relationship to other diseases.  
Arch Dermatol 1986; 122: 1388-90.
 4 Langerak AW, Szczpanski T, van der Burg M et al. Heteroduplex PCR analysis of rearranged T-cell 
receptor genes for clonality assessment in suspect T-cell proliferations.  
Leukemia 1997; 11: 2192-9.
5 Tsang WY, Chan JK, Ng CS et al. Utility of a paraffin section-reactive CD56 antibody (123C3) for 
characterization and diagnosis of lymphomas. Am J Surg Pathol 1996; 20: 202-10.
6 Slater DN . Cutaneous CD56 natural killer and natural killer-like T-cell lymphomas.  
Br J Dermatol 2000; 142: 853-6.
7 Cheung MMC, Chan JKC, Lau WH et al. Primary non-Hodgkin lymphoma of the nose and 
nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 
patients. J Clin Oncol 1998; 16: 70-7.
8 Chan JK, Sin VC, Wong KF et al. Nonnasal lymphoma expressing the natural killer cell marker 
CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm.  
Blood 1997; 89: 4501-13.
9 Takeshita M, Yoshida K, Suzumiya J et al. Cases of cutaneous and nasal CD56 (NCAM) -positive 
lymphoma in Japan have differences in immunohistology, genotype and etiology.  
Hum Pathol 1999; 30: 1024-34.
10 Bower CPR, Standen GR, Pawade J et al. Cutaneous presentation of steroid responsive blastoid 
natural killer cell lymphoma. Br J Dermatol 2000; 142: 1017-20.
11 DiGuiseppe JA, Louie DC, Williams JE et al. Blastic natural killer cell leukemia lymphoma: a 
clinicopathological study. Am J Surg Pathol 1997; 21: 1223-30.
12 Kuwabara H, Nagai M, Yamaoka G et al. Specific skin manifestations in CD56 positive acute 
myeloid leukemia. J Cutan Pathol 1999; 26: 1-5.
13 Salhany KE, Macon WR, Choi JK et al. Subcutaneous panniculitis-like T-cell lymphoma. 
Clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta 
subtypes. Am J Surg Pathol 1998; 22: 881-93.
14 Natkunam Y, Warnke RA, Haghighi B et al. Coexpression of CD56 and CD30 in lymphomas 
with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular 
analyses of seven cases. J Cutan Pathol 2000; 27: 392-9.
promotie.indb   91 18-01-2005   21:53:38
chapter 5  page 92
LYMPHOMATOID PAPULOSIS WITH A NATURAL KILLERCELL PHENOTYPE
15 Chang S-E, Park I-J, Huh J et al. CD56 expression a case of primary cutaneous CD30+ anaplastic 
large cell lymphoma. Br J Dermatol 2000; 142: 766-70.
16 Nakamura S, Suchi T, Koshikawa T et al. Clinicopathologic study CD56 (NCAM) -positive 
angiocentric lymphoma occurring in sites other than the upper and lower respiratory tract.  
Am J Surg Pathol 1995; 19: 284-96.
17 Gould JW, Eppes RB, Gilliam AC et al. Solitary primary cutaneous CD30+ large cell lymphoma of 
natural killer cell phenotype bearing the t(2;5)(p23;q35) translocation and presenting in a child. 
Am J Dermatopathol 2000; 22: 422-8.
18 Suzuki R, Kagami Y, Takeuchi K et al. Prognostic significance of CD56 expression for ALK-positive 
and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype.  
Blood 2000; 96: 2993-3000.
promotie.indb   92 18-01-2005   21:53:38
chapter 5  page 93
LYMPHOMATOID PAPULOSIS WITH A NATURAL KILLERCELL PHENOTYPE
promotie.indb   93 18-01-2005   21:53:38
promotie.indb   94 18-01-2005   21:53:39
chapter 6
Prognostic factors in primary cutaneous large B-cell lymphomas: 
a European multicenter study
J Clin Oncol. 2001;19:3602-3610
F. Grange 1






Chris JLM Meijer 8
R. Fink Puches 4
W. A. van Vloten 9
P. Joly 7
M. Bagot 3
Rein Willemze  1
1. Department of Dermatology, Hôpital Pasteur, Colmar, France 
2. Department of Dermatology, Leiden University Medical Centre, Leiden, the Netherlands 
3. Departments of Pathology and Dermatology, Hôpital Henri-Mondor, Créteil, France 
4. Department of Dermatology, University of Graz, Graz, Austria 
5. Department of Dermatology, University of Turin, Italy 
6. Department of Pathology, Institut Gustave Roussy, Villejuif, France 
7. Department of Dermatology, Hôpital Charles Nicolle, Rouen, France 
8. Departments of Pathology and Dermatology, Free University Hospital, Amsterdam, the Netherlands 
9. Department of Dermatology, University Medical Centre, Utrecht, the Netherlands
promotie.indb   95 18-01-2005   21:53:40
chapter 6  page 96
PROGNOSTIC FACTORS IN PRIMARY CUTANEOUS LARGE B-CELL LYMPHOMAS: A EUROPEAN MULTICENTER STUDY
ABSTRACT
Purpose
Most primary cutaneous B-cell lymphomas have an excellent prognosis. However, primary 
cutaneous large B-cell lymphomas (PCLBCLs) of the leg have been recognized as a distinct 
entity with a poorer prognosis in the European Organization for Research and Treatment of 
Cancer (EORTC) classification. This distinction on the basis of site has been debated. Our 
aim was to identify independent prognostic factors in a large European multicenter series of 
PCLBCL. 
Patients and methods
The clinical and histologic data of 145 patients with PCLBCL were evaluated. According 
to the EORTC classification, 48 patients had a PCLBCL of the leg and 97 had a primary 
cutaneous follicle center-cell lymphoma (PCFCCL). Data from both groups were compared. 
Univariate and multivariate analyses of specific survival were performed using a Cox 
proportional hazards model. 
Results
Compared with PCFCCL, PCLBCL-leg were characterized by an older age of onset, a more 
recent history of skin lesions, a more frequent predominance of tumor cells with round nuclei 
and positive bcl-2 staining, and a poorer 5-year disease-specific survival rate (52% v 94%; 
P < .0001). Univariate survival analysis in the entire study group showed that older age, a 
more recent onset of skin lesions, the location on the leg, multiple skin lesions, and the round-
cell morphology were significantly related to death. In multivariate analysis, the round-cell 
morphology (P < .0001), the location on the leg (P = .002), and multiple skin lesions (P = .01) 
remained independent prognostic factors. The round-cell morphology was an adverse 
prognostic factor both in PCLBCL-leg and in PCFCCL, whereas multiple skin lesions were 
associated with a poor prognosis only in patients with PCLBCL-leg.
Conclusion
With site, morphology, and number of tumors taken into account, guidelines for the 
management of PCLBCL are presented. 
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INTRODUCTION
Primary cutaneous B-cell lymphomas represent a heterogeneous group of B-cell neoplasms, 
which present in the skin without evidence of extracutaneous disease.1-8 The majority of these 
primary cutaneous B-cell lymphomas are large-cell lymphomas (primary cutaneous large 
B-cell lymphomas [PCLBCLs]).9 In the European Organization for Research and Treatment 
of Cancer (EORTC) classification for primary cutaneous lymphomas, two main groups of 
PCLBCL are distinguished.6 Most cases are included in the group of primary cutaneous follicle 
center-cell lymphomas (PCFCCLs). This term was introduced in 1987 5 as an encompassing 
term for cutaneous lymphomas that were composed of centroblasts and centrocytes of 
various sizes and that were classified as either centroblastic/centrocytic or centroblastic 
lymphomas according to the criteria of the Kiel classification.10 These PCFCCLs appeared 
as a well-defined group of primary cutaneous B-cell lymphomas which often presented with 
skin lesions confined to a limited skin area on the head or the trunk; they had an excellent 
prognosis, irrespective of the proportion of large cells and the histologic subclassification.5-8 
However, it was noted from the first publications regarding these PCFCCLs that patients 
presenting with skin tumors on the leg had a different clinical behavior.5 Since these tumors of 
the leg were consistently composed of a majority of large B-cells, the term primary cutaneous 
large B-cell lymphoma of the leg (PCLBCL-leg) was used.11 Recent studies have demonstrated 
that patients with PCLBCL-leg differed from patients with PCFCCLs arising at other sites 
by a higher age of onset, a poorer prognosis, and the almost constant expression of bcl-
2 protein.6,8,11,12 For these reasons, PCLBCL-leg was included as a separate entity in the 
EORTC classification.6 Although recent studies have confirmed that these PCLBCL-leg are a 
distinct group with an intermediate prognosis,8 the subdivision of primary cutaneous B-cell 
lymphomas into two main categories (PCLBCL-leg and PCFCCL) primarily based on site of 
presentation (leg v other sites) has been much disputed.13-17 Indeed, it remained unknown to 
what extent site, age, morphology, bcl-2 expression, or other parameters contribute to the 
difference in survival between these two groups. 
This prompted us to perform a large European study of primary cutaneous B-cell lymphomas, 
including both PCLBCL-leg and PCFCCL with a predominance of large cells (nonleg 
PCLBCLs). The main goals of this study were (1) to identify independent prognostic factors 
in the total group of PCLBCLs, (2) to find out whether PCLBCL-leg have indeed a different 
clinical behavior, and (3) to define additional prognostic parameters within pertinent 
subgroups of PCLBCL. The ultimate goal of this study was to provide practical guidelines 
to both pathologists and clinicians that may contribute to appropriate management and 
treatment of these PCLBCLs. 
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PATIENTS AND METHODS
The Dutch Cutaneous Lymphoma Working Group, the French Study Group on Cutaneous 
Lymphomas, and two departments of dermatology from other countries (Graz, Austria, and 
Turin, Italy) participated in the study. 
Inclusion Criteria
Patients included in the registry of one of the participating groups or departments were selected 
for analysis if they met the following criteria: (1) diagnosis of cutaneous B-cell lymphoma 
between January 1, 1979, and March 1, 1998; (2) absence of extracutaneous disease detected 
by a comprehensive staging procedure at diagnosis; and (3) histologic and immunophenotypic 
features showing a majority (ie, > 50%) of large cells among neoplastic B-cells. The staging 
procedure at diagnosis included in all cases physical examination, routine laboratory tests, 
chest radiograph or thoracic computed tomography scan, abdominal ultrasound tomography 
or abdominal computed tomography scan, and bone marrow cytology (3% of cases), bone 
marrow histology (8%), or both (89%). One hundred forty-five patients were included in the 
study. Twenty-three of them had been included in a previous prognostic study.8 According to 
the criteria of the Revised European-American Classification of Lymphoid Neoplasms18 and 
the World Health Organization classification,19 all 145 patients were classified as having a 
diffuse large B-cell lymphoma. 
Histologic Review
For each case, hematoxylin-eosin slides and CD3 and CD20 stainings were studied. In addition, 
bcl-2 expression was studied using formalin-fixed, paraffin-embedded sections deparaffinized 
and stained with an appropriate monoclonal antibody (clone 124; Dako, Copenhagen, 
Denmark), when available (55 of 145 cases). The bcl-2 staining was considered positive if 
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more than 25% of the neoplastic large cells showed an unequivocal bcl-2 positivity. Cases in 
which only a minor proportion of tumor cells weakly expressed bcl-2 protein were considered 
negative. Histologic subclassification was based essentially on the relative proportions of 
immunoblasts, centroblasts (large noncleaved cells), and large centrocytes (large cleaved 
cells), including multilobated cells, and all cases were classified into five categories following 
the criteria of the updated Kiel classification,10 with minor modifications (TABLE 1 and FIG 1). 
Because such a detailed subdivision was expected to result in a major interobserver variation, 
it was decided to distinguish two major subgroups depending on the presence or absence 
of more than 50% large B-cells with round nuclei. Skin biopsy specimens had first been 
reviewed separately by four (dermato)pathologists (J.W., C.J.L.M.M., L.C., and R.W.) from 
different centers who had no knowledge of the clinical data. Next, all cases were reviewed 
during a special meeting of this pathology panel using a multihead microscope and classified 
by consensus. The results of this histologic classification are presented in TABLE 1. 
Reproducibility Study
Since in the course of the study the distinction between cleaved-cell and round-cell PCLBCL 
appeared as a major independent prognostic parameter, we studied the reproducibility of 
this simple histologic subclassification in a sample of 38 randomly selected cases. Fourteen 
cases were reviewed by a panel of six pathologists from the Dutch group and 24 cases were 
reviewed by a panel of six pathologists from the French group. Participants had not taken 
part in the previous histologic review. They were asked to classify each tumor into one of the 
two main categories: cleaved-cell PCLBCL and round-cell PCLBCL. Results were compared 
with the final histologic classification obtained on the basis of consensus during the histologic 
review (TABLE 1) 
FIGURE 1. 
Histopathologic 
features in PCLBCLs 
(400): (A) round cells, 
immunoblastic; 
(B) round cells, 
polymorphous 
centroblastic; 
(C) round cells, 
centroblastic; 
(D) cleaved cells, 
centroblastic/
centrocytic; (E) 
cleaved cells, large 
centrocytic. A B C D E
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Data Collection
Variables analyzed for prognostic value were as follows: age at diagnosis; sex; anatomic site 
(head and neck, arm, anterior aspect of the trunk, posterior aspect of the trunk including the 
buttock, or leg); diameter of the largest skin lesion; number of skin lesions; cutaneous extent 
(“localized” when either one or multiple skin lesions were restricted to one anatomic site, and 
“disseminated” when several anatomic sites or several limbs were involved); duration of skin 
lesions before diagnosis; spontaneous regression of skin lesions; serum lactate dehydrogenase 
(LDH) level; and histologic group (round-cell v cleaved-cell morphology) as determined by 
the histologic review. Histories of noncutaneous lymphoma or leukemia, pseudolymphoma, 
or small-cell primary cutaneous B-cell lymphoma and the presence of B symptoms were 
registered but were not included in the prognostic analysis because they were observed in 
too small a number of patients. Bcl-2 protein expression was not included in the prognostic 
analysis because of insufficient data. 
Follow-Up Data
Follow-up information was recorded until December 1, 1998 (end point), and included 
therapy, achievement of a complete response, relapse, nodal or visceral progression of the 
disease, status at the end point or last follow-up, and date and cause of death. The follow-
up time ranged from 3 to 203 months (median, 41 months; mean, 53 months). A total of 
133 patients were followed up until death or until the end point or for a period greater than 
5 years. Twelve patients (8%) were lost to follow-up after a duration of 5 years (range, 10 to 
59 months). 
Statistical Analysis
Comparisons between different subgroups of patients were performed using the usual 2 test 
or Fisher’s exact test for categorical variables and Student’s t test or Mann-Whitney test for 
continuous variables. Survival duration was calculated from diagnosis to date of death or 
censoring. Observed survival, specific (disease-related) survival, and relative survival rates 
were estimated in the entire study group and in different subgroups of patients according 
to location and histology of skin lesions. Observed survival and specific survival rates were 
estimated using the method of Kaplan and Meier.20 For the estimation of observed survival, 
deaths were taken into account whatever the cause. For the specific survival analysis, only 
deaths from lymphoma were taken into account and patients who died from other causes 
were considered censored. For the relative survival analysis, a ratio between observed survival 
in the study population and expected survival according to general mortality was determined 
using tables of general mortality by age, sex, and period in every participating country.21,22 
Specific survival curves in different subgroups of patients were computed using the method 
of Kaplan and Meier. 
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Prognostic factors in the entire study group and in different subgroups of patients were 
evaluated by specific survival (disease-related) univariate and multivariate analyses using a 
Cox proportional hazards model.23 Factors significant at the .2 level in univariate analysis 
were included in a stepwise regression multivariate analysis. 
RESULTS
Clinical Characteristics of the Total Group of 145 PCLBCL Patients
The clinical characteristics and follow-up data of the 145 patients included in the study are 
summarized in Table 2. The ratio of men to women was 1 (72:73). The age at diagnosis 
ranged between 23 and 92 years (mean, 64 years; median, 68 years). None had any history 
of noncutaneous lymphoma or leukemia. Fifteen patients (10%) had a history of cutaneous 
pseudolymphoma. Only one patient had been diagnosed as having a small-cell primary 
cutaneous B-cell lymphoma before it evolved into a large B-cell lymphoma. Clinically, 
patients presented with cutaneous nodules or tumors (94%) or deeply infiltrated plaques 
(6%). Therapy resulted in a complete remission in 131 (90%) of 145 patients. Thirty-five 
(24%) of 145 patients developed extracutaneous disease. The mean time until extracutaneous 
dissemination was 22 months. The extracutaneous progression was restricted to the lymph 
nodes in 12 cases, whereas 23 patients developed a visceral disease either associated with 
lymph node involvement (nine cases) or not (14 cases). Anatomic sites of visceral dissemination 
included the CNS (four cases), the bone marrow (four cases), the bones (four cases), the lung 
(three cases), the small intestine (two cases), the spleen (two cases), the testis (two cases), 
the kidney (two cases), the heart (two cases), the breast (one case), the thyroid (one case), 
and the brachial plexus (one case). Twenty-six (18%) of 145 patients died of lymphoma, 
whereas 13 patients (9%) died of unrelated disease. Death from lymphoma occurred in 19 
of 26 patients within 3 years after diagnosis. Disease-related death was extremely rare in 
younger patients: no patient younger than 63 and only five patients younger than 70 at the 
time of diagnosis died of lymphoma. The overall and disease-specific 5-year survival rates 
were 72% and 81%, respectively. 
Prognostic Factors in the Total Group of PCLBCL Patients
Univariate and multivariate analyses of disease-specific survival were performed on the total 
group of 145 patients to identify independent prognostic factors. Univariate analysis showed 
that the following variables were related to death from lymphoma: older age (> 75 years; 
P < .0001); short duration of skin lesions before diagnosis (< 10 months; P = .0013); location 
on the leg (PCLBCL-leg v PCFCCL, P < .0001); presence of more than one skin lesion at 
diagnosis (P = .03); disseminated skin lesions (P = .036); increased LDH level (P = .05); and 
round-cell morphology (P < .0001). Sex, diameter of the largest skin lesion and occurrence of 
spontaneous regression had no significant effect on death from lymphoma. When multivariate 
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analysis was performed, the round-cell morphology (P < .0001), location on the leg (P 
= .002), and presence of more than one skin lesion at diagnosis (P = .01) remained significant 
independent factors associated with a poor prognosis (TABLE 3). In view of these results, the 
main features at diagnosis and follow-up data were studied within the four subgroups of 
patients determined by location and morphology, as well as within the two major EORTC 
groups (TABLE 2). Kaplan and Meier disease-specific survival curves of these different subgroups 
of patients are shown in FIG. 2. 
Comparison Between PCFCCL and PCLBCL-Leg
On the basis of the criteria of the EORTC classification,6 97 patients were assigned to the 
PCFCCL group and 48 patients were assigned to the PCLBCL-leg group according to site of 
presentation. In the PCFCCL group, the skin lesions were confined to the head and the neck 
(40 cases), a localized area on the trunk (45 cases), or the arm (one case), or they involved 
several anatomic sites excluding the leg (11 cases). The other clinical findings at diagnosis and 
follow-up data are listed in Table 2. In the PCFCCL group, 11 (11%) of 97 patients developed 
extracutaneous disease, six (6%) of 97 patients died of lymphoma, and the estimated overall 
and disease-specific 5-year survival rates were 85% and 94%, respectively. 
In the PCLBCL-leg group, the skin lesions were confined to one leg (34 patients) or both legs 
(eight patients) in 42 of 48 patients. The other six patients had tumors on one or both legs 
associated with skin lesions at other sites. Follow-up data in this group indicate that 24 (50%) 
of 48 patients developed extracutaneous disease, and 20 (42%) of 48 died of lymphoma. The 
estimated overall and disease-specific 5-year survival rates were 42% and 52%, respectively. 
A comparison between the two EORTC groups demonstrated that patients with PCLBCL-
leg were older than patients with PCFCCLs (mean age, 73 v 60 years, P < .0001) and had 
more frequently disseminated skin lesions (P = .01), short duration of lesions before diagnosis 
(P < .0001), elevated LDH levels (P = .04), round-cell morphology (75% v 17.5%, P < .0001), 
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extracutaneous disease (50% v 11%; P < .0001) and had a poorer 5-year disease-specific 
survival rate (52% v 94%; P < .0001) (TABLE 2 and FIG 2A). 
Prognostic Parameters Within the PCFCCL and PCLBCL-Leg Groups
Statistical analysis for potential risk factors within these two EORTC groups demonstrated 
the following results. Within the PCFCCL group, multivariate analysis of disease-specific 
survival showed that only round-cell morphology (P = .0002)—but not age, duration of skin 
lesions before diagnosis, size, or number and extent of skin lesions—was significantly related 
to death from lymphoma. Five of six lymphoma-related deaths in this group occurred in 
patients with round-cell morphology. 
Within the PCLBCL-leg group, multivariate analysis of disease-specific survival showed that 
multiple skin lesions at diagnosis (P = .001) and round-cell morphology (P = .003)—but 
not age, duration of skin lesions before diagnosis, or size and extent of skin lesions—were 
independent adverse prognostic factors. Further analysis of the relation between number 
and extent of skin lesions and survival showed that only one (9%) of 11 patients with a 
solitary tumor, compared with 12 (52%) of 23 patients with multiple tumors on one leg, and 
seven (50%) of 14 patients with generalized skin lesions including one or both legs died of 
lymphoma (P = .01). 
Reproducibility Study
Among 38 cases studied for reproducibility, 21 cases (55%) were classified consistently as 
either round-cell or cleaved-cell PCLBCL by all of the six pathologists, in accordance with 
the result obtained 
by consensus during 
the histologic review. 
In seven cases (18%), 
all but one of the six 
pathologists agreed with 
the classification. In 
the remaining 10 cases 
(26%), two or more 
pathologists disagreed 
with the others and 
with the result of the 
histologic review. There 
was no significant difference between the Dutch and the French panels of pathologists for the 
rate of misclassification. 
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DISCUSSION
Previous studies demonstrated that PCLBCL-leg differs from PCFCCL that arises at other 
sites by several characteristics, including age at presentation and bcl-2 protein expression, 
and by a more unfavorable prognosis.5,6,8,11,12,24 For these reasons, PCLBCL-leg was included 
as a separate group in the EORTC classification.6 However, delineation of this subgroup 
of PCLBCL patients on the basis of site has been much disputed.13-17 Indeed, the respective 
role of site and other potential clinical or histologic prognostic factors had to be evaluated 
in a large multivariate study. Such multivariate analyses were rarely performed in primary 
cutaneous lymphomas. In a recent evaluation of 158 patients with a primary cutaneous 
lymphoma other than mycosis fungoides and the Sézary syndrome,8 we found that the 
prognostic group according to the EORTC classification and the distribution of skin lesions 
were independent prognostic factors. However, this previous study included only a minority 
of patients with a PCLBCL and was unable to identify specific prognostic factors in these 
lymphomas which represent the most controversial group of the EORTC classification. In 
particular, the delineation of PCLBCL-leg as an independent subgroup had to be validated in 
a large international study restricted to PCLBCL. 
In this European multicenter study of 145 patients with PCLBCL, we found that round-cell 
morphology, the location on the leg, and multiple skin lesions at diagnosis were independent 
adverse prognostic factors. Other characteristics, including age, had no significant effect on 
death from lymphoma after morphology, site, and number of skin lesions were taken into 
account. 
This study shows that location is an independent prognostic factor in PCLBCL and provides 
further evidence that major differences exist between PCLBCL presenting on the leg and 
PCLBCL presenting at other sites. Patients from this latter group, included in the PCFCCL 
group in the EORTC classification for primary cutaneous lymphomas, presented with skin 
lesions on the head or trunk in most cases, rarely developed extracutaneous disease, and had 
an excellent prognosis with overall and disease-specific 5-year survival rates of 85% and 
94%, respectively. 
In contrast, patients with PCLBCL-leg were older, developed extracutaneous disease more 
often, and had a significantly poorer prognosis, with overall and disease-specific 5-year 
survival rates of 42% and 52%, respectively. In addition, the duration of skin lesions before 
diagnosis was much shorter in this group. In contrast to 14 (14%) of 97 patients with 
PCFCCL, only one (2%) of 48 patients with PCLBCL-leg had a history of a pseudo-B-cell 
lymphoma. Histologically, PCLBCL-leg much more frequently showed a predominance of 
round blasT-cells (75% v 17.5%; P < .0001) and much more often expressed bcl-2 protein 
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(TABLE 2). Expression of bcl-2 protein was not included in the multivariate prognostic analysis, 
since bcl-2–stained sections were only available in approximately 35% of cases. Therefore, 
additional studies are required to determine whether bcl-2 protein expression is primarily 
related to site or to a round-cell morphology and whether it represents an independent 
prognostic parameter in PCLBCL. In the present study, tumors were not investigated for the 
presence of the 14;18 translocation. However, a previous study demonstrated that the increased 
bcl-2 expression in PCLBCL-leg was not associated with the 14;18 translocation.12 
The most discriminating prognostic parameter in the total group of 145 patients with 
PCLBCL was a predominance (> 50%) of large B-cells with round nuclei. Although there 
was an important overlap between location and morphology, this parameter remained an 
independent prognostic factor both in the PCFCCL group and the PCLBCL-leg group. This 
observation has not been reported previously. Therefore, the question arises of whether 
PCLBCL should be subdivided primarily on the basis of morphology rather than site, as 
suggested in the EORTC classification. However, histologic subclassification of diffuse large 
B-cell lymphomas in a reproducible way is notoriously difficult (Revised European-American 
Lymphoma classification).18 Because of these difficulties, we preferred a simple subdivision on 
the basis of more or less than 50% blasT-cells with round nuclei. The reproducibility of this 
subdivision was evaluated in a small sample because it was not anticipated that multivariate 















promotie.indb   106 18-01-2005   21:53:47
chapter 6  page 107
PROGNOSTIC FACTORS IN PRIMARY CUTANEOUS LARGE B-CELL LYMPHOMAS: A EUROPEAN MULTICENTER STUDY
28 (74%) of 38 cases were classified consistently as either round-cell or cleaved-cell PCLBCL 
by all or all but one of six pathologists. This demonstrates that distinction on the basis of 
morphology may be difficult in some cases and that a primary subdivision of PCLBCL on 
this basis would probably have a lower reproducibility than the more simple classification 
according to location (EORTC).6 However, morphology constitutes an independent additional 
prognostic factor that should be taken into account for a more accurate management and 
treatment of PCLBCL (FIG 3). 
The presence of multiple skin lesions at diagnosis was the last independent prognostic factor 
associated with death from lymphoma in the total group of 145 PCLBCL patients. This result 
has to be interpreted in view of prognostic analyses in subgroups before being translated into 
guidelines for practical management of PCLBCL. Within the PCFCCL group, only round-cell 
morphology was associated with a poor prognosis. Neither the number of skin lesions nor the 
presence of multifocal as opposed to solitary or localized skin lesions was significantly related 
to survival, which is consistent with the results of previous studies.5,6,25 In contrast, both 
round-cell morphology and the presence of multiple skin lesions at diagnosis were significant 
adverse prognostic factors within the PCLBCL-leg group. Furthermore, the number of skin 
lesions was indeed the most important prognostic parameter in these patients. The 5-year 
survival rate was100% in patients with a single skin tumor on one leg versus 45% and 36% 
in patients with multiple tumors on one or both legs, respectively. Therefore, we suggest that 
only patients with a single tumor should be treated with radiotherapy. All other patients with 
PCLBCL-leg can probably best be treated with systemic chemotherapy. 
In view of the results of this prognostic analysis in 145 patients with PCLBCL, practical 
guidelines for appropriate management and treatment can be provided (FIG. 3). Four 
subgroups can be distinguished. PCFCCL with a cleaved-cell morphology is the most common 
subgroup. The disease-related 5-year survival rate in this group was 99% (FIG 2C), and the 
5-year relative survival rate was 100%. This indicates that mortality in these patients does 
not exceed mortality in a similar cohort matched by age and sex in the general population. 
Radiotherapy is the preferred mode of treatment in this group, probably even in patients 
presenting with multifocal skin lesions.25 PCFCCLs with a round-cell morphology are 
uncommon and have a more unfavorable prognosis. Although definite conclusions cannot 
be drawn from this small group, we suggest that patients presenting with a single lesion or 
few clustered lesions can best be treated with radiotherapy, whereas in case of multifocal skin 
lesions, systemic chemotherapy is required. Most patients with PCLBCL-leg have a round-
cell morphology. Cases of PCLBCL-leg with a cleaved-cell morphology are less common and 
have a somewhat better prognosis. However, irrespective of the histologic subtype, patients 
with PCLBCL-leg should be treated with systemic chemotherapy whenever possible.6,8,11,26 
Only in patients presenting with a single tumor may radiotherapy be preferred. However, no 
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definite conclusions can yet be drawn only on the basis of retrospective studies. Appropriate 
clinical trials are necessary to validate these therapeutic guidelines.
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ABSTRACT
Purpose
Although patients with primary cutaneous B-cell lymphoma (CBCL) and localized skin 
lesions are generally treated with radiotherapy and have an excellent prognosis, the clinical 
behavior and optimal treatment of CBCL presenting with multifocal skin lesions are less 
well defined. In this study, we evaluated the clinical behavior of and results of treatment for 
multifocal CBCL in 29 patients, and we formulated therapeutic guidelines. 
Patients and methods
The study group included 16 patients with primary cutaneous follicular center-cell lymphoma 
(PCFCCL), eight with primary cutaneous immunocytoma (PCI), and five with primary 
cutaneous large B-cell lymphoma presenting on the legs (PCLBCL of the leg). 
Results
Only one of the 24 patients with multifocal PCFCCL or PCI developed extracutaneous 
disease, and no patient died from lymphoma (median follow-up, 54 months). In patients with 
PCFCCL, treatment with either multiagent chemotherapy (nine patients) or radiotherapy 
directed toward all skin lesions (five patients) proved equally effective in terms of complete 
remission, relapse, and survival. In contrast, all five patients with PCLBCL of the leg developed 
extracutaneous disease, and four of the five died from systemic lymphoma, 8 to 36 months 
(median, 21 months) after diagnosis. 
Conclusion
The results of these preliminary studies suggest that patients with PCFCCL or PCI presenting 
with multifocal skin lesions have the same excellent prognosis that patients with localized 
PCFCCL or PCI have and that radiotherapy directed toward all skin lesions is as effective 
as multiagent chemotherapy. Patients with PCLBCL of the leg have a more unfavorable 
prognosis, particularly patients presenting with multifocal skin lesions. This last group should 
always be treated with multiagent chemotherapy. 
INTRODUCTION
Primary cutaneous B-cell lymphomas (CBCLs) constitute approximately 20% to 25% of 
all cutaneous lymphomas.1,2 The European Organization for Research and Treatment 
of Cancer (EORTC) divides primary CBCLs into primary cutaneous follicular center-cell 
lymphoma (PCFCCL), primary cutaneous immunocytoma (PCI), and primary cutaneous 
large B-cell lymphoma (PCLBCL) of the leg.2 PCFCCLs, which comprise malignant B-cell 
lymphomas classified as centroblastic/centrocytic or centroblastic lymphoma in the updated 
Kiel classification,3 represent the most common type of CBCL. These lymphomas generally 
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present with localized skin lesions (usually localized on the head or trunk), rarely disseminate 
to extracutaneous sites, and are associated with an excellent prognosis, with a 5-year survival 
rate of more than 95%.4-7 PCI more often presents with skin lesions on the arms and legs and 
is also associated with an excellent prognosis.8,9 Disease-related deaths have not been reported 
thus far. In the Revised European-American Lymphoma classification,10 similar lymphomas 
are designated primary cutaneous marginal zone B-cell lymphomas or mucosa-associated 
lymphoid tissue–type lymphomas.11-13 PCLBCLs of the leg, which histologically resemble 
centroblastic lymphomas in most cases and immunoblastic lymphomas less commonly, have 
recently been delineated as a separate group. This type of CBCL predominantly affects elderly 
patients, more often disseminates to extracutaneous sites, and is associated with a more 
unfavorable prognosis (5-year survival rate, 58%) compared with the other two groups.14 
In patients with CBCL presenting with solitary or localized skin lesions, radiotherapy is the 
preferred treatment.15,16 However, the optimal treatment for patients presenting with multifocal 
skin lesions, which is more uncommon, has not yet been well defined. Because patients 
with such lymphomas are considered to have a higher risk for developing extracutaneous 
disease, some studies suggest that these patients should be treated with aggressive multiagent 
chemotherapy.17 In the present study, we evaluated the clinical and histologic data from 
29 patients with primary CBCL and multifocal skin lesions who registered with the Dutch 
Cutaneous Lymphoma Group between 1985 and 1997. The main goals of this study were, 
first, to determine whether the clinical behavior of multifocal CBCL differs from that of the 
more common localized CBCL and, second, to formulate guidelines for the management and 
treatment of patients with multifocal CBCL. 
PATIENTS AND METHODS
All patients with primary CBCL with multifocal skin lesions at presentation who were 
registered with the Dutch Cutaneous Lymphoma Group were selected for this study. Multifocal 
skin disease was defined as skin involvement of at least two nonadjacent skin areas. Patients 
presenting with multiple skin lesions that did not fit into one radiation field were considered 
to have multifocal skin disease. Of the 149 patients with primary CBCL registered between 
1985 and 1997, 29 (14%) had multifocal lesions at the time of diagnosis, a proportion similar 
to those in other large series.7,18 In all cases, adequate staging procedures—including physical 
examination, complete blood cell counts, hepatic and renal function tests, chest radiography, 
abdominal computed tomography, and bone marrow cytology and histology—had been 
performed and extracutaneous disease had not been demonstrated. According to the EORTC 
classification for primary cutaneous lymphomas, this study group included 16 patients with 
PCFCCL (patients no. 1 through 16), eight with PCI (patients no. 17 through 24), and five 
with PCLBCL of the leg (patients no. 25 through 29) (TABLE 1). This latter group included 
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patients presenting with skin lesions on both lower legs, and three of these patients had skin 
lesions at other sites as well. Follow-up data had been collected each year from referring 
dermatologists or oncologists and were available for all cases in the registry of the Dutch 
Cutaneous Lymphoma Group. 
RESULTS
The main clinical characteristics of the three patient groups are presented in TABLES 1 and 2. 
The total group of 29 patients included 17 men and 12 women. The median age at the time 
of diagnosis was 56 years (range, 26 to 92 years). The length of time before diagnosis that 
patients had had skin lesions varied between 2 and 480 months (median, 24 months). In eight 
of the 29 patients, a diagnosis of pseudo–B-cell lymphoma had been made on viewing the 
same lesions (patient no. 17) or other lesions (patients no. 9, 10, 16, 20, 22, 23, and 24) 24 to 
192 months (median, 60 months) before a definite diagnosis of CBCL was made. 
The group of patients with PCFCCL was composed of 16 patients, 11 men and five women. 
The median age at the time of diagnosis was 56 years (range, 27 to 84 years). Clinically, these 
multifocal PCFCCLs usually involved the trunk (FIG 1). These 16 patients presented with 
multiple tumors, nodules, and/or plaques on the back (n = 16), the chest or abdomen (n = 10), 
the arms (n = 7), and/or the head and neck region (n = 2). Initial therapy consisted of six 
cycles of multiagent chemotherapy—including courses of cyclophosphamide, doxorubicin, 
vincristine, and prednisone (CHOP) therapy (in eight patients: patients no. 6 through 13) 
and courses of cyclophosphamide, vincristine, and prednisone therapy (patient no. 14)—or 
radiotherapy directed toward all visible skin lesions (in five patients: patients no. 1 through 5) 
(TABLE 1). Radiotherapy consisted of electron beam irradiation (4 to 10 million electron volts) 
with a radiation dose of 40 Gy. Of the two remaining patients, one patient (patient no. 15) 
refused any aggressive treatment and was therefore treated with topical corticosteroids only, 
and the other patient (patient no. 16) did not receive any treatment, because the skin lesions 
showed the tendency to regress spontaneously. 
Initial treatment in the PCFCCL group resulted in complete remission in 15 of 16 patients, 
including patient no. 16, all of whose skin lesions disappeared without any therapy. The 
disease-free survival time for these 15 patients varied between 11 and 72 months (median, 
38 months). Cutaneous relapse was noted in four of 16 patients (patients no. 11, 14, 15, and 
16). Only one patient (patient no. 12) developed positive cervical lymph nodes, but these 
lesions regressed spontaneously and the patient did not require additional treatment. It is 
interesting to note that cutaneous or extracutaneous relapse occurred in three of the nine 
patients treated with multiagent chemotherapy but in none of the five patients in whom all 
initial skin lesions had been treated with radiotherapy. Follow-up data indicated that none of 
promotie.indb   114 18-01-2005   21:53:51
chapter 7  page 115
TREATMENT OF MULTIFOCAL PRIMARY CUTANEOUS B-CELL LYMPHOMA: A CLINICAL FOLLOW-UP STUDY OF 29 PATIENTS
promotie.indb   115 18-01-2005   21:53:52
chapter 7  page 116
TREATMENT OF MULTIFOCAL PRIMARY CUTANEOUS B-CELL LYMPHOMA: A CLINICAL FOLLOW-UP STUDY OF 29 PATIENTS
these 16 patients died from lymphoma, after a median follow-up of 52 months (range, 20 to 
179 months). 
The group of patients with PCI consisted of five men and three women. The median age at the 
time of diagnosis was 43 years (range, 26 to 80 years). Consistent with findings of previous 
studies, these lymphomas usually involved the arms and/or legs (seven of eight cases), whereas 
the head and trunk were involved in 
one and four cases, respectively. Initial 
treatment was more varied than that 
in the PCFCCL group and consisted of 
multiagent chemotherapy (patients no. 
17 and 21), single-agent chemotherapy 
(patient no. 22), radiotherapy or 
surgical excision of only some of 
the skin lesions (patients no. 18, 19, 
and 20), or treatment with topical 
corticosteroids (patients no. 23 and 24) 
(Table 1). Only the patient who was 
treated with CHOP therapy achieved 
complete remission. Cutaneous relapse 
occurred in all eight patients, including 
the patient treated with CHOP therapy. 
However, none of these eight patients 
developed extracutaneous disease or 
died from lymphoma, after a median 
follow-up of 65 months (range, 14 
to 149 months). Partial spontaneous 
regression occurred in 50% of cases; 
complete spontaneous regression of all 
lesions did not occur. 
The group of patients with PCLBCL 
of the leg included four women and 
one man. The median age at diagnosis 
was 76 years (range, 35 to 92 years). 
Clinically, these patients presented with 
plaques and tumors on both lower legs 
(patients no. 25 and 26) or on the leg 
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or legs and other sites as well (Fig 2). Initial therapy, which was often suboptimal because 
of the age and general condition of the patients, consisted of single-agent or multiagent 
chemotherapy (patients no. 26 through 29) or radiotherapy directed toward all skin lesions 
(patient no.  25). 
Only two patients with PCLBCL of the leg achieved complete remission, which was, 
however, short-lived (6 and 7 months). All five patients developed extracutaneous disease, 
7 to 36 months (median, 18 months) after diagnosis. Two patients (patients no. 25 and 27) 
died rapidly, before further treatment could be initiated. In two patients (patients no. 26 and 
29), treatment with more aggressive chemotherapy (CHOP or CHOP-like therapy) resulted 
in only partial remission. One patient (patient no. 28), a 35-year-old man who only partially 
responded to cyclophosphamide, etoposide, and vincristine therapy, received an autologous 
bone marrow transplant, which resulted in sustained complete remission. Follow-up data 
indicated that four (80%) of the five patients in this group died from systemic lymphoma, 
8 to 36 months after diagnosis; only one patient remained alive and well. The median survival 
time for this group was 31 months (range, 8 to 85 months). 
DISCUSSION
Although there is general consensus among cutaneous lymphoma centers that primary CBCL 
presenting with solitary or localized skin lesions, irrespective of clinical or histologic subtype, 
should be treated with optimal doses of radiotherapy (40 Gy), the optimal treatment for the 
rare CBCL presenting with skin lesions at multiple sites has not been well defined. Some 
anecdotal reports suggest that patients with multifocal CBCL have a more unfavorable 
prognosis and should therefore be treated with aggressive multiagent chemotherapy.17 The 
guidelines of the Dutch Cutaneous Lymphoma Group, most recently revised in 1990, also 
indicate that patients with PCFCCL and PCLBCL of the leg presenting with multifocal skin 
lesions are best treated with systemic chemotherapy. Patients with multifocal PCI are treated 
less aggressively because they rarely develop extracutaneous disease, and lymphoma-related 
deaths in this group have not yet been reported.8,9 
These therapeutic guidelines, however, are mainly based on clinical experience and are not 
supported by published studies. In fact, follow-up data from large groups of patients with 
multifocal CBCL have never been published. In recent years, in view of the favorable prognosis 
for most patients with CBCL, there has been increasing reluctance to treat these patients with 
multifocal CBCL with multiagent chemotherapy, particularly when they present with only 
two or three skin lesions at different sites. In such patients, radiotherapy directed toward 
all visible skin lesions is considered an attractive alternative. In an attempt to create new 
guidelines for the treatment of patients with multifocal CBCL, we first evaluated clinical, 
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histologic, and follow-up data from 29 patients with multifocal CBCL who were registered 
with the Dutch Cutaneous Lymphoma Group between 1985 and 1997. We first wanted to 
determine whether the clinical behavior of multifocal primary CBCL differs from that of 
CBCL presenting with localized skin lesions. 
Only six of the 29 patients in our study developed extracutaneous disease, and only four died 
from systemic lymphoma. However, analysis of the data for the separate groups of CBCL 
recognized in the EORTC classification for primary cutaneous lymphomas showed that only 
one of the 24 patients with PCFCCL or PCI developed extracutaneous disease and that none 
of these patients died from lymphoma, after a median follow-up of 54 months (range, 14 to 
179 months). These data clearly indicate that patients with multifocal PCFCCL and those 
with multifocal PCI have the same low tendency to develop extracutaneous disease, and 
the same excellent prognosis, as do patients with the more common CBCLs presenting with 
localized skin lesions. Similar results can be found in the report of a study by Santucci et al,7 
in which 11 of 83 patients presented with multifocal skin lesions. In contrast, in our group 
FIGURE 1. PCFCCL. 
Note the many 
plaques and nodules 
on the chest, 
abdomen, and back. 
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of patients with PCLBCL of the leg, all five patients developed extracutaneous disease, and 
four of the patients died from systemic lymphoma. These findings confirm the results of 
recent studies indicating that PCLBCLs of the leg represent a separate group, with a higher 
tendency to disseminate to extracutaneous sites and associated with a more unfavorable 
prognosis.14,19 Most recently, it was found that PCLBCLs of the leg consistently express bcl-
2 protein as well as Fas (CD95) ligand, whereas expression of Fas (CD95) is variable.20,21 
In contrast, PCFCCLs do not or rarely express bcl-2 protein and Fas ligand, whereas Fas is 
always strongly expressed. The differing expression of these apoptosis-related molecules may 
explain, at least in part, the different clinical behavior of these two types of primary CBCL. 
Compared with our previous study of PCLBCL of the leg (18 patients),14 in the present study 
the rates of extracutaneous relapse (38% v 100%) and lymphoma-related death (28% v 
80%) were considerably higher. This increase may be related to the small sample size in the 
current study. However, recent evaluation of 21 patients with PCLBCL of the leg who were 
registered with the Dutch Cutaneous Lymphoma Group, including the 18 patients described 
previously,14 shows that only one of six patients presenting with a single tumor on one leg 
died from lymphoma, after a median follow-up of 40 months (range, 18 to 120 months) 
(unpublished data). It is therefore possible that in this particular group, patients presenting 
with multifocal skin lesions (eg, skin lesions on both legs) have a worse prognosis than do 
FIGURE 2. PCLBCL of 
the leg. Note the 
many tumors (some 
confluent) on both 
lower legs. 
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patients presenting with a skin lesion or lesions limited to one leg. A European multicenter 
study of more than 150 primary cutaneous large B-cell lymphomas has recently been started 
and will address this issue. 
The ultimate goal of the present study was to create new guidelines for the treatment of 
patients with multifocal CBCL. The central issue to be addressed was which patients should 
be treated with aggressive multiagent chemotherapy (CHOP or CHOP-like therapy). The 
guidelines of the Dutch Cutaneous Lymphoma Group, formulated in 1990, indicated that all 
patients with multifocal CBCL, except for patients with PCI, should be treated with CHOP 
or CHOP-like therapy. However, the results of the present study indicate that in patients 
with multifocal PCFCCL, irradiation of all visible sites may be equally effective. Such an 
approach was taken in five patients (patients no. 1 through 5) and resulted in sustained 
complete remission, with a median disease-free survival time of almost 5 years. Relapse was 
not noted in these patients. In contrast, two of eight patients with multifocal PCFCCL treated 
with CHOP therapy had multiple cutaneous relapses (patient no. 11) or an extracutaneous 
relapse (patient no. 12). The other patients treated with CHOP achieved sustained complete 
remission, varying in length between 20 and 59 months. No major differences were found 
between the patients treated with radiotherapy and those treated with CHOP in terms of 
histologic subtype (centrocytic/centroblastic or centroblastic lymphoma), the number of 
affected skin sites, or total tumor burden. Taken together, these preliminary findings suggest 
that in patients with multifocal PCFCCL, irrespective of histologic appearance, radiotherapy 
directed toward all skin lesions is an effective and safe alternative. Only in exceptional cases—
FIGURE 3. Dutch 
Cutaneous 
Lymphoma Group 
guidelines for the 
treatment of CBCL. 
In cases of Borrelia 
burgdorferi infection, 
antibiotic therapy 
should be tried 
first. *Use when 
radiotherapy is nearly 
impossible (when 
there are numerous 
or extremely thick 
lesions). MZB, 
marginal zone B-cell 
lymphoma. 
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involving numerous or extremely thick tumors—should CHOP therapy still be considered. 
In cases of cutaneous relapse with only one or a few skin lesions, radiotherapy is again the 
preferred treatment. 
The prolonged complete remissions (up to 6 years or more) achieved in these patients with 
multifocal PCFCCL after irradiation of all visible skin lesions are intriguing. In particular, in 
such multifocal cases, one would expect low levels of circulating clonal B-cells and—given 
that these cells are unlikely to be affected by radiotherapy—recurring disease. However, the 
presence of circulating clonal B-cells in patients with CBCL has not been investigated thus 
far. These prolonged remissions are reminiscent of the results of total-skin electron beam 
irradiation in patients with early (patch/plaque)-stage mycosis fungoides (MF), namely 5-year 
relapse-free survival rates of 25% to 50%, depending on the extent of skin involvement.22,23 
Muche et al24 demonstrated circulating clonal T-cells in more than 50% of patients with 
early MF but considered a relationship between the presence of circulating clonal T-cells 
and poor prognosis unlikely. Nevertheless, studies on the relationship between the presence 
of circulating clonal T-cells (in MF) or clonal B-cells (in CBCL) and disease-free survival 
would be of interest because they may provide a rationale for the optimal treatment in these 
conditions. 
PCIs show the characteristic clinical behavior of low-grade malignant (small-cell) B-cell 
lymphomas.25 Spontaneous regression of (part of the) skin lesions is frequently noted, and 
prognosis is excellent, as it is in patients with multifocal skin lesions. In addition, most 
patients have recurrent or persistent disease, and sustained complete remission or cure 
is rarely achieved. Therefore, these multifocal PCIs are best treated with radiotherapy or 
excision of individual skin lesions. When excision or radiation is no longer an option, because 
patients have too many lesions, nonaggressive chemotherapy—such as chlorambucil and/or 
prednisone therapy or perhaps even courses of cyclophosphamide, vincristine, and prednisone 
therapy—may be considered. Intralesional administration of recombinant interferon alfa has 
been suggested as an effective alternative in the treatment of both PCI and PCFCCL and 
could be a useful addition to the nonaggressive therapeutic options for these lymphomas, but 
the number of patients so treated who have reported on thus far is still small.26-28 Moreover, 
the advantage of interferon alfa over radiotherapy is uncertain and further study is needed. In 
cases of small recurrent skin lesions, topical or intralesional administration of corticosteroids 
may be considered. Borrelia burgdorferi infections have been implicated in the pathogenesis 
of both pseudo–B-cell lymphomas and CBCLs, including PCI and PCFCCL.29,30 In patients 
with serologic, bacteriologic, or molecular evidence of B. burgdorferi infection, treatment with 
antibiotics may result in complete remission and should therefore be attempted first.29,30 
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In accordance with previous findings by our group,14 patients with PCLBCL of the leg with or 
without involvement of other cutaneous sites have a more unfavorable prognosis. In this type 
of CBCL, multifocal skin lesions (eg, on both lower legs) might be an additional risk factor. 
With the exception of patients presenting with one solitary tumor, patients with PCLBCL 
of the leg should be treated with CHOP or CHOP-like therapy whenever possible. Less 
aggressive therapies, sometimes necessary because of the age of these patients, are unlikely to 
result in sustained complete remission. 
Finally, the results of the present study are also important for patients suspected of having CBCL 
and in whom a definite diagnosis cannot or cannot yet be made. The clinical consequences 
of not making a final diagnosis are generally minor, particularly in patients presenting with 
a solitary lesion. In such cases, radiotherapy or surgical excision may be a simple solution. 
However, in rare cases of suspected but not definite CBCL presenting with multifocal skin 
lesions, it is often difficult to decide whether aggressive chemotherapy should be given. The 
results of the present study clearly indicate that in such patients a conservative approach 
may be taken. This recommendation is supported by follow-up data from 14 patients with 
suspected CBCL, which is considered a separate type in the Dutch registry. Treatment for 
these patients consisted of topical and/or intralesional administration of corticosteroids, low-
dose radiotherapy, or excision. In none of the patients was there progression to genuine 
CBCL, after a median follow-up of 36 months. 
In conclusion, the results of this and other studies suggest that not only in CBCL patients 
with solitary or localized skin lesions but also in CBCL patients presenting with skin 
lesions at multiple sites, irradiation of all visible skin lesions is equally effective and may be 
preferable because of less systemic toxicity (Fig 3). Only in patients with PCLBCL of the leg 
(with the exception of those presenting with one solitary tumor) and patients with PCFCCL 
and numerous or extremely thick skin lesions is CHOP or CHOP-like therapy indicated. 
However, it must be noted that although this study, compared with other studies to date, 
involves by far the largest group of patients with multifocal primary CBCL, these guidelines 
are based on findings for relatively small groups of patients and therefore require additional 
confirmation. 
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ABSTRACT
Background
Primary cutaneous B-cell lymphoma (CBCL) constitutes 20% of all primary cutaneous 
lymphomas. Apart from primary cutaneous large B-cell lymphoma presenting on the 
legs (PCLBCL-leg), primary CBCLs run an indolent clinical course, rarely disseminate to 
extracutaneous sites, and have an excellent prognosis. Because of recent observations in two 
patients who developed central nervous system (CNS) involvement, follow-up data of all 
primary CBCL patients registered at the Dutch Cutaneous Lymphoma Group between 1985 
and 1998 were investigated for evidence of CNS involvement. 
Methods
Follow-up data from 160 primary CBCLs were evaluated. This group included 122 primary 
cutaneous follicle center cell lymphomas (PCFCCLs), 16 primary cutaneous immunocytomas 
or marginal zone B-cell lymphomas, and 22 PCLBCL-leg.
 
Results
Of all 160 patients with primary CBCLs, 11 died of lymphoma, including 4 of 122 patients 
(3%) with PCFCCL and 7 of 22 patients (32%) with PCLBCL-leg. Four of these 11 patients, 
including 3 with PCFCCL and 1 with PCLBCL-leg, had developed CNS involvement 3-93 
months (median, 30 months) after diagnosis. All patients died 1-9 months (median, 7 months) 
after the development of CNS involvement. In the group of 122 patients with PCFCCL, CNS 
involvement occurred in 3 of 7 patients (43%) who developed extracutaneous disease and 
accounted for 3 of 4 lymphoma-related deaths (75%). 
Conclusions
The results of this study indicate that approximately 2% of all primary CBCLs may develop 
CNS involvement. Whereas, in rare PCFCCL patients, developing extracutaneous disease 
CNS involvement was an important cause of death, patients with PCLBCL-leg and secondary 
CBCL died more frequently due to involvement of non-CNS organ systems.
INTRODUCTION
Cutaneous B-cell lymphomas (CBCLs) are a rare group of malignant B-cell lymphomas that 
present in the skin without evidence of extracutaneous involvement at the time of diagnosis. 
The recently proposed European Organization for Research and Treatment of Cancer 
(EORTC) classification1 recognizes three different types of CBCL: primary cutaneous follicle 
center cell lymphoma (PCFCCL), primary cutaneous immunocytoma or marginal zone 
B-cell lymphoma, and primary cutaneous large B-cell lymphoma of the leg (PCLBCL-leg). 
Primary cutaneous plasmacytoma and primary cutaneous intravascular B-cell lymphoma are 
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extremely rare and have been included as provisional entities in the EORTC classification. 
Both PCFCCL and primary cutaneous immunocytomas are known for their indolent clinical 
behavior, their extremely low tendency to disseminate to extracutaneous sites, and their 
excellent prognosis (5-year survival rage > 95%).2-6 Radiotherapy is the preferred mode of 
treatment not only for patients with solitary or localized skin lesions (±85% of patients) but 
probably also for patients with multifocal skin lesions.7-9 PCLBCL-leg predominantly affects 
elderly patients, and these patients develop extracutaneous disease more often and have an 
intermediate prognosis (5-year-survival rate, 58%).10,11
The EORTC classification is clinically validated by long term follow-up data from a large 
group of primary cutaneous lymphomas registered at the Dutch Cutaneous Lymphoma 
Group.1 Recently, the French Cutaneous Lymphoma Group confirmed the prognostic value 
of this classification.12 From all of the patients in our registry, follow-up data are collected 
yearly. Recently, follow-up information was provided on two patients with primary CBCL 
who had developed involvement of the central nervous system (CNS), which proved fatal 
within several months.
CNS involvement has been reported regularly in patients with advanced stages of mycosis 
fungoides13-18 and is common in patients with intravascular lymphoma.19,20 However, detailed 
reports on CNS involvement in patients with a primary CBCL have not been published.
Because of these observations, the follow-up data from 168 primary CBCL patients registered 
at the Dutch Cutaneous Lymphoma Group were evaluated for evidence of CNS involvement. 
The results of this study, which revealed four primary CBCL patients with ultimate CNS 
involvement, are presented.
MATERIALS AND METHODS
From October 1985 to September 1998, 168 patients with primary CBCL were included 
in the registry of the Dutch Cutaneous Lymphoma Group. This group was comprised of 
122 patients with PCFCCL, 16 patients with primary cutaneous immunocytoma, 22 patients 
with PCLBCL-leg, and a miscellaneous group of 8 patients with CBCL, including 4 patients 
with primary cutaneous intravascular large B-cell lymphoma who are not discussed further 
in this report. The diagnosis was based on a combination of histologic, immunophenotypic, 
and clinical criteria that have been described previously.1 Briefly, PCFCCL is defined as 
CBCL composed of variable proportions of centrocytes (small or large, cleaved follicle center 
cells) and centroblasts (large, noncleaved follicle center cells), which are classified as either 
centroblastic-centrocytic or centroblastic in the updated Kiel classification.21 In the majority 
of these patients, PCFCCLs are diffuse large cell lymphomas. Most patients (> 80%) with 
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PCFCCL have localized skin lesions either on the head or on the trunk at presentation. Patients 
with diffuse large cell lymphomas presenting with skin lesions on the leg(s) are considered as a 
separate group in the EORTC classification. Primary cutaneous immunocytoma or marginal 
zone B-cell lymphoma are defined by the presence of a proliferation of small lymphocytes, 
lymphoplasmacytoid cells, and plasma cells. In all 160 patients, adequate staging procedures 
(physical examination, complete blood cell counts, hepatic and renal function tests, chest 
radiography, abdominal computed tomography (CT), and bone marrow histology and 
cytology) at the time of diagnosis had failed to demonstrate extracutaneous disease.
For the purpose of comparison, 40 patients who were included in the registry with secondary 
CBCLs were evaluated as well. These patients had either presented with both cutaneous 
and extracutaneous localizations (n = 35 patients) or had a history of systemic lymphoma 
prior to the development of skin lesions (n = 5 patients). Histologic classification (updated 
Kiel classification) had shown 3 centrocytic lymphomas, 5 centroblastic/centrocytic 
lymphomas, 20 centroblastic lymphomas, 2 immunoblastic lymphomas, 9 immunocytomas, 
and 1 plasmacytoma. In all patients, follow-up data were evaluated for CNS involvement. 
Wherever necessary, additional information was obtained from the referring clinician.
RESULTS 
Evaluation of follow-up data of 160 primary CBCLs revealed 4 patients who developed CNS 
involvement. This concerned 3 patients with PCFCCL and 1 patient with PCLBCL-leg. It is of 
interest to note that, in the group with PCFCCL, after a median survival of 49 months (range, 
6-162 months), only 4 patients died of lymphoma and that 3 of these patients died of CNS 
involvement. In the group of 40 patients with secondary CBCLs, only 1 patient developed 
CNS involvement. Follow-up data and the relative frequency of CNS involvement for the 
different groups of CBCL are summarized in TABLE 1. The clinical details of the four primary 
CBCL patients who developed CNS involvement are summarized in TABLE 2 and are discussed 
in more detail below. 
Patient 1
A man age 65 years presented in 1990 with a solitary tumor with a greatest dimension of 4 cm 
on the left side of the chest. Histologic examination showed a diffuse proliferation of medium-
sized to large centrocytes and centroblasts and was classified as a centroblastic/centrocytic 
lymphoma (updated Kiel classification). Staging procedures, including physical examination, 
complete blood cell counts, hepatic and renal function tests, chest radiography, abdominal 
CT, and bone marrow histology and cytology, did not show evidence of extracutaneous 
involvement. According to the EORTC classification, this patient was classified with a 
PCFCCL. Local electron beam radiotherapy (4 megaelectron volts [MeV]; cumulative dose, 
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40 grays [Gy] in 20 fractions) resulted in complete remission. The patient had two cutaneous 
recurrences on the forehead (after 40 months and 72 months) that were treated with local 
electron beam radiotherapy (4 MeV; cumulative dose, 20 Gy in 5 fractions), again resulting in 
a complete remission. In May 1997, 81 months after the initial diagnosis, the patient presented 
with severe headache, exophthalmus, and diplopia. A brain CT scan revealed an orbital 
mass on the right side spreading to the cavernous and sphenoid sinuses without evidence of 
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bone destruction. Histologic examination showed a diffuse proliferation of centrocytes or 
centrocyte-like B-cells. Restaging did not reveal other lymphoma localizations. Cerebrospinal 
fluid examination (five samples) also was without abnormalities. Treatment with six cycles 
of multiagent chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone 
[CHOP]) combined with the intrathecal administration of methotrexate and prednisone 
again resulted in complete remission. However in, May 1998, the patient complained of gait 
instability. A CT scan showed an enhancing lesion in the right frontal region of the brain. 
Although there was no histologic confirmation of the lesion, a lymphoma localization was 
considered most likely because of the history of (recurrent) lymphoma, CNS signs, structural 
abnormalities on CT scan, and objective response to radiation treatment.22 He was treated 
with hyperfractionated photon therapy (6 MeV; cumulative dose, 40 Gy), which resulted in 
partial remission. However, 9 months later, he was admitted again to the hospital because of 
lowered consciousness and diabetes insipidus due to a recurrence of the lesion. Apart from 
the CNS lesions, multiple lymphoma localizations were present in the cervical region. He died 
shortly after admission and had received treatment only with palliative measures. An autopsy 
was not performed.
Patient 2
In 1993, a man age 68 years presented with two slowly progressive tumors measuring 9 × 7 cm 
and 2 × 3 cm that were close to one another on the left side of the chest and had appeared 1 year 
earlier. Histologic examination showed a centroblastic-centrocytic lymphoma (updated Kiel 
classification). Staging procedures (see above) revealed no extracutaneous disease. According 
to the criteria of the EORTC classification, a diagnosis of PCFCCL was made. Treatment, 
consisting of surgical excision followed by electron beam radiotherapy (4 MeV; cumulative 
dose, 40 Gy in 20 fractions) of the affected skin area, resulted in complete remission. In 
September 1995, the patient complained about backache. An X-ray of the vertebral column 
showed osteolysis of the first lumbar vertebra. Histologic examination showed a B-cell 
lymphoma. Treatment with chlorambucil as monoagent chemotherapy resulted in a partial 
remission. In February 1996, 30 months after initial diagnosis, the patient was admitted to 
the hospital because of lowered consciousness with left-sided facial paresis. A CT scan of the 
brain revealed multiple cerebral lesions suggestive of lymphoma localizations. Examination of 
the cerebrospinal fluid was not performed. Despite treatment with high dose corticosteroids, 
his neurologic condition deteriorated, and he died 1 month later. Permission for an autopsy 
was not granted.
Patient 3
In 1996, a woman age 66 years presented with a 6-month history of progressive papules 
and nodules on both the left hip and the buttock. Histologic examination showed a diffuse 
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proliferation of centroblasts and admixed immunoblasts, which was classified as a centroblastic 
lymphoma, polymorphic subtype. There were no B symptoms. Her general medical history 
revealed urticaria, Morbus Sjögren, hypercholesterolemia, and cardiac arrhythmia. Extensive 
staging (see Patient 1) revealed no extracutaneous localizations. According to the EORTC 
classification, this patient was diagnosed with PCFCCL. Because all skin lesions had 
disappeared spontaneously after biopsy, no treatment was given. However, 6 months later, she 
was admitted to the hospital with headache, acute disorientation, and left-sided homonymous 
hemianopia. A CT scan of the brain showed a single lesion in the right parietooccipital area. 
Cytologic examination of the cerebrospinal fluid showed a population of CD20 positive, 
atypical B-cells. Treatment with high dose corticosteroids was initiated; however, gradually, 
her neurologic status worsened, and she died 8 months after CNS involvement was diagnosed. 
An autopsy was not performed.
Patient 4
A woman age 71 years presented in February 1994 with a 1-month-history of rapidly 
growing nodules and plaques on both lower legs. Histologic examination showed a diffuse 
large B-cell lymphoma with a mixed population of large centrocytes (large cleaved cells) and 
classical centroblasts. Staging did not show evidence of extracutaneous disease. There were 
no B symptoms. According to the EORTC classification, the diagnosis PCLBCL of the leg was 
made. Treatment with 8 cycles of multiagent chemotherapy (cyclophosphamide, vincristine, 
and prednisone), resulted in complete remission. Between February 1995 and September 1996, 
the patient had multiple skin recurrences that were treated subsequently with cyclofosfamide, 
mitoxantrone, oncovin, and prednisone; a combination of chlorambucil and prednisone with 
additional radiotherapy; and etopside. In October 1996, she was admitted to the hospital 
with headache, right-sided ptosis, and paresis of the left arm. A magnetic resonance image 
of the brain showed no abnormalities. However, examination of the cerebrospinal fluid 
revealed the presence of neoplastic CD20 positive B-cells. Treatment consisted of whole brain 
radiotherapy and high dose corticosteroids. Nevertheless, her neurologic status deteriorated, 
resulting in epileptic fits, followed by coma. She died in December 1996, 34 months after 
the initial diagnosis. An autopsy revealed only gliosis, probably due to the radiotherapy that 
was given shortly before death. The adrenal glands and a small part of the liver (near the gall 
bladder) were involved by lymphoma. No other lymphoma localizations were found.
DISCUSSION
In the current report, we describe 4 patients with primary CBCL who developed CNS 
involvement. This group included 3 patients with PCFCCL and 1 patient with PCLBCL-leg. 
CNS involvement occurred after a median period of 30 months (range, 3-93 months) after the 
initial diagnosis and proved fatal after 1-9 months (median, 7 months). Presenting neurologic 
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complaints were headache, focal deficits, lowered consciousness, and disorientation.
Evaluation of follow-up data in the 122 patients with PCFCCL who were included in 
the Dutch registry revealed that only 7 patients had developed extracutaneous disease. In 
3 of these 7 patients, dissemination to (peripheral) lymph nodes had occurred. Multiagent 
chemotherapy resulted in sustained complete remissions in all 3 patients. The other 4 patients 
died of lymphoma. It is noteworthy that 3 of these 4 patients died of CNS involvement. 
CNS involvement was the first manifestation of extracutaneous disease in 1 patient and was 
preceded by ocular or focal bone involvement in the other 2 patients. The fourth patient 
who died of disseminated PCFCCL also presented with neurologic symptoms (sensorimotor 
deficit and pain of the left leg) but was not considered to have CNS involvement. This patient 
had been in complete remission for more than 7 years after multiagent chemotherapy (six 
CHOP courses) because of a PCFCCL presenting on the back. In this patient, the neurologic 
symptoms were caused by a large abdominal mass invading the spinal column with spinal 
cord compression.
In the group of patients with PCLBCL-leg, which is known as a lymphoma with an intermediate 
prognosis, 7 of 22 patients (32%) died of lymphoma, but only 1 patient died with CNS 
involvement (Patient 4). In addition, of the 40 patients with secondary CBCL who had been 
included in the Dutch registry, 20 patients (50%) died of lymphoma, and involvement of 
the CNS had been observed in only 1 of them. This woman age 72 years had presented with 
slowly progressive plaques on the right lower leg that showed the histologic appearance of a 
B-immunoblastic lymphoma. However, because a bone marrow biopsy showed a population 
of small neoplastic B-cells, she was considered to have a secondary CBCL. The results of 
further staging procedures were completely negative. After several skin recurrences, but never 
evidence of extracutaneous disease (apart from the bone marrow mentioned above), she 
developed CNS involvement 41 months after diagnosis and died 1 month later. The initial 
treatment of patients who developed CNS involvement was not different (except for Patient 
3) than in patients who showed no recurrences. Most patients received appropriate therapy 
for their lymphoma: radiotherapy for PCFCCL patients (Patients 1 and 2) and multiagent 
chemotherapy in multifocal PCLBCL-leg (Patient 4).9 All patients reached a complete 
remission. Therefore, CNS involvement in this group of patients cannot be explained by 
differences in their treatment.
Data from literature suggest that the overall risk of secondary CNS involvement for patients 
with non-Hodgkin lymphoma is 6%.23 Involvement of the eye, testis, peripheral blood, bone, 
bone marrow, or (para)-nasal sinuses by lymphoma has been reported to be a risk factor for 
dissemination to the CNS.23 In another report, the involvement of two or more extralymph 
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node sites and elevated lactose dehydrogenase also were described as independent risk factors 
for CNS involvement.24
Reports on CNS involvement in patients with primary cutaneous lymphoma mainly concern 
cutaneous T-cell lymphoma, particularly in patients with advanced stages of mycosis 
fungoides.13-18 In addition, in patients with intravascular large cell lymphoma, both the skin 
and the CNS are preferential sites of involvement.19,20 However none of the four patients 
with a primary cutaneous intravascular large B-cell lymphoma who were included in the 
registry of the Dutch Cutaneous Lymphoma Group between 1985 and 1998 developed CNS 
involvement (data not shown). Reports on CNS involvement in patients with primary CBCL 
are extremely rare. Recently, a report on 4 patients with PCLBCL-leg mentioned briefly that, 
in 2 of these 4 patients, CNS involvement had occurred, but detailed information was not 
provided.11 In addition, a patient with an extramedullary plasmacytoma presenting in the 
skin and disseminating to the CNS after a follow-up of 10 months has been reported.25
The prognosis of patients with non-Hodgkin lymphoma with secondary CNS involvement is 
poor. A median survival of only 2 months after CNS involvement has been reported,26 even 
with intensive treatment. The patients in this study had a comparable median life expectancy 
of 7 months (range, 1-9 months) after CNS involvement was confirmed.
In conclusion, the results of the current study indicate that aproximately 2% of patients 
with primary CBCL may develop CNS involvement. However, major differences were found 
between patients with the different types of CBCL. In the group of patients with PCFCCL, 
in which extracutaneous dissemination and lymphoma-related mortality are rare, CNS 
involvement was noted in 3 of 7 patients (43%) who developed extracutaneous disease and 
accounted for 3 of 4 lymphoma-related deaths (75%). In contrast, in the group of patients with 
PCLBCL-leg and in the group of patients with secondary CBCL, mortality generally resulted 
from the presence of widespread disease and uncommonly was caused by CNS involvement. 
An explanation for the high frequency of CNS involvement in patients with PCFCCL 
developing extracutaneous disease is not readily available. It is of interest that dissemination 
in these lymphomas often involves extralymph node sites. For instance, in the 7 patients 
who showed extracutaneous spreading who were included in this study, dissemination to 
bone (4 patients), CNS (3 patients), kidney (1 patient), orbit (1 patient), and paranasal sinus 
(1 patient), was documented in addition to lymph nodes (4 patients). Involvement of two or 
more extralymph node sites is considered an independent risk factor.24 Recent studies indicate 
that there is frequent CNS involvement in patients with primary mediastinal large B-cell 
lymphomas, which also showed a propensity to involve various extralymph node sites.27 The 
molecular mechanisms underlying this peculiar dissemination pattern in the group of patients 
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with PCFCCL is unknown at present. In particular, adhesion molecules involved in CNS 
involvement by non-Hodgkin lymphomas have not been identified.
REFERENCES
1. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC classification for 
primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the 
European Organization for Research and Treatment of Cancer. Blood 1997; 90: 354-71. 
2. Garcia CF, Weiss LM, Warnke RA, Wood GS. Cutaneous follicular lymphoma.  
Am J Surg Pathol 1986; 10: 454-63. 
3. Willemze R, Meijer CJLM, Sentis HJ, Scheffer E, van Vloten WA, Toonstra J, et al. Primary 
cutaneous large cell lymphomas of follicular center cell origin.  
J Am Acad Dermatol 1987; 16: 518-26. 
4. Pimpinelli N, Santucci M, Giannotti B. Cutaneous lymphoma: a clinically relevant classification. 
Int J Dermatol 1993; 32: 695-700. 
5. Pimpinelli N, Santucci M, Mori M, Vallecchi C, Giannotti B. Primary cutaneous B-cell lymphoma: 
a clinically homogeneous entity? J Am Acad Dermatol 1997; 37: 1012-6. 
6. Rijlaarsdam JU, van der Putte SC, Berti E, Kerl H, Rieger E, Toonstra J, et al. Cutaneous 
immunocytomas: a clinicopathologic study of 26 cases. Histopathology 1993; 23: 117-25. 
7. Piccinno R, Caccialanza M, Berti E, Baldini L. Radiotherapy of cutaneous B-cell lymphomas: our 
experience in 31 cases. Int J Radiat Oncol Biol Phys 1993; 27: 385-9. 
8. Rijlaarsdam JU, Toonstra J, Meijer OW, Noordijk EM, Willemze R. Treatment of primary 
cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 
patients treated with radiotherapy or polychemotherapy. J Clin Oncol 1996; 14: 549-55. 
9. Bekkenk MW, Vermeer MH, Geerts ML, Noordijk EM, Heule F, van Voorst Vader PC, et al. 
Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 
patients. J Clin Oncol 1999; 17: 2471-8. 
10. Vermeer MH, Geelen FAMJ, van Haselen CW, van Voorst Vader PC, Geerts ML, van Vloten WA, 
et al. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell 
lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group.  
Arch Dermatol 1996;132: 1304-8.
11. Starz H, Balda BR, Bachter D, Buchels H, Vogt H. Secondary lymph node involvement from 
primary cutaneous large B-cell lymphoma of the leg - sentinel lymph nodectomy as a new 
strategy for staging circumscribed cutaneous lymphomas. Cancer 1999; 85: 199-207. 
12. Grange F, Hedelin G, Joly P, Beylot-Barry M, D’Incan M, Delaunay M, et al. Prognostic factors in 
primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome.  
Blood 1999; 93: 3637-42. 
13. van Erp M, van Vloten WA, de Groot-Verhaar JC, Buruma OJ. Neurological sequelae in mycosis 
fungoides. Report of a case. Eur Neurol 1981;20: 388-93. 
promotie.indb   136 18-01-2005   21:54:03
chapter 8  page 137
FREQUENCY OF CENTRAL NERVOUS SYSTEM INVOLVEMENT IN PRIMARY CUTANEOUS B-CELL LYMPHOMA
14. Zackheim HS, Lebo CF, Wasserstein P, McNutt NS, Epstein EH Jr., Meyler S, et al. Mycosis 
fungoides of the mastoid, middle ear, and CNS. Literature review of mycosis fungoides of the 
CNS. Arch Dermatol 1983;119: 311-8. 
15. Sentis HJ, Padberg G, Buruma OJ, Bots GT, Willemze R, van Vloten WA. Neurological 
complications in patients with cutaneous T-cell lymphoma. Br J Dermatol 1986; 114: 359-66. 
16. Grevelink SA, Fuller GN, Olsen EA. Central nervous system involvement by cutaneous T-cell 
lymphoma. J Am Acad Dermatol 1991; 25: 542-9. 
17. Leal Filipe P, Sousa Coutinho V, Canhão P, Gouveia R, Cabeçadas J, Osório, et al. Mycosis 
fungoides with early central nervous system involvement. Acta Dermato-Venereol 1994; 74: 63-4. 
18. Peris K, Fargnoli MC, Berardelli A, Crecco M, Tomaselli R, Chimenti S. Peripheral nervous 
system involvement in a patient with large T-cell lymphoma arising from a pre-existing mycosis 
fungoides. Br J Dermatol 1998; 139: 299-301. 
19. Demirer T, Dail DH, Aboulafia DM. Four varied cases of intravascular lymphomatosis and a 
literature review. Cancer 1994; 73: 1738-45.
20. Bogomolski-Yahalom V, Lossos IS, Okun E, Sherman Y, Lossos A, Polliack A. Intravascular 
lymphomatosis - an indolent or aggressive entity?. Leukemia Lymphoma 1998;29: 585-93. 
21. Stansfeld AG, Diebold J, Noel H, Kapanci Y. Rilke F, Kelenyi G, et al. Updated Kiel classification 
for lymphomas. Lancet 1988;1: 292-93.
22. Mackintosh FR, Colby TV, Podolsky WJ, Burke JS, Hoppe RT, Rosenfelt FP, et al. Central nervous 
system involvement in non-Hodgkin’s lymphoma: an analysis of 105 cases.  
Cancer 1982; 49: 586-95. 
23. Liang R, Chiu E, Loke SL. Secondary central nervous system involvement by non-Hodgkin’s 
lymphoma: the risk factors. Hematol Oncol 1990; 8: 141-5. 
24. van Besien K, Ha CS, Murphy S, McLaughlin P, Rodriguez A, Amin K, et al. Risk factors, 
and outcome of central nervous system recurrence in adults with intermediate-grade and 
immunoblastic lymphoma. Blood 1998; 91: 1178-84. 
25. Prost C, Reyes F, Wechsler J, Gaston A, Richard I, Poirier J. High-grade malignant cutaneous 
plasmacytoma metastatic to the central nervous system. A case report with electron microscopy, 
immunohistological, and neuropathological studies. Am J Dermatopathol 1987;9: 30-6. 
26. Bollen EL, Brouwer RE, Hamers S, Hermans J, Kluin PhM, Sanskatsing SUC, et al. Central nervous 
system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients.  
Arch Neurol 1997; 54: 854-9. 
27. Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC. CNS involvement in primary 
mediastinal large B-cell lymphoma. J Clin Oncol 1999; 17: 2479-85.
promotie.indb   137 18-01-2005   21:54:04
promotie.indb   138 18-01-2005   21:54:06
CHAPTER 9
General discussion
promotie.indb   139 18-01-2005   21:54:07
chapter 9  page 140
GENERAL DISCUSSION
Nowadays cutaneous lymphomas can be classified by the EORTC or the WHO classification, 
but both systems have their shortcomings. The studies presented in this thesis have been 
focused particularly on those groups of cutaneous lymphomas that are classified differently 
in the EORTC and WHO classification. The initial goal of our studies was to formulate 
suggestions for an updated version of the EORTC classification. However, very recently 
discussions between representatives of the EORTC and the WHO group resulted in a new 
classification for cutaneous lymphomas. This new consensus classification is further referred 
to as the WHO-EORTC classification for cutaneous lymphomas.1 In this chapter the results of 
our studies which made an important contribution to this new classification are discussed. In 
addition, guidelines for the treatment of different types of CTCL and CTCL are presented.
CLASSIFICATION OF CTCL
Mycosis fungoides, variants of MF and Sézary’s syndrome
Since there are no differences between the EORTC classification and the WHO classification 
regarding the terminology and classification of MF, MF variants and SS, these conditions 
will not further be discussed. In the WHO-EORTC classification the term MF-associated 
follicular mucinosis will be replaced by folliculotropic MF as a more appropriate term for 
this specific variant of MF. Moreover, the criteria for the diagnosis of SS have been modified 
and are now consistent with recent proposals of the International Society for Cutaneous 
Lymphomas.2
Primary cutaneous CD30-positive lymphoproliferative disorders
Both in the EORTC classification and in the WHO classification it is recognized that primary 
cutaneous CD30-positive lymphoproliferative disorders (CD30+ LPD) represent a spectrum of 
disease, which includes primary cutaneous CD30-positive (anaplastic) large T-cell lymphoma 
(LTCL), lymphomatoid papulosis (LyP), and borderline cases.3,4 However, the different terms 
used for the primary cutaneous CD30-positive (anaplastic) LTCL in the EORTC and WHO 
classification has resulted in confusion, misclassification and inappropriate treatment.5,6,7,8 
Most cases of primary cutaneous CD30-positive LTCL have the morphology of large 
anaplastic cells, similar to those in systemic CD30-positive ALCL. However, in ca. 20% of 
cases they have a pleomorphic or immunoblastic (non-anaplastic) morphology.9 Consistent 
with previous studies, our study presented in chapter 2 confirmed that there are no differences 
in clinical presentation and clinical behavior between anaplastic and non-anaplastic cases.10 
For that reason, in the EORTC classification the term primary cutaneous CD30-positive large 
T-cell lymphoma has always been preferred. This term emphasizes the importance of CD30 
expression, c.q. differentiation from CD30-negative LTCL, and indicates that cytomorphology 
(anaplastic or non-anaplastic) is not important. In contrast, in the WHO classification the 
term cutaneous anaplastic large cell lymphoma (C-ALCL), as opposed to systemic ALC, is 
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Primary cutaneous CD30+ lymphoproliferative disorders
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Subcutaneous panniculitis-like T-cell lymphoma 




Extranodal NK/T-cell lymphoma, nasal-type
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Cutaneous γ/δ-positive T-cell lymphoma (provisional entity)
Primary cutaneous peripheral T-cell lymphoma, unspecified
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Primary cutaneous follicle center lymphoma
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Primary cutaneous diffuse large B-cell lymphoma, leg-type
Primary cutaneous diffuse large B-cell lymphoma, other  
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used. This term has given the impression that cases with a non-anaplastic morphology do not 
belong to this group, but should be classified and thus treated as peripheral T-cell lymphoma, 
not otherwise specified (PTL, NOS).5,7 
Nevertheless, consistent with the WHO terminology, in the WHO-EORTC classification 
the term C-ALCL will be used both for cases with an anaplastic and for cases with a non-
anaplastic morphology. However, together with LyP these C-ALCL are part of a broad 
diagnostic category of primary cutaneous CD30+ LPD. Thus, consistent with the common 
practice within the Dutch Cutaneous Lymphoma group over the last ten years, differentiation 
is first made between primary cutaneous CD30+ LPD on the one hand, and systemic ALCL 
involving the skin secondarily and other types of CTCL expressing CD30 on the other. Based 
on the clinical behavior, ie the presence or absence of recurrent self-healing skin lesions 
distinction should then be made between LyP and C-ALCL Following this two step approach 
it becomes rather irrelevant whether the term primary cutaneous CD30-positive LTCL or 
C-ALCL is used, since cases have already been assigned to the group of primary cutaneous 
CD30+ LPD, which should guarantee appropriate (non-aggressive) treatment. 
Classification of CTCL other than MF, SS and CD30+ LPD 
The studies presented in chapters 3 and 4 were focused on the group of CTCL other than 
MF, SS and CD30+ LPD. The classification of this remaining group of CTCL is difficult 
and confusing, which is not surprising given the heterogeneity and rarity of these tumors. 
In the EORTC classification most of these lymphomas were grouped together in the group 
of primary cutaneous CD30-negative large T-cell lymphoma or in the provisional group of 
primary cutaneous small/medium-sized pleomorphic CTCL (TABLE 2). Distinction between 
the two categories, which was based on the presence of more or less than 30% large 
neoplastic T-cells, was considered useful because several studies demonstrated a significant 
difference in survival between these two groups.3,11,12,13 However, our studies presented in 
chapter 3 suggest that this more favorable prognosis is restricted to small/medium-sized 
pleomorphic CTCL with a CD4+ T-cell phenotype, in particular when presenting with 
localized disease, but does not hold true for cases with a CD8+ T-cell phenotype.14 In 
CD8+ CTCL (non-MF) no difference in clinical behaviour and outcome was seen between 
cases with a small cell or large cell morphology.14 Moreover, the EORTC category of 
CD30-negative large cell CTCL has become quite heterogeneous by the recognition 
of new diagnostic categories, such as different types of subcutaneous panniculitis-like 
T-cell lymphoma (SPTL), extranodal NK/T-cell lymphoma, nasal-type, CD4+, CD56+ 
hematodermic neoplasm (formerly also designated as blastic NK-cell lymphoma), 
primary cutaneous aggressive epidermotropic CD8-positive cytotoxic T-cell lymphoma 
and cutaneous gamma/delta positive T-cell lymphoma.15 In the WHO classification SPTL, 
nasal-type NK/T-cell lymphoma and blastic NK-cell lymphoma were included as separate 
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entities, whereas the other entities are included in the broad category of PTL, NOS (SEE 
TABLE 2).
In the WHO-EORTC classification extranodal NK/T-cell lymphoma, nasal-type and CD4+, 
CD56+ hematodermic neoplasm (blastic NK-cell lymphoma in the WHO classification) 
are also included as separate entities. In chapter 4 a large group of CD56+ cutaneous NK/
T-cell lymphoma, nasal-type and CD4+, CD56+ hematodermic neoplasms (blastic NK-cell 
lymphomas) was evaluated.16 In the group of extranodal NK/T-cell lymphoma, nasal-type the 
skin is the second most common site of involvement after the nasal cavity/ nasopharynx. Skin 
lesions are generally a secondary manifestation of the disease, but rare primary cutaneous 
cases have been reported as well. The most important factor predicting poor outcome was 
the presence of extracutaneous involvement at presentation. In patients presenting with only 
skin lesions a median survival of 27 months was found, compared to 5 months for patients 
presenting with cutaneous and extracutaneous disease. However, all patients with nasal-type 
NK/T-cell lymphoma presenting in the skin should be considered to have aggressive disease, 
which is commonly resistant to conventional chemotherapy.
CD4+, CD56+ hematodermic neoplasms (blastic NK-cell lymphomas) frequently present 
in the skin with or without extracutaneous disease. However, in patients presenting with 
only skin lesions rapid involvement of bone marrow, peripheral blood, lymph nodes and 
extranodal sites is the rule. In our study presented in chapter 4 patients presenting with only 
skin lesions had a slightly better prognosis than patients presenting with both cutaneous and 
extracutaneous disease (median survival 21 versus 12 months, respectively). 
Comparison between CD4+, CD56+ hematodermic neoplasms and CD56+ myelomonocytic 
leukemias presenting in the skin showed striking similarities in histology, immunophenotype 
and clinical presentation, including the percentage of bone marrow involvement at presentation 
and prognosis. Consistently, recent studies suggested that these CD4+, CD56+ hematodermic 
neoplasms are conceptually similar to so-called “aleukemic leukemia cutis”.15 
The overlapping clinical, histological and immunophenotypical features between CD4+, 
CD56+ hematodermic neoplasms and CD56+ myeloid leukemias presenting in the skin suggest 
that both conditions are closely related and also provide a rationale to treat these patients 
with more aggressive regimens used in myeloid leukemias rather than with conventional 
CHOP(-like) regimens. 
With respect to the group of SPTL recent studies showed both clinical, histological and 
immunophenotypical differences between cases with an α/β T-cell phenotype and cases with 
a γ/δ T-cell phenotype, suggesting that these may represent different entities. Whereas SPTL 
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with an α/β T-cell phenotype represent a homogeneous group with in many patients a rather 
indolent clinical behaviour, SPTL with a γ/δ T-cell phenotype overlap with other types of γ/δ 
–positive T-cell lymphoma and invariably run a very aggressive clinical course.15,17-20 In the 
WHO-EORTC the term SPTL is restricted for SPTL with an α/β T-cell phenotype.15 
With respect to the original group of PTL, NOS in the WHO classification, there was consensus 
that primary cutaneous small-medium CD4+ T-cell lymphoma, primary cutaneous aggressive 
epidermotropic CD8+ cytotoxic T-cell lymphoma and cutaneous gamma-delta positive 
T-cell lymphoma can be separated out as provisional disease entities. This latter group also 
includes SPTL with a gamma/delta phenotype. In the WHO-EORTC classification the term 
PTL, unspecified is maintained for cases not belonging to either of these entities. This group 
includes cases classified as primary cutaneous CD30-negative large T-cell lymphomas in the 
EORTC classification and a small group of unclassifiable CTCL.
CLASSIFICATION OF CBCL
Primary cutaneous marginal zone B-cell lymphoma
As already indicated in chapter 1, the term primary cutaneous marginal zone B-cell lymphoma 
(PCMZL) is nowadays preferred for post-germinal center B-cell neoplasms composed of 
variable numbers of marginal zone cells, lymphoplasmacytoid cells and plasma cells. Also 
in the WHO-EORTC classification the term PCMZL is used. Moreover, exceptional cases of 
primary cutaneous plasmacytoma, (extramedullary plasmacytoma of the skin), included as a 
provisional entity in the EORTC classification, show considerable overlap with PCMZL, and 
is therefore included in the spectrum of PCMZL.
Primary cutaneous follicle center cell lymphoma and primary cutaneous large 
B-cell lymphoma of the leg
In the EORTC classification primary cutaneous follicle center cell lymphomas (PCFCCL) 
and primary cutaneous large B-cell lymphoma of the leg (PCLBCL-leg) are recognized as 
distinct entities. PCFCCL are characterized by a proliferation of small and more often large 
centrocytes with a follicular and more a commonly a diffuse growth pattern, and clinically by 
the presence of localized skin lesions mostly on the head or trunk and an excellent prognosis. 
PCLBCL-leg is characterized by a diffuse proliferation of centroblasts and immunoblasts, and 
skin tumors on the (lower) legs in particular in elderly females and an intermediate prognosis. 
In contrast to PCFCCL, these PCLBCL-leg almost consistently show strong expression of 
bcl-2 and Mum-1/IRF4.21,22
The WHO did not adopt these entities. In this classification PCFCCL with a (partly) follicular 
growth pattern are classified as cutaneous follicle center lymphoma, whereas PCFCCL with 
a diffuse proliferation of large centrocytes are classified as diffuse large B-cell lymphoma. 
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PCLBCL-leg cases are also classified as diffuse large B-cell lymphoma. The distinction between 
two types of PCLBCL primarily on the basis of site has been much disputed,8,22 and was the 
main reason to perform a European multicenter study on a large group of PCLBCL. The 
results of this study described in chapter 6, confirmed that PCLBCL-leg and PCFCCL with a 
diffuse large cell histology are distinct entities.23 In addition, a predominance of tumor cells 
with round nuclei (centroblasts and immunoblasts) was found to be an adverse prognostic 
factor in both groups, whereas the presence of multiple skin lesions was associated with a 
poor prognosis only in patients with a PCLBCL-leg, but not in patients with a PCFCCL. 
In the WHO-EORTC classification it is recognized that PCFCCL as defined in the EORTC 
classification indeed form a spectrum of disease which includes cases with a follicular, a 
follicular and diffuse and a diffuse growth pattern. This group will further be referred 
to as primary cutaneous follicle center lymphoma. However, in contrast to the EORTC 
classification tumors showing a diffuse proliferation of centroblasts and immunoblasts not 
arising on the leg are no longer classified as PCFCL, but as PCLBCL, which is in line with 
the results of our study described in chapter 6. Thus it is acknowledged that, while most 
cases showing a diffuse proliferation of centroblasts and immunoblasts and strong expression 
of bcl-2 and Mum-1/IRF4 are localized on the leg, cases with a similar morphology and 
immunophenotype may sometimes arise at sites other than the leg.23 In the WHO-EORTC 
classification the term PCLBCL, leg type is proposed for both lesions on the legs and similar 
lesions at other skin sites. In addition, the term PCLBCL, other is introduced for rare cases 
of PCLBCL not belonging to the group of PCLBCL, leg type or PCFCL with a diffuse growth 
pattern. This group includes rare morphologic variants of PCLBCL, such as anaplastic and 
plasmablastic variants and T-cell/histiocytes-rich large B-cell lymphoma and rare cases of 
primary cutaneous intravascular large B-cell lymphoma (SEE TABLE 1).
GUIDELINES FOR THE TREATMENT OF CUTANEOUS LYMPHOMAS
One of the goals of the studies presented in this thesis was to define therapeutic guidelines 
for the different types of primary cutaneous lymphoma. Specific questions concerned the 
treatment of a) primary cutaneous CD30-positive LTCL presenting with multifocal skin 
lesions (chapter 2), b) CTCL other than MF, SS and CD30+ LPD, and c) CBCL presenting 
with multifocal skin lesions. The main results and conclusions of these studies are briefly 
discussed below. Based on the results of these studies, the therapeutic guidelines of the Dutch 
Cutaneous Lymphoma Group and other national guidelines published recently,24,25 the first 
choice of treatment and alternative therapies for the different types of cutaneous lymphoma 
included in the WHO-EORTC classification are summarized in TABLES 2 and 3.
Primary cutaneous CD30-positive LTCL presenting with multifocal skin lesions
There is almost general agreement that patients with a primary cutaneous CD30+ LTCL 
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TABLE 2. Therapeutic guidelines for most common types of cutaneous lymphoma according to the WHO-
EORTC classification
WHO-EORTC Classification First line Second line Experimental 
Cutaneous T-cell lymphoma
Limited patches and plaques (<10% 
skin surface) PUVA; topical steroids
UV-B/UV-B narrow band
Topical chemotherapy (1) Bexarotene gel (2)
Generalized patches/plaques (>10% 
skin surface) PUVA
Topical chemotherapy; 





Tumor stage PUVA + RT; TSEB






Lymph node involvement TSEB/RTSystemic chemotherapy Systemic chemotherapy
Denileukin diftitox (2)
Alemtuzumab; PBSCT





Folliculotropic MF See tumor stage MF
Pagetoid reticulosis Radiotherapy PUVA
Granulomatous slack skin Radiotherapy; Excision








Primary cutaneous anaplastic large cell 
lymphoma
Radiotherapy; excision; 
methotrexate (multifocal) Systemic chemotherapy Anti-CD30 moab
Lymphomatoid papulosis Wait & see Methotrexate; PUVA; topical chemotherpy










extranodal NK/T-cell lymphoma, nasal type
aggressive CD8+ CTCL PBSCT
Cutaneous γ/δ-positive T-cell lymphoma
Primary cutaneous PTL, unspecified
CD4+, CD56+ hematodermic neoplasm Treat as acute leukemia
Cutaneous B-cell lymphoma










Primary cutaneous follicle center  
lymphoma RT




Primary cutaneous diffuse large B-cell 
lymphoma, leg type and other (incl. 
primary cutaneous intravascular B-cell 
lymphoma
Systemic chemotherapy CHOP + rituximabRT (small, solitary lesion)
LEGEND:




(2):  not registered in 
the Netherlands;
(3):  not available in 
the Netherlands; 
TSEB:  
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presenting with localized skin lesions can best be treated with radiotherapy or, in case of 
a solitary tumor, even with simple excision. However, the treatment of patients presenting 
with multifocal skin lesions was more controversial. According to the 1991 guidelines of 
the Dutch Cutaneous Lymphoma Group such patients should be treated with doxorubicin-
based multi-agent chemotherapy. However, the results of our studies presented in chapter 2 
demonstrated that all patients who were treated with CHOP courses because of multifocal 
skin lesions had one or several skin relapses afterwards.26 These results indicate that skin-
limited CD30+ LTCL with multifocal skin lesions should not be treated routinely with 
systemic chemotherapy, but can better be treated with radiotherapy in case of only few skin 
lesions or low-dose methotrexate as in LyP.27,28 Multiagent chemotherapy is only indicated 
in patients with or developing extracutaneous disease, or rare cases with progressive skin 
lesions that can not be controlled in other ways.
CTCL other than MF, SS and CD30+ LPD
With the exception of the group of SPTL (with an α/β T-cell phenotype) and the group of 
primary cutaneous small-medium CD4+ T-cell lymphoma, all entities within this category have 
a very poor prognosis, also in cases presenting with only skin lesions. Therefore, distinction 
between “primary” and “secondary” cutaneous involvement seems less important than for 
other types of malignant lymphoma involving the skin. 
Patients with a SPTL are generally treated with chemotherapy and radiotherapy. However, 
recent studies suggest that many patients can be controlled for long periods of time with systemic 
corticosteroids.15,19 Patients presenting with a solitary tumor can be treated with radiotherapy. 
In patients with a CD4+ small/medium pleomorphic CTCL presenting with solitary 
localized skin lesions surgical excision or radiotherapy is the preferred mode of treatment. 
Cyclophosphamide as single-agent therapy and interferon alpha have been reported effective 
in patients with more generalized skin disease.29 However, the optimal treatment for this 
group has still to be defined.
Other types of cutaneous T- and NK-cell lymphomas in this category are generally treated 
with doxorubicin-based multi-agent chemotherapy, but the results are often disappointing. 
In patients with a CD4+, CD56+ hematodermic neoplasm systemic chemotherapy usually 
results in a complete remission, but quick relapses unresponsive to further chemotherapy are 
the rule. Recent studies suggest that patients can best be treated with regimens used in acute 
leukemias. Both in our study30 as in recent studies by other authors31,32 the best results were 
seen in patients treated with allogeneic bone marrow transplantation. 
CBCL presenting with multifocal skin lesions
In patients with a PCFCL or PCMZL presenting with localized skin lesions radiotherapy is 
the preferred mode of treatment.26,33 The results of our studies presented in chapter 7 suggest 
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that patients with a PCFCL or PCMZL presenting with multifocal skin lesions have the 
same excellent prognosis as patients presenting with localized disease, and that radiotherapy 
directed towards all skin lesions is as effective as multi-agent chemotherapy. Only in patients 
with very extensive cutaneous disease, patients with extremely thick skin tumors and patients 
developing extracutaneous disease systemic chemotherapy is required.23,26 Patients with 
PCLBCL, leg type which are in many ways similar to other systemic diffuse large B-cell 
lymphomas, should always be treated with doxorubicin-based multi-agent chemotherapy. By 
exception patients presenting with a small solitary tumor can be treated with radiotherapy. 
Recent studies report beneficial effects of systemic of intralesional administration of anti-
CD20 antibody (Rituximab) therapy in small series of PCFCL and PCLBCL, leg type, but 
long-term follow-up data are not available and the place of rituximab in the treatment of 
PCLBCL, either as single agent therapy or in combination with systemic chemotherapy 
remains to be established.34,35
CONCLUSION AND FUTURE DIRECTIONS
The studies presented in this thesis, aimed at improved guidelines for the classification and 
treatment of cutaneous lymphomas, have contributed to a new classification for cutaneous 
lymphomas. This WHO-EORTC classification is expected to contribute to a more uniform 
diagnosis and hence a more uniform treatment of patients with a cutaneous lymphoma.
The new definitions of the group of PCFCL, PCLBCL leg-type and PCLBCL, other will 
allow a more reliable distinction between indolent and more aggressive types of CBCL, and 
facilitate the decision whether radiotherapy or systemic chemotherapy should be selected as 
first choice of treatment. Large multicenter studies are now required to validate the current 
proposals, and in particular to investigate the diagnostic and prognostic value of bcl-2 and 
Mum-1/IRF4 protein expression.22,36
The classification of CTCL other than MF, SS and the group of primary cutaneous CD30-
positive LPD is still difficult, as it requires accurate clinicopathologic correlation and a 
number of complementary techniques to arrive at a definite diagnosis. Apart from the group 
of SPTL and the group of CD4+ small/medium-sized pleomorphic CTCL these rare types of 
CTCL have a very poor prognosis and are generally resistant to conventional chemotherapy. 
More aggressive regimens, including allogeneic bone marrow transplantation, are currently 
under investigation. Recently, studies have started to investigate gene and protein expression 
profiles in different types of (cutaneous) lymphoma.37 It is expected that these studies will 
not only contribute to a better understanding of the molecular pathways involved in the 
development and progression of these lymphomas, but will also provide new molecular targets 
for diagnosis and therapeutic intervention as well as more refined classification schemes.
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CHAPTER 10
Summary
Primary cutaneous lymphoma form a seperate group of non-Hodgkin lymphoma. Apart from 
the usual nodal presentation of a lymphoma, less frequently a lymphoma develops in an 
extranodal site. The skin is, after the gastrointestinal tract, the most frequent site of extranodal 
lymphoma. If the skin is the primary site of involvement, i.e. no extracutaneous sites are 
involved at diagnosis, these lymphomas are called primary cutaneous lymphoma. In this thesis 
different types of primary cutaneous lymphoma are evaluated and discussed. In chapter 2 a 
large group of primary cutaneous CD30+ lympoproliferations is described and compared 
with a group of systemic CD30+ ALCL with skin localisations. Lymphomatoid papulosis and 
primary cutaneous CD30+ CTCL are closely related conditions and should be considered 
as a spectrum, with a comparable, excellent, prognosis. Multiagent chemotherapy (MAC) 
could not induce long lasting remissions, in fact all patients treated with MAC developed 
one or more (cutaneous) relapses. Therefor MAC is only indicated in case of extracuteneous 
localisations. In chapter 3 a group of CD30-negative T-cell lymphomas presenting in the 
skin that could not be diagnosed as MF, SS or SPTL are evaluated. In this group there were 
few survivors, apart from a rare group of patients with primary cutaneous lymphoma with 
small-medium sized CD4+/CD8-neoplastic T-cells (less than 30% large cells). In particular, 
patients with localized disease had an excellent prognosis. In chapter 4 haematological 
malignancies presenting in the skin and expressing CD56 were collected, both from the Dutch 
cutaneous lymphoma group and literature. In general these types of malignancies had a poor 
prognosis, except for patients with primary cutaneous CD30+ LPD, that showed a similar 
good prognosis as CD56-negative cases.  Most cases belonged to the group of nasal-type 
NK/T-cell lymphoma and the group of CD4+, CD56+ hematodermic neoplasm (formerly 
also designated as blastic NK-cell lymphoma. In addition, CD56 was expressed in some 
SPTL,  rare primary cutaneous CD30-negative large T-cell lymphomas, skin localisations of 
acute myeloid leukemia and CD30+ CTCL. In most of these groups CD56 expression did not 
affect prognosis. However, in SPTL CD56 expression proved a marker for gamma/delta T-cell 
origin and these cases showed a poorer prognosis as compared to SPTL with an alpha/beta 
phenotype (that were usually CD56-negative). In the new WHO-EORTC classification the 
category of SPTL only includes cases with an alpha/beta-positive phenotype, whereas cases 
with a gamma/delta positive phenotype are included in the provisional category of cutaneous 
gamma/delta-positive T-cell lymphoma. In chapter 5 a rare case of lymphomatoid papulosis 
with CD56-expression was presented and the frequency of co-expression of CD56 in primary 
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cutaneous CD30+ LPD was analyzed. CD56 expression was found in approximately 10% of 
CD30+ LPD (both LyP and primary CD30+ CTCL). However, these CD56+ cases were not 
found to have a different prognosis from CD56 negative cases. 
In chapter 6 a European multicenter study on primary cutaneous large B-cell lymphomas is 
presented. Patients with primary cutaneous large B-cell lymphoma of the leg showed a poorer 
prognosis as patients with primary cutaneous follicle center cell lymphoma (PCFCCL). 
Moreover, round cell morphology was identified as a poor prognostic parameter. Although 
this was closely related to presentation on the leg(s), also in the group of PCFCCL the 
presence of a predominance of cells with round nuclei (centroblasts and immunoblasts) was 
associated with a poorer prognosis. The results of this study contributed to a new category 
in the WHO-EORTC classification, designated primary cutaneous large B-cell lymphoma 
(PCLBCL), leg-type, indicating that both patients with the classical presentation on the 
leg(s) as patients showing the same morphology and immunophenotype (bcl-2+, Mum-1/
IRF4+) on other sites are included in this group. Presentation with multifocal lesions proved 
to be a poor prognostic parameter for PCLBCL-leg-type, but not for PCFCCL. In chapter 
7 treatment results in multifocal primary CBCL were analyzed. The main question in this 
study was if PCFCCL presenting with multifocal skin lesions should be treated with MAC. 
The study showed that MAC is only indicated in PCLBCL, leg-type and not in (multifocal) 
PCFCCL. Radiotherapy on multiple sites appeared equally effective as MAC in these patients. 
In chapter 8 the frequency of CNS-involvement in CBCL patients of the Dutch cutaneous 
lymphoma group. was evaluated. The frequency was low. Only 4/140 patients with a primary 
CBCL developed CNS involvement in the course of their disease. Interestingly 3 of these 
4 patients were PCFCCL, a lymphoma usually with an excellent prognosis. Only 4 disease 
related deaths were reported in this group of which 3 with CNS involvement. The reason for 
this relatively high prevalence of CNS involvement in PCFCCL is unclear.
The studies presented in this thesis have provided important information, which has 
contributed to the recent development of the WHO-EORTC classification. Moreover, they 
have contributed to updated guidelines for the treatment of the different types of primary 
cutaneous lymphomas, as presented in TABLE 2 in chapter 9.
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Samenvatting voor de leek
Maligne lymfomen zijn kwaadaardige woekeringen van verschillende typen witte bloedcellen. 
Deze aandoeningen ontstaan meestal in lymfklieren (lymfklierkanker), maar in ca. 40% van 
de patiënten komen deze voor het eerst tot uiting in zogenaamde extranodale organen, zoals 
het maagdarmstelsel of de huid. Het in dit proefschrift beschreven onderzoek is met name 
gericht op zogenaamde primair cutane lymfomen, dat wil zeggen maligne lymfomen die zich 
in de huid presenteren en waarbij bij nader onderzoek (stagering) geen andere localisaties 
gevonden worden. Deze groep is erg heterogeen en bestaat uit entiteiten afkomstig van 
verschillende types witte bloedcellen. Het grootst is de groep van cutane T-cel lymfomen 
(ca. 75%), daarna de groep van cutane B-cel lymfomen (ca. 20%) en slechts incidenteel 
wordt een NK-cel origine of overige/onbekende vroege voorlopercel origine gevonden. Een 
groot aantal van deze primair cutane lymfomen waren goed gekarakteriseerd in de EORTC 
classificatie. Een groot deel van, vooral Amerikaanse, artsen gebruikte voor primaire cutane 
lymfomen echter de REAL classificatie, die nauwelijks oog had voor de specifieke diagnostiek 
en behandeling van deze lymfomen. Haar opvolger de WHO classificatie had duidelijk meer 
aandacht voor primaire cutane lymfomen en een groot gedeelte van de EORTC classificatie 
werd overgenomen in deze classificatie. Ondanks de sterk verbeterde aandacht voor primair 
cutane lymfomen bleef er discrepantie en discussie over diagnostiek en behandeling van 
een aantal primair cutane lymfomen. Aangezien de benaming van lymfomen veelal direct 
resulteert in een specifieke behandeling, is classificatie meer dan een academische discussie. 
In dit proefschrift worden de voor- en nadelen van de EORTC en de WHO schema’s bij de 
classificatie van de verschillende typen primair cutane lymfomen onderzocht. Tevens werden 
de bestaande behandelingsprotocollen van een aantal groepen kritisch geëvalueerd.
In hoofdstuk 2 wordt het spectrum van primair cutane CD30-positieve cutane lymfomen 
besproken. Deze groep blijkt een uitstekende prognose te hebben, onafhankelijk van 
verschillende klinische en histologische parameters. Chemotherapie heeft nagenoeg geen 
plaats binnen deze groep wanneer er enkel huidafwijkingen zijn. In tegenstelling tot deze groep 
met gunstige prognose bestaat er een groep van CD30-negatieve T-cel lymfomen (hoofdstuk 
3), die niet als mycosis fungoïdes of Sézary syndroom kunnen worden geclassificeerd. Deze 
heterogene groep blijkt een slechte prognose te hebben met uitzondering van, vooral op een 
beperkt gebied van de huid gelokaliseerde, CD4+/CD8- klein tot middelgrootcellige primair 
cutane T-cel lymfomen. De prognose voor de overige patiënten met een dergelijk CD30-
negatief T-cel lymfoom is slecht, ook wanneer intensieve chemotherapie wordt gegeven. 
Nieuwe therapieën moeten dan ook worden gezocht. In hoofdstuk 4 wordt een relatief 
nieuwe groep cutane lymfomen beschreven, die nog niet apart vermeld werd in de EORTC 
classificatie. Binnen deze CD56+ cutane lymfomen blijken klinisch en histologisch goed 
afgrensbare groepen te bestaan. De belangrijkste zijn het NK/T-cel lymfoom en het blastair 
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NK-cel lymfoom (tegenwoordig meestal CD4+CD56+ haematodermic neoplasm genoemd).
Daarnaast kan CD56 tot expressie komen bij bekende typen cutane T-cel lymfomen en 
huidlokalisaties van een myeloide leukemie. Alle genoemde groepen hebben over het algemeen 
een zeer slechte prognose. Uitzondering hierop zijn primair cutaan CD30+ lymfomen en 
lymfomatoide papulose die ook met co-expressie van CD56 hun uitstekende prognose blijven 
behouden (hoofdstuk 5). 
Binnen de groep primair cutane B-cel lymfomen was vooral de subclassificatie van het 
grootcellig B-cel lymfoom van het been in de EORTC classificatie reden tot veel ophef. 
Een studie in samenwerking met een aantal Europese instituten (hoofdstuk 6), beschrijft de 
verschillende risicofactoren waarbij het grootcellig B-cel lymfoom van het been inderdaad 
een slechtere prognose te hebben. Naast de lokalisatie op het been blijkt de morfologie van 
de tumorcellen sterk gecorreleerd met de lokalisatie en dus ook prognose. In hoofdstuk 7 
wordt de behandeling van multifocale B-cel lymfomen besproken. In tegenstelling tot de oude 
consensus van de Nederlandse Werkgroep Cutane Lymfomen blijkt bij alle B-cel lymfomen, 
behalve het grootcellig B-cel lymfoom op het been, lokaal radiotherapie afdoende te zijn. Bij 
het grootcellig B-cel lymfoom van het been is alleen bij een kleine solitaire tumor radiotherapie 
te overwegen, maar bij meerdere laesies is chemotherapie geïndiceerd. De prognose blijkt dan 
ook slechter bij multipele laesies bij een grootcellig B-cel lymfoom op het been, terwijl bij de 
andere types de prognose even goed blijft. Tijdens het verzamelen van de follow-up gegevens 
voor hoofdstuk 6 en 7 werd bij een aantal patiënten uitzaaiing naar het centraal zenuwstelsel 
(CZS) gemeld. Lokalisaties in het CZS werden nooit eerder in de literatuur gemeld en zijn nu 
beschreven in hoofdstuk 8. Recidieven buiten de huid van het primair cutane B-cel lymfoom 
zijn zeldzaam en opvallend vaak bleek dan juist het CZS aangedaan, vooral bij het primair 
cutaan follikel centrum cel lymfoom. Een verklaring hiervoor is nog niet gevonden. 
De artikelen beschreven in dit proefschrift hebben een belangrijke rol gespeeld bij consensus 
bijeenkomsten, waarbij door vertegenwoordigers van de EORTC en van de WHO classificatie 
een nieuwe classificatie is opgesteld: de WHO-EORTC classificatie. Tevens hebben de 
resultaten van de in dit proefschrift beschreven studies geleid tot nieuwe richtlijnen voor 
behandeling van verschillende typen van primair cutane lymfomen.
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